Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
J Infect
    January 2025
  1. RJOOB K, Antonelli M, Murray B, Molteni E, et al
    Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post COVID-19 Syndrome After SARS-CoV-2 Vaccination Versus Influenza Vaccination.
    J Infect. 2025 Jan 10:106406. doi: 10.1016/j.jinf.2024.106406.
    >> Share

    December 2024
  2. MOK CKP, Tang YS, Tan CW, Chong KC, et al
    Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.
    J Infect. 2024;90:106374.
    >> Share

  3. CITRON MP, Zang X, Leithead A, Meng S, et al
    Evaluation of a non-nucleoside inhibitor of the RSV RNA-dependent RNA polymerase in translatable animals models.
    J Infect. 2024;89:106325.
    >> Share

  4. ALOISIO GM, Nagaraj D, Murray AM, Schultz EM, et al
    Infant-derived human nasal organoids exhibit relatively increased susceptibility, epithelial responses, and cytotoxicity during RSV infection.
    J Infect. 2024;89:106305.
    >> Share

    November 2024
  5. LUO H, Cui Y, Yu W, Li G, et al
    The impact of urbanization in China on influenza incidence across neighboring cities.
    J Infect. 2024 Nov 28:106370. doi: 10.1016/j.jinf.2024.106370.
    >> Share

  6. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    >> Share

  7. CHOW KN, Tsang YW, Chan YH, Telaga SA, et al
    The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis.
    J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358.
    >> Share

  8. REN Z, Yang M, Su G, Qian G, et al
    Real-world effectiveness and safety of Azvudine in hospitalized patients with SARS-CoV-2 infection: a multicenter, retrospective cohort study.
    J Infect. 2024 Nov 17:106355. doi: 10.1016/j.jinf.2024.106355.
    >> Share

  9. LIU Q, Zhong P, Wei Q, Wang X, et al
    Mechanisms of MHC-II Binding by Novel Influenza A Viruses and Their Cross-Species Transmission Potential.
    J Infect. 2024 Nov 16:106354. doi: 10.1016/j.jinf.2024.106354.
    >> Share

  10. MCLEOD C, Dymock M, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
    J Infect. 2024 Nov 14:106346. doi: 10.1016/j.jinf.2024.106346.
    >> Share

  11. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    >> Share

  12. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    >> Share

  13. HO A, McInnes N, Blunsum A, Quinn J, et al
    Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
    J Infect. 2024;89:106338.
    >> Share

    October 2024
  14. WANG H, Zhou Y, Chu L, Chen K, et al
    Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
    J Infect. 2024;89:106333.
    >> Share

  15. KUMAR NP, Balaji S, Devi PG, Ramraj B, et al
    Inflammatory Cytokine Responses in Pediatric tuberculosis with or without SARS-CoV-2 seropositivity.
    J Infect. 2024 Oct 17:106314. doi: 10.1016/j.jinf.2024.106314.
    >> Share

  16. WEI X, Wang L, Li M, Qi J, et al
    Novel imported clades accelerated the RSV surge in Beijing, China, 2023-2024.
    J Infect. 2024 Oct 17:106321. doi: 10.1016/j.jinf.2024.106321.
    >> Share

  17. MEIRMAN TD, Shapira B, Balicer RD, Rokach L, et al
    Trends of Common Laboratory Biomarkers after SARS-CoV-2 Infection.
    J Infect. 2024 Oct 16:106318. doi: 10.1016/j.jinf.2024.106318.
    >> Share

  18. CHEN X, Meng X, Wu Q, Lim WW, et al
    Assessment of Neutralizing Antibody Response as a Correlate of Protection against Symptomatic SARS-CoV-2 Infections after Administration of two doses of the CoronaVac inactivated COVID-19 Vaccine: A Phase III Randomized Controlled Trial.
    J Infect. 2024 Oct 16:106315. doi: 10.1016/j.jinf.2024.106315.
    >> Share

  19. MADSEN AMR, Gehrt L, Schaltz-Buchholzer F, Moller S, et al
    Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: a randomised clinical trial.
    J Infect. 2024 Oct 16:106319. doi: 10.1016/j.jinf.2024.106319.
    >> Share

  20. MARCHESE AM, Fries L, Beyhaghi H, Vadivale M, et al
    Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines.
    J Infect. 2024 Oct 15:106317. doi: 10.1016/j.jinf.2024.106317.
    >> Share

  21. LI Y, Zhang X, Yi J, Chen Y, et al
    Synergistic evolution: the dynamic adaptation of SARS-CoV-2 and human protective immunity in the real world.
    J Infect. 2024 Oct 9:106310. doi: 10.1016/j.jinf.2024.106310.
    >> Share

  22. MUSCATELLO DJ, Rose N, Paul KK, Ware S, et al
    Epidemiological comparison of emergency department presentations with seasonal influenza or COVID-19 and an outcome of intensive care admission or death: a population-based records linkage study in New South Wales, Australia.
    J Infect. 2024 Oct 8:106307. doi: 10.1016/j.jinf.2024.106307.
    >> Share

  23. LI Y, Sun Z, Liu X, Wei S, et al
    Highly Pathogenic Avian Influenza A(H5N1) Virus infection in dairy cattle:threat of bird flu has expanded to open-air farmed livestock.
    J Infect. 2024 Oct 7:106311. doi: 10.1016/j.jinf.2024.106311.
    >> Share

  24. AMARILLA-IRUSTA A, Zenarruzabeitia O, Sevilla A, Sanda V, et al
    CD151 identifies a NK cell subset that is enriched in COVID-19 patients and correlates with disease severity.
    J Infect. 2024 Oct 5:106304. doi: 10.1016/j.jinf.2024.106304.
    >> Share

  25. FYLES M, Overton CE, Ward T, Bennett E, et al
    Modelling multiplex testing for outbreak control.
    J Infect. 2024 Oct 1:106303. doi: 10.1016/j.jinf.2024.106303.
    >> Share

    September 2024
  26. AKSU MD, van der Ent T, Zhang Z, Riza AL, et al
    Regulation of plasma soluble receptors of TNF and IL-1 in patients with COVID-19 differs from that observed in sepsis.
    J Infect. 2024 Sep 30:106300. doi: 10.1016/j.jinf.2024.106300.
    >> Share

  27. DEHLIA A, Guthridge MA
    The persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Infect. 2024 Sep 29:106297. doi: 10.1016/j.jinf.2024.106297.
    >> Share

  28. KIRWAN PD, Foulkes S, Munro K, Sparkes D, et al
    Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024.
    J Infect. 2024 Sep 27:106293. doi: 10.1016/j.jinf.2024.106293.
    >> Share

  29. MAZZOTTA V, Mazzaferri F, Lanini S, Mirandola M, et al
    Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
    J Infect. 2024 Sep 27:106294. doi: 10.1016/j.jinf.2024.106294.
    >> Share

  30. BENNETT C, Hoosain Z, Koen A, Lalloo U, et al
    Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in South African People Living With and Without HIV-1 Infection: A Phase 2 Randomised Trial.
    J Infect. 2024 Sep 27:106285. doi: 10.1016/j.jinf.2024.106285.
    >> Share

  31. VEGA-PIRIS L, Carretero SG, Mayordomo JL, Zarzuelo MBR, et al
    Severity of Respiratory Syncytial Virus compared with SARS-CoV-2 and Influenza among hospitalised adults >/=65 years.
    J Infect. 2024 Sep 26:106292. doi: 10.1016/j.jinf.2024.106292.
    >> Share

  32. RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al
    N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial.
    J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288.
    >> Share

  33. CHEN X, Balliew J, Bauer CX, Deegan J, et al
    Revealing patterns of SARS-CoV-2 variant emergence and evolution using RBD amplicon sequencing of wastewater.
    J Infect. 2024 Sep 26:106284. doi: 10.1016/j.jinf.2024.106284.
    >> Share

  34. SABATE-ELABBADI A, Brolon L, Brun-Buisson C, Guillemot D, et al
    Trends in hospitalisations for lower respiratory infections after the COVID-19 pandemic in France.
    J Infect. 2024 Sep 26:106287. doi: 10.1016/j.jinf.2024.106287.
    >> Share

  35. MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
    J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286.
    >> Share

  36. CHRISTENSEN J, Johansen ND, Janstrup KH, Modin D, et al
    Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: a post-hoc analysis of the DANFLU-1 randomized clinical trial.
    J Infect. 2024 Sep 18:106276. doi: 10.1016/j.jinf.2024.106276.
    >> Share

  37. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
    Corrigendum to "The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials" [J Infect 89 (2024) 106187].
    J Infect. 2024;89:106270.
    >> Share

  38. MCDONALD E, Pittet LF, Barry SE, Bonten M, et al
    Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: insights from prospectively collected data in the BRACE trial.
    J Infect. 2024 Sep 6:106267. doi: 10.1016/j.jinf.2024.106267.
    >> Share

  39. CHAPMAN ME, Brendish NJ, Morris M, Spalluto CM, et al
    Real-world performance of a single-use, analyser-free, molecular point-of-care test for COVID-19 used in the emergency department: results of a prospective trial (ED-POC).
    J Infect. 2024 Sep 5:106264. doi: 10.1016/j.jinf.2024.106264.
    >> Share

    August 2024
  40. AZIZ AB, Sugimoto JD, Hong SL, You YA, et al
    Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: a cluster randomised analysis.
    J Infect. 2024 Aug 30:106260. doi: 10.1016/j.jinf.2024.106260.
    >> Share

  41. GRAM MA, Thiesson EM, Pihlstrom N, Perala J, et al
    Comparative effectiveness of bivalent BA.4-5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study.
    J Infect. 2024;89:106261.
    >> Share

  42. HASAN T, Zhu NJ, Pearson C, Aylin P, et al
    Increased 30-day all-cause mortality associated with Gram-negative bloodstream infections in England during the COVID-19 pandemic.
    J Infect. 2024 Aug 29:106256. doi: 10.1016/j.jinf.2024.106256.
    >> Share

  43. HOBBS FR, Gbinigie OA, Shanyinde M, Yu LM, et al
    Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
    J Infect. 2024 Aug 29:106248. doi: 10.1016/j.jinf.2024.106248.
    >> Share

  44. FOULKES S, Evans J, Neill C, Bishop J, et al
    Prevalence and impact of persistent symptoms following SARS-CoV-2 infection among healthcare workers: a cross-sectional survey in the SIREN cohort.
    J Infect. 2024 Aug 28:106259. doi: 10.1016/j.jinf.2024.106259.
    >> Share

  45. GOTTLIEB RL, Clement M, Cook P, Deveikis A, et al
    The IL-6 Hypothesis in COVID-19: A Phase 2, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Free IL-6 Sequestration by the Monoclonal Antibody Sirukumab in Severe and Critical COVID-19.
    J Infect. 2024 Aug 23:106241. doi: 10.1016/j.jinf.2024.106241.
    >> Share

  46. LI Y, Yin Z, Wang J, Xu Y, et al
    Surveillance of avian influenza viruses in Hebei Province of China from 2021 to 2023: identification of a novel reassortant H3N3.
    J Infect. 2024 Aug 20:106240. doi: 10.1016/j.jinf.2024.106240.
    >> Share

  47. FRYER HA, Geers D, Gommers L, Zaeck LM, et al
    Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    J Infect. 2024 Aug 8:106246. doi: 10.1016/j.jinf.2024.106246.
    >> Share

  48. MESSINA NL, Pittet LF, McDonald E, Moore C, et al
    BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial.
    J Infect. 2024 Aug 8:106245. doi: 10.1016/j.jinf.2024.106245.
    >> Share

  49. WANG HI, Doran T, Crooks MG, Khunti K, et al
    Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England.
    J Infect. 2024;89:106235.
    >> Share

  50. QUEK AML, Wang S, Teng O, Shunmuganathan B, et al
    Hybrid immunity augments cross-variant protection against COVID-19 among immunocompromised individuals.
    J Infect. 2024 Aug 7:106238. doi: 10.1016/j.jinf.2024.106238.
    >> Share

  51. SILVA-COSTA C, Gomes-Silva J, Pinho M, Friaes A, et al
    Rebound of pediatric invasive pneumococcal disease in Portugal after the COVID-19 pandemic was not associated with significant serotype changes.
    J Infect. 2024 Aug 6:106242. doi: 10.1016/j.jinf.2024.106242.
    >> Share

    July 2024
  52. LI J, Zhang Y, Liu Z, Yang Z, et al
    Increased SARS-CoV-2 reinfection frequency, attenuated severity, and risk factor analysis in patients with hematological malignancies.
    J Infect. 2024;89:106233.
    >> Share

  53. BECHMAN K, Green A, Russell MD, Yang Z, et al
    The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19.
    J Infect. 2024 Jul 15:106227. doi: 10.1016/j.jinf.2024.106227.
    >> Share

  54. ANDREWS N, Osuntoki I, Stowe J, Kirsebom FCM, et al
    The impact of Covid-19 vaccine spring boosters on Covid-19 hospital admissions in England 2022/23.
    J Infect. 2024 Jul 10:106221. doi: 10.1016/j.jinf.2024.106221.
    >> Share

  55. KADAMBARI S, Abdullahi F, Celma C, Ladhani S, et al
    Epidemiological trends in viral meningitis in England: prospective national surveillance, 2013-2023.
    J Infect. 2024 Jul 8:106223. doi: 10.1016/j.jinf.2024.106223.
    >> Share

  56. STARKE KR, Kaboth P, Rath N, Reissig D, et al
    Cardiovascular disease risk after a SARS-CoV-2 infection: a systematic review and meta-analysis.
    J Infect. 2024 Jul 4:106215. doi: 10.1016/j.jinf.2024.106215.
    >> Share

  57. HALME ALE, Laakkonen S, Rutanen J, Nevalainen OPO, et al
    Short- and long-term effects of imatinib in hospitalised COVID-19 patients: A randomised trial.
    J Infect. 2024 Jul 3:106217. doi: 10.1016/j.jinf.2024.106217.
    >> Share

  58. MOKRANI D, Le Hingrat Q, Thy M, Choquet C, et al
    Clinical characteristics and outcomes of respiratory syncytial virus-associated ARF in immunocompetent patients: A seven-year experience at a tertiary hospital in France.
    J Infect. 2024;89:106180.
    >> Share

    June 2024
  59. BOOM TT, de Hoog MLA, Westerhof I, Jaddoe V, et al
    Age-specific SARS-CoV-2 transmission differed from human rhinovirus in households during the early COVID-19 pandemic.
    J Infect. 2024 Jun 29:106218. doi: 10.1016/j.jinf.2024.106218.
    >> Share

  60. BOYS R, Plank J, Bird P, Fletcher O, et al
    Impact of COVID-19 restrictions on the incidence of respiratory viruses in two British Antarctic Survey bases.
    J Infect. 2024;89:106196.
    >> Share

  61. DU Z, Wang S, Chen R, Shan S, et al
    Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults.
    J Infect. 2024;89:106211.
    >> Share

  62. CHAKA A, Pan D, Irshad M, Piranie H, et al
    Inclusion of racial and ethnic groups in clinical trials for COVID-19 and post-acute COVID-19 syndrome: an analysis of studies registered on ClinicalTrials.gov.
    J Infect. 2024 Jun 20:106207. doi: 10.1016/j.jinf.2024.106207.
    >> Share

  63. GONG X, Peng L, Wang F, Liu J, et al
    Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    J Infect. 2024;89:106208.
    >> Share

  64. PEREZ-GARCIA C, Sempere J, de Miguel S, Hita S, et al
    Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023).
    J Infect. 2024;89:106204.
    >> Share

  65. ZHAI K, Dong J, Zeng J, Cheng P, et al
    Global Antigenic Landscape and Vaccine Recommendation Strategy for Low Pathogenic Avian Influenza A(H9N2) Viruses.
    J Infect. 2024 Jun 18:106199. doi: 10.1016/j.jinf.2024.106199.
    >> Share

  66. LIU B, Xu L, Ma Y, Wang H, et al
    Evidence of immunity gap: Decline in antibodies against M. pneumoniae during the COVID-19 pandemic.
    J Infect. 2024 Jun 18:106209. doi: 10.1016/j.jinf.2024.106209.
    >> Share

  67. KAJIHARA T, Yahara K, Kamigaki T, Hirabayashi A, et al
    Effects of coronavirus disease 2019 on the spread of respiratory-transmitted human-to-human bacteria.
    J Infect. 2024 Jun 17:106201. doi: 10.1016/j.jinf.2024.106201.
    >> Share

  68. MIKOLAJCZYK R, Diexer S, Klee B, Pfrommer L, et al
    Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).
    J Infect. 2024 Jun 17:106206. doi: 10.1016/j.jinf.2024.106206.
    >> Share

  69. JIANG J, Li Y, Jiang Q, Jiang Y, et al
    Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis.
    J Infect. 2024 Jun 2:106190. doi: 10.1016/j.jinf.2024.106190.
    >> Share

  70. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous boosters for Omicron.
    J Infect. 2024;88:106165.
    >> Share

  71. CAI J, Lai L, Li R, Lin Q, et al
    The H5 subtype of avian influenza virus jumped across species to humans - a view from China.
    J Infect. 2024 Jun 1:106193. doi: 10.1016/j.jinf.2024.106193.
    >> Share

    May 2024
  72. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
    The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials.
    J Infect. 2024;89:106187.
    >> Share

  73. HAN B, Li XM, Li R, Ning W, et al
    Epidemiological Surveillance of Acute Respiratory Infections Based on Targeted Metagenomic Next Generation Sequencing During the Flu Season after COVID-19 Pandemic in Beijing.
    J Infect. 2024 May 22:106188. doi: 10.1016/j.jinf.2024.106188.
    >> Share

  74. YANG X, Li X, Qiu S, Liu C, et al
    Global antimicrobial resistance and antibiotic use in COVID-19 patients within health facilities: a systematic review and meta-analysis of aggregated participant data.
    J Infect. 2024 May 14:106183. doi: 10.1016/j.jinf.2024.106183.
    >> Share

  75. AMANO M, Ichikawa Y, Matsumoto S, Higashi-Kuwata N, et al
    Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccination.
    J Infect. 2024;89:106179.
    >> Share

  76. KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al
    Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177.
    >> Share

  77. HALVORSEN B, Viermyr HK, Ueland T, Sagen EL, et al
    IL-22 is increased in hospitalized patients with COVID-19 and associates with cardiac involvement.
    J Infect. 2024 May 6:106176. doi: 10.1016/j.jinf.2024.106176.
    >> Share

  78. CAINI S, Casalegno JS, Rodrigues AP, Lee V, et al
    Change in Age profile of Respiratory Syncytial Virus disease over the course of annual epidemics: a multi-national study.
    J Infect. 2024;88:106154.
    >> Share

    April 2024
  79. CANE J, Sanderson N, Barnett S, Vaughan A, et al
    Nanopore sequencing of influenza A and B in Oxfordshire and the United Kingdom, 2022-23.
    J Infect. 2024 Apr 29:106164. doi: 10.1016/j.jinf.2024.106164.
    >> Share

  80. CHUN JY, Jeong SJ, Kim S, Choi S, et al
    Performance of the Galactomannan Test for the Diagnosis of Invasive Pulmonary Aspergillosis using Non-invasive Proximal Airway Samples.
    J Infect. 2024 Apr 17:106159. doi: 10.1016/j.jinf.2024.106159.
    >> Share

  81. PINANA M, Gonzalez-Sanchez A, Andres C, Vila J, et al
    Genomic evolution of human respiratory syncytial virus during a decade (2013-2023): bridging the path to monoclonal antibody surveillance.
    J Infect. 2024 Apr 6:106153. doi: 10.1016/j.jinf.2024.106153.
    >> Share

  82. COLSON P, Chaudet H, Delerce J, Pontarotti P, et al
    Role of SARS-CoV-2 mutations in the evolution of the COVID-19 pandemic.
    J Infect. 2024 Apr 1:106150. doi: 10.1016/j.jinf.2024.106150.
    >> Share

    March 2024
  83. GAYLIS NB, Yang OO
    Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC) - The hunt for effective treatments.
    J Infect. 2024 Mar 24:106146. doi: 10.1016/j.jinf.2024.106146.
    >> Share

  84. SALMAN M, Rana MS, Usman M, Tahir M, et al
    Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider booster vaccination strategies.
    J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.
    >> Share

  85. SUN L, Man Q, Zhang H, Xia S, et al
    Strong cross immune responses against sarbecoviruses but not merbecoviruses in SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19 vaccination.
    J Infect. 2024;88:106138.
    >> Share

  86. MORENO-TORRES V, Martinez-Urbistondo M, Calderon-Parra J, de Mendoza C, et al
    COVID-19 Mortality Amongst the Immunosuppresed.
    J Infect. 2024 Mar 11:106137. doi: 10.1016/j.jinf.2024.106137.
    >> Share

  87. FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
    Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: results from a randomized controlled study.
    J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
    >> Share

  88. POWELL AA, Dowell AC, Moss P, Ladhani SN, et al
    Current state of COVID-19 in children: 4 years on.
    J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134.
    >> Share

    February 2024
  89. LIU P, Cai J, Tian H, Li J, et al
    Intra-host genetic diversity of SARS-CoV-2 Omicron variants in children.
    J Infect. 2024 Feb 29:106132. doi: 10.1016/j.jinf.2024.106132.
    >> Share

  90. MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
    AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study.
    J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
    >> Share

  91. HAYWARD G, Yu LM, Little P, Gbinigie O, et al
    Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
    J Infect. 2024 Feb 29:106130. doi: 10.1016/j.jinf.2024.106130.
    >> Share

  92. ZHOU J, Lan L, Ai S, Lin J, et al
    People Living with HIV who have poor immune status are a key population for SARS-CoV-2 prevention.
    J Infect. 2024 Feb 15:106122. doi: 10.1016/j.jinf.2024.106122.
    >> Share

  93. HITES M, Massonnaud CR, Jamard S, Goehringer F, et al
    Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial.
    J Infect. 2024 Feb 15:106120. doi: 10.1016/j.jinf.2024.106120.
    >> Share

  94. YAO Z, Zhang L, Duan Y, Tang X, et al
    Molecular Insights into the Adaptive Evolution of SARS-CoV-2 Spike Protein.
    J Infect. 2024 Feb 15:106121. doi: 10.1016/j.jinf.2024.106121.
    >> Share

  95. KALKERI R, Zhu M, Cloney-Clark S, Plested JS, et al
    Altered IgG4 Antibody Response to Repeated mRNA versus Recombinant Protein SARS-CoV-2 Vaccines.
    J Infect. 2024 Feb 13:106119. doi: 10.1016/j.jinf.2024.106119.
    >> Share

  96. XIE L, Luo G, Yang Z, Wu WC, et al
    The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract.
    J Infect. 2024 Feb 9:S0163-4453(24)00036-7. doi: 10.1016/j.jinf.2024.
    >> Share

  97. HUNG KC, Chen IW, Sun CK
    Pulmonary dysfunction severity may impact optimal dexamethasone dosing in patients with COVID-19.
    J Infect. 2024 Feb 1:S0163-4453(24)00031-8. doi: 10.1016/j.jinf.2024.
    >> Share

    January 2024
  98. LESTON M, Elson W, Ordonez-Mena JM, Kar D, et al
    Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic Review and Meta-analysis for Enhanced Disease Surveillance.
    J Infect. 2024 Jan 30:S0163-4453(24)00028-8. doi: 10.1016/j.jinf.2024.
    >> Share

  99. KE YK, Han XY, Lin SR, Wu HG, et al
    Emergence of a triple reassortment avian influenza virus (A/H5N6) from wild birds.
    J Infect. 2024 Jan 17:S0163-4453(24)00024-0. doi: 10.1016/j.jinf.2024.
    >> Share

  100. MURRAY JM, Murray DD, Schvoerer E, Akand EH, et al
    SARS-CoV-2 Delta and Omicron community transmission networks as added value to contact tracing.
    J Infect. 2024 Jan 17:S0163-4453(24)00023-9. doi: 10.1016/j.jinf.2024.
    >> Share

  101. CORNISH EF, van der Meeren LE, van der Hoorn MP, Schoenmakers S, et al
    Stillbirths due to placental COVID infection associated with chronic histiocytic intervillositis do not recur in subsequent pregnancies.
    J Infect. 2024 Jan 11:S0163-4453(24)00020-3. doi: 10.1016/j.jinf.2024.
    >> Share

  102. ZHANG H, Zhou K, Peng F, Gao Z, et al
    Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency.
    J Infect. 2024 Jan 6:S0163-4453(23)00600-X. doi: 10.1016/j.jinf.2023.
    >> Share

    December 2023
  103. ZONG K, Yuan P, Wang R, Luo Q, et al
    Characteristics of innate, humoral and cellular immunity in children with non-severe SARS-CoV-2 infection.
    J Infect. 2023 Dec 13:S0163-4453(23)00589-3. doi: 10.1016/j.jinf.2023.
    >> Share

  104. FERNANDEZ-DE-LAS-PENAS C, Notarte KI, Macasaet R, Velasco JV, et al
    Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Infect. 2023 Dec 13:S0163-4453(23)00590-X. doi: 10.1016/j.jinf.2023.
    >> Share

  105. STRAHM C, Kahlert CR, Gusewell S, Vuichard-Gysin D, et al
    Evolution of symptoms compatible with post-acute sequelae of SARS-CoV-2 (PASC) after Wild-type and/or Omicron BA.1 infection: A prospective healthcare worker cohort.
    J Infect. 2023 Dec 7:S0163-4453(23)00588-1. doi: 10.1016/j.jinf.2023.
    >> Share

  106. PAN D, Hui DSC, Tang JW
    Defining infection transmission pathways for future pandemic preparedness - An urgent public health research priority.
    J Infect. 2023;87:595-597.
    >> Share

  107. AO G, Li T, Nasr B, Wang Y, et al
    The effect of dupilumab on clinical outcomes in patients with COVID-19: A meta-analysis.
    J Infect. 2023;87:e107-e109.
    >> Share

  108. LIU Y, Sun R, Zhang H, Huang J, et al
    Trends and predictions of tuberculosis notification in mainland China during and after the COVID-19 pandemic.
    J Infect. 2023;87:e100-e103.
    >> Share

    November 2023
  109. PHAN J, Eslick GD, Elliott EJ
    Demystifying the global outbreak of severe acute hepatitis of unknown aetiology in children: A systematic review and meta-analysis.
    J Infect. 2023 Nov 24:S0163-4453(23)00580-7. doi: 10.1016/j.jinf.2023.
    >> Share

  110. GRAU S, Vela JM, Gurt A, Barcelo-Vidal J, et al
    Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients.
    J Infect. 2023 Nov 20:S0163-4453(23)00562-5. doi: 10.1016/j.jinf.2023.
    >> Share

  111. DIEP AN, Schyns J, Gourzones C, Goffin E, et al
    How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity dynamics: an 18-month longitudinal study.
    J Infect. 2023 Nov 17:S0163-4453(23)00558-3. doi: 10.1016/j.jinf.2023.
    >> Share

  112. BRENDISH NJ, Davis C, Chapman ME, Borca F, et al
    Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation.
    J Infect. 2023 Nov 15:S0163-4453(23)00556-X. doi: 10.1016/j.jinf.2023.
    >> Share

  113. LIECHTI FD, Bijlsma MW, Brouwer MC, van Sorge NM, et al
    Impact of the COVID-19 pandemic on incidence and serotype distribution of pneumococcal meningitis - A prospective, nationwide cohort study from the Netherlands.
    J Infect. 2023 Nov 8:S0163-4453(23)00555-8. doi: 10.1016/j.jinf.2023.
    >> Share

  114. HALL VJ, Insalata F, Foulkes S, Kirwan P, et al
    Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
    J Infect. 2023 Nov 3:S0163-4453(23)00553-4. doi: 10.1016/j.jinf.2023.
    >> Share

  115. LUNT R, Quinot C, Kirsebom F, Andrews N, et al
    The Impact of Vaccination and SARS-CoV-2 Variants on the Virological Response to SARS-CoV-2 Infections during the Alpha, Delta, and Omicron waves in England.
    J Infect. 2023 Nov 3:S0163-4453(23)00547-9. doi: 10.1016/j.jinf.2023.
    >> Share

    October 2023
  116. BRUHN M, Obara M, Chiyyeadu A, Costa B, et al
    Memory B cells anticipate SARS-CoV-2 variants through somatic hypermutation.
    J Infect. 2023 Oct 30:S0163-4453(23)00551-0. doi: 10.1016/j.jinf.2023.
    >> Share

  117. JIANG W, Xu L, Wang Y, Hao C, et al
    Exploring immunity debt: Dynamic alterations in RSV antibody levels in children under 5 years during the COVID-19 pandemic.
    J Infect. 2023 Oct 29:S0163-4453(23)00550-9. doi: 10.1016/j.jinf.2023.
    >> Share

  118. JIN Z, Wu J, Wang Y, Huang T, et al
    Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
    J Infect. 2023 Oct 26:S0163-4453(23)00543-1. doi: 10.1016/j.jinf.2023.
    >> Share

  119. HA L, Levian C, Greene N, Goldfarb I, et al
    Association between acceptance of routine pregnancy vaccinations and COVID-19 vaccine uptake in pregnant patients.
    J Infect. 2023 Oct 19:S0163-4453(23)00541-8. doi: 10.1016/j.jinf.2023.
    >> Share

  120. MARJANEH MM, Challenger JD, Salas A, Gomez-Carballa A, et al
    Analysis of blood and nasal epithelial transcriptomes to identify mechanisms associated with control of SARS-CoV-2 viral load in the upper respiratory tract.
    J Infect. 2023 Oct 18:S0163-4453(23)00540-6. doi: 10.1016/j.jinf.2023.
    >> Share

  121. FENWICK C, Turelli P, Duhoo Y, Lau K, et al
    Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys.
    J Infect. 2023 Oct 16:S0163-4453(23)00539-X. doi: 10.1016/j.jinf.2023.
    >> Share

  122. LU XM, Feng XY, Wu Y, Wen CB, et al
    Genetic characterization of a novel H5N6 subtype highly pathogenic avian influenza virus from goose in China.
    J Infect. 2023 Oct 12:S0163-4453(23)00533-9. doi: 10.1016/j.jinf.2023.
    >> Share

  123. BEARD KR, Borca F, Phan H, Brown E, et al
    Routine, molecular point-of-care testing for SARS-CoV-2 and other respiratory viruses within an acute oncology service improves patient care.
    J Infect. 2023 Oct 4:S0163-4453(23)00514-5. doi: 10.1016/j.jinf.2023.
    >> Share

  124. TIAN S, Liu T, Zhao XJ, Liu XL, et al
    Neutralization against emerging Omicron subvariants after SARS-CoV-2 reinfection.
    J Infect. 2023 Oct 4:S0163-4453(23)00515-7. doi: 10.1016/j.jinf.2023.
    >> Share

    September 2023
  125. VELLAS C, Latour J, Tremeaux P, Ranger N, et al
    Molecular Evolution of Omicron Variant in Immunocompromised Individuals with Chronic SARS-CoV-2 Infection.
    J Infect. 2023 Sep 30:S0163-4453(23)00513-3. doi: 10.1016/j.jinf.2023.
    >> Share

  126. ANTONELLI M, Penfold RS, Canas LDS, Sudre C, et al
    SARS-CoV-2 infection following booster vaccination: illness and symptom profile in a prospective, observational community-based case-control study.
    J Infect. 2023 Sep 28:S0163-4453(23)00461-9. doi: 10.1016/j.jinf.2023.
    >> Share

  127. GAO Y, Zhang Y, Mou K, Man S, et al
    Alterations in the outer retina and choroid in patients after COVID-19 infection.
    J Infect. 2023 Sep 27:S0163-4453(23)00512-1. doi: 10.1016/j.jinf.2023.
    >> Share

  128. YAMAMOTO S, Mizoue T, Konishi M, Oshiro Y, et al
    Kinetics and durability of nucleocapsid-specific antibodies after SARS-CoV-2 reinfection.
    J Infect. 2023 Sep 26:S0163-4453(23)00511-X. doi: 10.1016/j.jinf.2023.
    >> Share

  129. SNOW TAC, Arulkumaran N, Singer M, Choi SH, et al
    Effect of dexamethasone dose on outcomes in acute COVID-19 disease: a systematic review and meta-analysis.
    J Infect. 2023 Sep 25:S0163-4453(23)00510-8. doi: 10.1016/j.jinf.2023.
    >> Share

  130. MATSUO OM, Lindoso L, Sousa Marques HH, Polanczyk GV, et al
    Mental health among children and adolescents after SARS-CoV-2 infection: a prospective study in a tertiary university hospital.
    J Infect. 2023 Sep 20:S0163-4453(23)00507-8. doi: 10.1016/j.jinf.2023.
    >> Share

  131. ALPIZAR SA, Accini J, Anderson DC, Eysa B, et al
    Molnupiravir for Intra-Household Prevention of COVID-19: the MOVe-AHEAD Randomized, Placebo-Controlled Trial.
    J Infect. 2023 Sep 8:S0163-4453(23)00500-5. doi: 10.1016/j.jinf.2023.
    >> Share

  132. CHEN JM, Tan SM, Chen RX, Gong HY, et al
    Distribution and risks of the infections of humans and other mammals with H5 subtype highly pathogenic avian influenza viruses in 2020-2023.
    J Infect. 2023 Sep 7:S0163-4453(23)00505-4. doi: 10.1016/j.jinf.2023.
    >> Share

  133. CLARK SA, Campbell H, Ribeiro S, Bertran M, et al
    Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England.
    J Infect. 2023 Sep 7:S0163-4453(23)00504-2. doi: 10.1016/j.jinf.2023.
    >> Share

  134. DOWELL AC, Tut G, Begum J, Bruton R, et al
    Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection.
    J Infect. 2023 Sep 1:S0163-4453(23)00465-6. doi: 10.1016/j.jinf.2023.
    >> Share

    August 2023
  135. GUAN X, Huang Q, Dong M, Li M, et al
    SARS-CoV-2-specific antibody and T-cell immunity in convalescents after infection wave in Beijing in late 2022.
    J Infect. 2023 Aug 29:S0163-4453(23)00462-0. doi: 10.1016/j.jinf.2023.
    >> Share

  136. WHITAKER HJ, Tsang RS, Byford R, Aspden C, et al
    COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study.
    J Infect. 2023 Aug 12:S0163-4453(23)00456-5. doi: 10.1016/j.jinf.2023.
    >> Share

  137. WAGENHAUSER I, Mees J, Reusch J, Lam TT, et al
    Determinants of Influenza A Infection Rate in Post-COVID-19 Era.
    J Infect. 2023 Aug 9:S0163-4453(23)00455-3. doi: 10.1016/j.jinf.2023.
    >> Share

  138. FAUSTINI SE, Cook A, Hill H, Al-Taei S, et al
    Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination.
    J Infect. 2023 Aug 3:S0163-4453(23)00439-5. doi: 10.1016/j.jinf.2023.
    >> Share

    July 2023
  139. YAO XY, Lian CY, Lv ZH, Zhang XL, et al
    Emergence of a novel reassortant H5N6 subtype highly pathogenic avian influenza virus in farmed dogs in China.
    J Infect. 2023 Jul 26:S0163-4453(23)00386-9. doi: 10.1016/j.jinf.2023.
    >> Share

  140. SUN B, Gao F
    Investigation of escape mechanisms of SARS-CoV-2 Omicron sub-lineages and exploration of potential antibodies for XBB.1.
    J Infect. 2023 Jul 26:S0163-4453(23)00387-0. doi: 10.1016/j.jinf.2023.
    >> Share

  141. PIERANGELI A, Nenna R, Fracella M, Scagnolari C, et al
    Genetic diversity and its impact on disease severity in respiratory syncytial virus subtype-A and -B bronchiolitis before and after pandemic restrictions in Rome.
    J Infect. 2023 Jul 24:S0163-4453(23)00381-X. doi: 10.1016/j.jinf.2023.
    >> Share

  142. THEODOSIOU AA, Read RC
    Artificial Intelligence, Machine Learning and Deep Learning: Potential Resources for the Infection Clinician.
    J Infect. 2023 Jul 17:S0163-4453(23)00379-1. doi: 10.1016/j.jinf.2023.
    >> Share

  143. KAMBOJ M, Laracy JC, Usiak S, Babady NE, et al
    Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants.
    J Infect. 2023 Jul 13:S0163-4453(23)00378-X. doi: 10.1016/j.jinf.2023.
    >> Share

  144. FEELISCH M, Clark AD, Cumpstey AF, Santolini J, et al
    Long COVID: Potential role of the Reactive Species Interactome.
    J Infect. 2023 Jul 11:S0163-4453(23)00376-6. doi: 10.1016/j.jinf.2023.
    >> Share

  145. RISSMANN M, Veldhuis Kroeze EJB, Tielens AGM, Rockx B, et al
    Influence of a chronic Schistosoma mansoni infection on the outcomes of a SARS-CoV-2 infection in the hamster model.
    J Infect. 2023 Jul 5:S0163-4453(23)00374-2. doi: 10.1016/j.jinf.2023.
    >> Share

  146. BAYHAN GI, Guner R, Yahsi A, Ozkul A, et al
    Evaluation of the neutralizing antibody response against the omicron variant produced by heterologous or hybrid immunity: How does the fifth dose of COVID-19 vaccine affect the neutralizing antibody response?
    J Infect. 2023 Jul 4:S0163-4453(23)00369-9. doi: 10.1016/j.jinf.2023.
    >> Share

  147. TAUCHER C, Lazarus R, Dellago H, Maurer G, et al
    Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COM
    J Infect. 2023 Jul 3:S0163-4453(23)00367-5. doi: 10.1016/j.jinf.2023.
    >> Share

    June 2023
  148. VARASI I, Lai A, Fiaschi L, Bergna A, et al
    Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination.
    J Infect. 2023 Jun 30:S0163-4453(23)00342-0. doi: 10.1016/j.jinf.2023.
    >> Share

  149. WU JY, Hsu WH, Tsai YW, Liu TH, et al
    The association between zinc deficiency, and clinical outcomes of COVID-19.
    J Infect. 2023 Jun 29:S0163-4453(23)00343-2. doi: 10.1016/j.jinf.2023.
    >> Share

  150. DOWELL AC, Waiblinger D, Wright J, Ladhani SN, et al
    Nucleocapsid-Specific Antibodies as a Correlate of Protection against SARS-CoV-2 Reinfection in Children.
    J Infect. 2023 Jun 28:S0163-4453(23)00340-7. doi: 10.1016/j.jinf.2023.
    >> Share

  151. SU HC, Lai ZL, Chang YC, Cheng MY, et al
    Genomic characteristics of SARS-CoV-2 variants and their clinical impact on patients with COVID-19 in Taiwan.
    J Infect. 2023 Jun 27:S0163-4453(23)00341-9. doi: 10.1016/j.jinf.2023.
    >> Share

  152. HAGIYA H, Osaki Y, Yamamoto M, Niimura T, et al
    Global trends of seasonal influenza-associated mortality in 2001-2018: A longitudinal epidemiological study.
    J Infect. 2023 Jun 16:S0163-4453(23)00334-1. doi: 10.1016/j.jinf.2023.
    >> Share

  153. KELLY E, Greenland M, de Whalley PCS, Aley PK, et al
    Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial.
    J Infect. 2023 Jun 16:S0163-4453(23)00330-4. doi: 10.1016/j.jinf.2023.
    >> Share

  154. STANKUNAS M, Dziugys A, Skarbalius G, Misiulis E, et al
    AUTHORS' REPLY TO A COMMENTARY ON THE POTENTIAL IMPACT OF COVID-19 PASSPORTS TO EPIDEMIOLOGICAL SITUATION.
    J Infect. 2023 Jun 15:S0163-4453(23)00333-X. doi: 10.1016/j.jinf.2023.
    >> Share

  155. FALLET B, Foglierini M, Porret R, Alcaraz A, et al
    Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
    J Infect. 2023 Jun 13:S0163-4453(23)00329-8. doi: 10.1016/j.jinf.2023.
    >> Share

  156. BISHARAT N, Campisi-Pinto S
    Determinants of reinfection with SARS-CoV-2 Omicron variant.
    J Infect. 2023 Jun 9:S0163-4453(23)00325-0. doi: 10.1016/j.jinf.2023.
    >> Share

  157. CAI J, Ruan J, Lin Q, Ren T, et al
    China faces the challenge of influenza A virus, including H3N8, in the post-COVID-19 era.
    J Infect. 2023 Jun 7:S0163-4453(23)00324-9. doi: 10.1016/j.jinf.2023.
    >> Share

  158. MOHN KG, Bredholt G, Onyango TB, Brokstad KA, et al
    SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity.
    J Infect. 2023 Jun 7:S0163-4453(23)00302-X. doi: 10.1016/j.jinf.2023.
    >> Share

  159. PASCALL DJ, Vink E, Blacow R, Bulteel N, et al
    Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent.
    J Infect. 2023 Jun 1:S0163-4453(23)00297-9. doi: 10.1016/j.jinf.2023.
    >> Share

    May 2023
  160. LIU P, Cheng F, Su L, Ye Z, et al
    An outbreak of influenza A in Shanghai after ending the zero-COVID policy in February-March 2023.
    J Infect. 2023 May 27:S0163-4453(23)00301-8. doi: 10.1016/j.jinf.2023.
    >> Share

  161. NG RW, Sze RK, Chong KC, Zhao S, et al
    Effectiveness of mRNA and inactivated COVID-19 vaccines: a test-negative study in an infection-naive Hong Kong population.
    J Infect. 2023 May 26:S0163-4453(23)00298-0. doi: 10.1016/j.jinf.2023.
    >> Share

  162. ZHAO T, Li Y, Xu M, Wang W, et al
    High proportion of H3 avian influenza virus circulating in chickens-an increasing threat to public health.
    J Infect. 2023 May 24:S0163-4453(23)00296-7. doi: 10.1016/j.jinf.2023.
    >> Share

  163. FAVRESSE J, Cabo J, Douxfils J
    Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infection.
    J Infect. 2023 May 19:S0163-4453(23)00292-X. doi: 10.1016/j.jinf.2023.
    >> Share

  164. DIAN Y, Meng Y, Sun Y, Deng G, et al
    Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities.
    J Infect. 2023 May 17:S0163-4453(23)00290-6. doi: 10.1016/j.jinf.2023.
    >> Share

  165. NAOURI D, Pham T, Dres M, Vuagnat A, et al
    Differences in clinical characteristics and outcomes between COVID-19 and influenza in critically ill adult patients: a national database study.
    J Infect. 2023 May 16:S0163-4453(23)00289-X. doi: 10.1016/j.jinf.2023.
    >> Share

  166. ZHONG X, Pate A, Yang YT, Fahmi A, et al
    The impact of COVID -19 on antibiotic prescribing in primary care in England: evaluation and risk prediction of appropriateness of type and repeat prescribing.
    J Infect. 2023 May 12:S0163-4453(23)00288-8. doi: 10.1016/j.jinf.2023.
    >> Share

  167. PINANA M, Gonzalez-Sanchez A, Andres C, Abanto M, et al
    The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain.
    J Infect. 2023 May 11:S0163-4453(23)00262-1. doi: 10.1016/j.jinf.2023.
    >> Share

  168. LV W, He J, Shao J, Chen Y, et al
    Causal relationships between short-chain fatty acids and L-isoleucine biosynthesis and susceptibility and severity of COVID-19: Evidence from Mendelian randomization.
    J Infect. 2023 May 5:S0163-4453(23)00258-X. doi: 10.1016/j.jinf.2023.
    >> Share

  169. GAO M, Ao G, Hao X, Xie B, et al
    Casirivimab-Imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis.
    J Infect. 2023 May 3:S0163-4453(23)00256-6. doi: 10.1016/j.jinf.2023.
    >> Share

    April 2023
  170. XU J, Mao D, Liang P, Du P, et al
    Undetectable intrauterine transmission during the first trimester of pregnancy in woman after COVID-19 infection.
    J Infect. 2023 Apr 26:S0163-4453(23)00255-4. doi: 10.1016/j.jinf.2023.
    >> Share

  171. AWAN UA, Hussain M, Qureshi M, Siddique Z, et al
    From COVID-19 to Measles: Prioritizing Immunization in Pakistan's Far-Flung Regions.
    J Infect. 2023 Apr 26:S0163-4453(23)00253-0. doi: 10.1016/j.jinf.2023.
    >> Share

  172. ZHOU Y, Yan H, Zhou Q, Feng R, et al
    Impact of COVID-19 control measures on Legionella pneumophila infections in children in Henan, China.
    J Infect. 2023 Apr 26:S0163-4453(23)00254-2. doi: 10.1016/j.jinf.2023.
    >> Share

  173. AZIZ NA, Nash SG, Zaidi A, Nyberg T, et al
    Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England.
    J Infect. 2023 Apr 24:S0163-4453(23)00249-9. doi: 10.1016/j.jinf.2023.
    >> Share

  174. FURUSE Y
    Estimation of excess cardiovascular deaths after COVID-19 in 2020.
    J Infect. 2023 Apr 24:S0163-4453(23)00251-7. doi: 10.1016/j.jinf.2023.
    >> Share

  175. LIU X, Munro APS, Wright A, Feng S, et al
    Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    J Infect. 2023 Apr 19:S0163-4453(23)00247-5. doi: 10.1016/j.jinf.2023.
    >> Share

  176. LUO J, Li A, Liu C, Wang Y, et al
    The effect of bebtelovimab on clinical outcomes in patients with COVID-19: a meta-analysis.
    J Infect. 2023 Apr 19:S0163-4453(23)00210-4. doi: 10.1016/j.jinf.2023.
    >> Share

  177. WEN F, Chen G, Guo J, Guan M, et al
    Identification of a duck H9N2 influenza virus possessing tri-basic hemagglutinin cleavage sites genetically close to the human H9N2 isolates in China, 2022.
    J Infect. 2023 Apr 17:S0163-4453(23)00207-4. doi: 10.1016/j.jinf.2023.
    >> Share

  178. PIGHI L, Henry BM, De Nitto S, Salvagno GL, et al
    Cellular immunity against SARS-CoV-2 depends on the serological status.
    J Infect. 2023 Apr 13:S0163-4453(23)00203-7. doi: 10.1016/j.jinf.2023.
    >> Share

  179. TEYSSOU E, Marot S, Gothland A, Malet I, et al
    SARS-CoV-2 variant-dependent inflammasome activation.
    J Infect. 2023 Apr 13:S0163-4453(23)00205-0. doi: 10.1016/j.jinf.2023.
    >> Share

  180. MORRISON H, Perrin F, Dedicoat M, Ahmed R, et al
    Impact of COVID-19 on NHS Tuberculosis Services: Results of a UK-wide survey.
    J Infect. 2023 Apr 10:S0163-4453(23)00204-9. doi: 10.1016/j.jinf.2023.
    >> Share

  181. SHAW RH, Greenland M, Stuart AS, Aley PK, et al
    Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
    J Infect. 2023 Apr 5:S0163-4453(23)00199-8. doi: 10.1016/j.jinf.2023.
    >> Share

  182. ZHAO D, Yi H, Dian Y, Meng Y, et al
    Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients.
    J Infect. 2023 Apr 3:S0163-4453(23)00200-1. doi: 10.1016/j.jinf.2023.
    >> Share

  183. CHEN H, Zhang L, Zhang Y, Chen G, et al
    Prevalence and clinical features of long COVID from omicron infection in children and adults.
    J Infect. 2023;86:e97-e99.
    >> Share

    March 2023
  184. GAO Y, Luo Z, Ren S, Duan Z, et al
    Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19.
    J Infect. 2023 Mar 30:S0163-4453(23)00192-5. doi: 10.1016/j.jinf.2023.
    >> Share

  185. KELLENI MT
    SARS CoV-2 Genetic Jump to a New SARS CoV-3 Pandemic: Let's Be Prepared.
    J Infect. 2023 Mar 21:S0163-4453(23)00147-0. doi: 10.1016/j.jinf.2023.
    >> Share

  186. NAMGUNG SH, Jung J, Kim SK, Kim EO, et al
    Incidence of tuberculosis infection in healthcare workers in high-risk departments for tuberculosis after universal wearing of KF94 mask during COVID-19 pandemic.
    J Infect. 2023 Mar 21:S0163-4453(23)00146-9. doi: 10.1016/j.jinf.2023.
    >> Share

  187. HSU WH, Shiau BW, Tsai YW, Wu JY, et al
    The effect of molnupiravir on post-acute outcome of COVID-19 survivors.
    J Infect. 2023 Mar 21:S0163-4453(23)00145-7. doi: 10.1016/j.jinf.2023.
    >> Share

  188. DANIAL-FARRAN N, Khlaila M, Avraham-Kelbert M, Chazan B, et al
    Genetic Variant in Complement Receptor 1 (CR1, CD35) is Associated with A Cluster of Severe Fatal COVID-19 in a Family.
    J Infect. 2023 Mar 14:S0163-4453(23)00143-3. doi: 10.1016/j.jinf.2023.
    >> Share

  189. CLARK TW, Lindsley K, Wigmosta TB, Bhagat A, et al
    Rapid Multiplex PCR for Respiratory Viruses Reduces Time to Result and Improves Clinical Care: Results of a Systematic Review and Meta-Analysis.
    J Infect. 2023 Mar 9:S0163-4453(23)00134-2. doi: 10.1016/j.jinf.2023.
    >> Share

  190. SHAO JW, Zhang XL, Sun J, Liu H, et al
    Infection of wild rats with H5N6 subtype highly pathogenic avian influenza virus in China.
    J Infect. 2023 Mar 7:S0163-4453(23)00136-6. doi: 10.1016/j.jinf.2023.
    >> Share

  191. WANG H, Liu Y, Li P, Liu C, et al
    Emergence of epidemic variants of SARS-CoV-2 by acquiring combinations of new highly mutable nucleotides in its genome.
    J Infect. 2023 Mar 6:S0163-4453(23)00133-0. doi: 10.1016/j.jinf.2023.
    >> Share

  192. QUILES-JIMENEZ A, Sousa M, Huse C, Dyrhol-Riise AM, et al
    Severely-ill COVID-19 patients have altered circulating levels of proteins controlling the epitranscriptome.
    J Infect. 2023 Mar 6:S0163-4453(23)00132-9. doi: 10.1016/j.jinf.2023.
    >> Share

  193. SIVAKUMARAN S, Alsallakh MA, Lyons RA, Quint JK, et al
    Estimating the contribution of respiratory pathogens to acute exacerbations of COPD using routine data.
    J Infect. 2023;86:233-238.
    >> Share

  194. LIU P, Xu J
    Genomic surveillance of SARS-CoV-2 in mainland China after ending the zero-COVID policy, December 2022 - January 2023.
    J Infect. 2023 Mar 1:S0163-4453(23)00127-5. doi: 10.1016/j.jinf.2023.
    >> Share

    February 2023
  195. SCARPA F, Imperia E, Azzena I, Giovanetti M, et al
    Genetic and structural genome-based survey reveals the low potential for epidemiological expansion of the SARS-CoV-2 XBB.1.5 sublineage.
    J Infect. 2023 Feb 28:S0163-4453(23)00126-3. doi: 10.1016/j.jinf.2023.
    >> Share

  196. SHAVA E, Izu A, Gaolathe T, Walker A, et al
    Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.
    J Infect. 2023 Feb 28:S0163-4453(23)00123-8. doi: 10.1016/j.jinf.2023.
    >> Share

  197. DENG Y, Han S, Liu J, Guo L, et al
    The risks of death and hospitalizations associated with SARS-CoV-2 Omicron declined after lifting testing and quarantining measures.
    J Infect. 2023 Feb 27:S0163-4453(23)00118-4. doi: 10.1016/j.jinf.2023.
    >> Share

  198. ZHOU P, Gong F, Ji T, Cao C, et al
    Enriched CXCR3(+) CXCR5(+) CD8(+) T cells in SARS-CoV-2 infected and vaccinated individuals effectively respond to the antigen in recall.
    J Infect. 2023 Feb 23:S0163-4453(23)00109-3. doi: 10.1016/j.jinf.2023.
    >> Share

  199. GUO H, Zhao T
    Multiple mutations of IFITM3 are associated with COVID-19 susceptibility.
    J Infect. 2023 Feb 23:S0163-4453(23)00120-2. doi: 10.1016/j.jinf.2023.
    >> Share

  200. YANG F, Zhang N, Meng R, Wang K, et al
    Non-causal Association of COVID-19 with Systemic Lupus Erythematosus: Evidence from a Bidirectional Mendelian RandomizationRunning title: Association of COVID-19 with SLE.
    J Infect. 2023 Feb 21:S0163-4453(23)00115-9. doi: 10.1016/j.jinf.2023.
    >> Share

  201. UELAND T, Aikas LAO, Dahl TB, Gregersen I, et al
    Low-Density Lipoprotein Particles Carrying Proinflammatory Proteins with Altered Aggregation Pattern Detected in COVID-19 Patients 3 Months After HospitalizationRunning title: Low-Density Lipoprotein Particles in COVID-19 Patients.
    J Infect. 2023 Feb 21:S0163-4453(23)00111-1. doi: 10.1016/j.jinf.2023.
    >> Share

  202. PUTRI DU, Huang CK, Ou TY, Lin CF, et al
    Persistent dysregulation of cellular immunity following COVID-19 recovery despite minimal post-COVID-19 sequelae manifestationRunning title: Occult post-COVID immune dysregulation.
    J Infect. 2023 Feb 21:S0163-4453(23)00112-3. doi: 10.1016/j.jinf.2023.
    >> Share

  203. ZHANG K, Chen R, Jiang Q
    Allopurinol Increased the Risk of COVID-19 Hospitalization Mediated by E-Selectin Downregulation.
    J Infect. 2023 Feb 21:S0163-4453(23)00116-0. doi: 10.1016/j.jinf.2023.
    >> Share

  204. MEI R, Kwok SLL, Lau EHY, Lo THK, et al
    Battle of Polio eradication in the Western Pacific Region in the transition to COVID-19 endemicity.
    J Infect. 2023 Feb 21:S0163-4453(23)00113-5. doi: 10.1016/j.jinf.2023.
    >> Share

  205. WAN EYF, Wang B, Mathur S, Chan CIY, et al
    Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase.
    J Infect. 2023 Feb 21:S0163-4453(23)00117-2. doi: 10.1016/j.jinf.2023.
    >> Share

  206. VALENTINI D, Carfi A, Di Paola A, Yarci-Carrion A, et al
    Factor associated with SARS-CoV-2 vaccination serological efficacy in adolescents and adults with Down syndrome: data from an international, collaborative initiative of the Trisomy 21 Research SocietyRUNNING TITLE: Factors determining COVID-19 vaccine
    J Infect. 2023 Feb 20:S0163-4453(23)00090-7. doi: 10.1016/j.jinf.2023.
    >> Share

  207. POWELL AA, Ireland G, Leeson R, Lacey A, et al
    National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021.
    J Infect. 2023 Feb 15:S0163-4453(23)00085-3. doi: 10.1016/j.jinf.2023.
    >> Share

  208. BIRD PW, Pan D, Martin CA, Gogoi M, et al
    Awareness of HIV, Hepatitis B, Hepatitis C, Tuberculosis and COVID-19 in Migrant Students in the UK - A Pilot Survey from an Institute of Higher Education.
    J Infect. 2023 Feb 14:S0163-4453(23)00086-5. doi: 10.1016/j.jinf.2023.
    >> Share

  209. ZHANG W, Sun M, Zhang P, Liang Y, et al
    Epidemiological characteristics of Cytomegalovirus infection in children before and after the COVID-19 pandemic in Henan, China, 2016 - 2022.
    J Infect. 2023 Feb 10:S0163-4453(23)00081-6. doi: 10.1016/j.jinf.2023.
    >> Share

  210. MENG R, Zhang N, Yang F, Xu Z, et al
    Blood Transcriptome Analysis Revealed the Crosstalk Between Severe COVID-19 and Systemic Lupus Erythematosus.
    J Infect. 2023 Feb 10:S0163-4453(23)00080-4. doi: 10.1016/j.jinf.2023.
    >> Share

  211. LI L, Jia R, Zhang Y, Sun H, et al
    Changes of parainfluenza virus infection in children before and after the COVID-19 pandemic in Henan, China.
    J Infect. 2023 Feb 9:S0163-4453(23)00078-6. doi: 10.1016/j.jinf.2023.
    >> Share

  212. HSU WH, Tsai YW, Wu JY, Liu TH, et al
    Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors.
    J Infect. 2023 Feb 9:S0163-4453(23)00076-2. doi: 10.1016/j.jinf.2023.
    >> Share

  213. EVANS A, Qi C, Adebayo JO, Underwood J, et al
    Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study.
    J Infect. 2023 Feb 9:S0163-4453(23)00082-8. doi: 10.1016/j.jinf.2023.
    >> Share

  214. LI L, Song X, Sun H, Ma J, et al
    Changes of pathogen distribution in children with wound infections before and after the COVID-19 pandemic in Henan, China.
    J Infect. 2023 Feb 9:S0163-4453(23)00079-8. doi: 10.1016/j.jinf.2023.
    >> Share

  215. HU S, Zhang S, You Y, Tang J, et al
    Olfactory dysfunction after COVID-19; metanalysis reveals persistence in one third of patients six months after initial infection.
    J Infect. 2023 Feb 9:S0163-4453(23)00068-3. doi: 10.1016/j.jinf.2023.
    >> Share

  216. LI R, Wang M, Li D, Zhang Y, et al
    The impact of the COVID-19 pandemic on the number of hand, foot, and mouth disease due to enterovirus 71 infections.
    J Infect. 2023 Feb 8:S0163-4453(23)00075-0. doi: 10.1016/j.jinf.2023.
    >> Share

  217. CAILLARD S, Laugel E, Benotmane I, Kremer SF, et al
    Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding.
    J Infect. 2023 Feb 8:S0163-4453(23)00070-1. doi: 10.1016/j.jinf.2023.
    >> Share

  218. GRAY EJ, Nguyen-Van-Tam JS
    Molnupiravir for SARS-CoV-2 infection: Public health and policy implications.
    J Infect. 2023;86:121-122.
    >> Share

    January 2023
  219. AMANO M, Ichikawa Y, Uemura Y, Matsumoto S, et al
    Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines.
    J Infect. 2023 Jan 31:S0163-4453(23)00066-X. doi: 10.1016/j.jinf.2023.
    >> Share

  220. LIANG J, Liu R, He W, Zeng Z, et al
    70% COVID-19 infection within three weeks in the population of Macao, China.
    J Infect. 2023 Jan 30:S0163-4453(23)00035-X. doi: 10.1016/j.jinf.2023.
    >> Share

  221. CHANG YH, Liu TH, Wu JY, Lai CC, et al
    The association between corticosteroids and aspergillosis among COVID-19 patients.
    J Infect. 2023 Jan 27:S0163-4453(23)00055-5. doi: 10.1016/j.jinf.2023.
    >> Share

  222. RANA MS, Usman M, Alam MM, Tahir M, et al
    The emergence of Mumps after the COVID-19 Pandemic in Pakistan: time to consider MMR vaccination strategies.
    J Infect. 2023 Jan 26:S0163-4453(23)00057-9. doi: 10.1016/j.jinf.2023.
    >> Share

  223. NISAR MI, Ansari N, Malik AA, Shahid S, et al
    Assessing the effectiveness of COVID-19 vaccines in Pakistan: a test-negative case-control study.
    J Infect. 2023 Jan 25:S0163-4453(23)00021-X. doi: 10.1016/j.jinf.2023.
    >> Share

  224. HANI E, Bertran M, Powell A, Williams H, et al
    Significantly lower infection fatality rates associated with SARS-CoV-2 Omicron (B.1.1.529) infection in children and young people: active, prospective national surveillance, January-March 2022, England.
    J Infect. 2023 Jan 24:S0163-4453(23)00037-3. doi: 10.1016/j.jinf.2023.
    >> Share

  225. GENTRY CA, Nguyen P, Thind SK, Kurdgelashvili G, et al
    Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    J Infect. 2023 Jan 23:S0163-4453(23)00023-3. doi: 10.1016/j.jinf.2023.
    >> Share

  226. KELLENI MT
    Evolution of SARS CoV-2 Omicron Subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID Restrictions.
    J Infect. 2023 Jan 23:S0163-4453(23)00030-0. doi: 10.1016/j.jinf.2023.
    >> Share

  227. WU JY, Liu TH, Huang PY, Tsai YW, et al
    The effect of zinc on the outcome of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    J Infect. 2023 Jan 21:S0163-4453(23)00028-2. doi: 10.1016/j.jinf.2023.
    >> Share

  228. ZHAN H, Yang L, Liu Y, Li H, et al
    Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.
    J Infect. 2023 Jan 21:S0163-4453(23)00034-8. doi: 10.1016/j.jinf.2023.
    >> Share

  229. LIU X, Lv Z, Wang J, Zhou Y, et al
    IL1RA Mediated the Effects of Aspirin on Covid-19 severity: a Mendelian Randomization Study.
    J Infect. 2023 Jan 20:S0163-4453(23)00031-2. doi: 10.1016/j.jinf.2023.
    >> Share

  230. LIANG Y, Hou L, Hou G, Zhang X, et al
    The influences of the COVID-19 pandemic on Epstein-Barr virus infection in children, Henan, China.
    J Infect. 2023 Jan 20:S0163-4453(23)00026-9. doi: 10.1016/j.jinf.2023.
    >> Share

  231. SALTO-ALEJANDRE S, Carretero-Ledesma M, Camacho-Martinez P, Berastegui-Cabrera J, et al
    Serum IFN-gamma and RNAemia temporal profiles as biomarkers of severe COVID-19 in solid organ transplant and immunocompetent patients.
    J Infect. 2023 Jan 20:S0163-4453(23)00024-5. doi: 10.1016/j.jinf.2023.
    >> Share

  232. KANG SW, Kim JW, Kim JY, Lim SY, et al
    Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study.
    J Infect. 2023 Jan 19:S0163-4453(23)00029-4. doi: 10.1016/j.jinf.2023.
    >> Share

  233. RANA MS, Usman M, Alam MM, Tahir M, et al
    Changes in the prevalence of infectious diseases before and after the COVID-19 pandemic in Pakistan.
    J Infect. 2023 Jan 19:S0163-4453(23)00025-7. doi: 10.1016/j.jinf.2023.
    >> Share

  234. RU X, Chen S, Zhang T, Ding Z, et al
    Nonpharmaceutical intervention is an effective measure to block respiratory virus coinfections with SARS-CoV-2.
    J Infect. 2023 Jan 18:S0163-4453(23)00018-X. doi: 10.1016/j.jinf.2023.
    >> Share

  235. SHAH RA, Mentzer AJ, James T, Cox S, et al
    A novel near-patient host-protein score predicts COVID-19 deterioration at presentation to secondary care.
    J Infect. 2023 Jan 18:S0163-4453(23)00022-1. doi: 10.1016/j.jinf.2023.
    >> Share

  236. KANG SW, Park H, Kim JY, Lim SY, et al
    Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study.
    J Infect. 2023 Jan 18:S0163-4453(23)00020-8. doi: 10.1016/j.jinf.2023.
    >> Share

  237. LIU TH, Wu JY, Huang PY, Tsai YW, et al
    The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients.
    J Infect. 2023 Jan 14:S0163-4453(23)00017-8. doi: 10.1016/j.jinf.2023.
    >> Share

  238. REACHER M, Warne B, Verlander NQ, Popay A, et al
    Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,064 patients hospitalised during the 2016-17 and 2017-18 influenza seasons.
    J Infect. 2023 Jan 13:S0163-4453(23)00003-8. doi: 10.1016/j.jinf.2023.
    >> Share

  239. LI X, Li T, Chen N, Kang P, et al
    Changes of Mycoplasma pneumoniae infection in children before and after COVID-19 pandemic in Henan, China.
    J Infect. 2023 Jan 13:S0163-4453(23)00012-9. doi: 10.1016/j.jinf.2022.
    >> Share

  240. TSAI YW, Tsai CF, Wu JY, Huang PY, et al
    The risk of methicillin-resistant Staphylococcus aureus infection following COVID-19 and influenza: A retrospective cohort study from the TriNetX network.
    J Infect. 2023 Jan 9:S0163-4453(23)00007-5. doi: 10.1016/j.jinf.2023.
    >> Share

  241. DING X, Liang H, Qi X, Sun G, et al
    Changes of Klebsiella pneumoniae infection and carbapenem resistance in ICU elderly infected patients before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2023 Jan 9:S0163-4453(23)00009-9. doi: 10.1016/j.jinf.2023.
    >> Share

  242. XU J, Wang Y, Duan G, Liu F, et al
    Impact of non-pharmaceutical interventions during COVID-19 pandemic on measles and mumps in mainland China.
    J Infect. 2023 Jan 9:S0163-4453(23)00008-7. doi: 10.1016/j.jinf.2023.
    >> Share

  243. PATIL S, Chen H, Dong S, Liu S, et al
    Klebsiella pneumoniae infection in the paediatric population before and after the COVID-19 pandemic in Shenzhen, China.
    J Infect. 2023 Jan 8:S0163-4453(23)00004-X. doi: 10.1016/j.jinf.2023.
    >> Share

  244. LI Y, Liang H, Ding X, Cao Y, et al
    Effectiveness of COVID-19 vaccine in children and adolescents with the Omicron variant: A systematic review and meta-analysis.
    J Infect. 2023 Jan 6:S0163-4453(23)00001-4. doi: 10.1016/j.jinf.2023.
    >> Share

  245. YU Z, Xu S, Li L, Li M, et al
    Changes of Cytomegalovirus infection in neonates before and after the COVID19 pandemic in Zhengzhou, China.
    J Infect. 2023 Jan 5:S0163-4453(23)00002-6. doi: 10.1016/j.jinf.2023.
    >> Share

  246. ZHAO S, Sha T, Xue Y, Chen H, et al
    Flattening the Curve is Imperative: When China Relaxes the Dynamic Zero COVID-19 Policy.
    J Infect. 2023 Jan 2:S0163-4453(22)00748-4. doi: 10.1016/j.jinf.2022.
    >> Share

  247. PEGORARO F, Barbati F, Pisano L, Moriondo M, et al
    Pre-admission RT-qPCR based RSV screening reduces nosocomial RSV infections during epidemic outbreaks.
    J Infect. 2023;86:66-117.
    >> Share

  248. HIROTSU Y, Omata M
    Detection of the Omicron BA.2.75 subvariant in Japan.
    J Infect. 2023;86:e5-e7.
    >> Share

  249. XIA J, Zhu Y, Bi H, Wu X, et al
    Respiratory virus infections among hospitalized children aged 7 years and younger in Wuhan, China, 2017-2021.
    J Infect. 2023;86:e1-e4.
    >> Share

  250. CAMACHO J, Zulaica J, Gimenez E, Rusu L, et al
    Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in SARS-CoV-2 experienced versus naive individuals in the general population.
    J Infect. 2023 Jan 1:S0163-4453(22)00755-1. doi: 10.1016/j.jinf.2022.
    >> Share

    December 2022
  251. CILLONIZ C, Motos A, Castaneda T, Gabarrus A, et al
    Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study.
    J Infect. 2022 Dec 31:S0163-4453(22)00753-8. doi: 10.1016/j.jinf.2022.
    >> Share

  252. LIANG Y, Li J, Hou L, Zhang X, et al
    Changes of Staphylococcus aureus infection in children before and after the COVID-19 pandemic, Henan, China.
    J Infect. 2022 Dec 28:S0163-4453(22)00751-4. doi: 10.1016/j.jinf.2022.
    >> Share

  253. FERNANDEZ-DE-LAS-PENAS C, Arendt-Nielsen L, Diaz-Gil G, Gil-Crujera A, et al
    ACE1 rs1799752 Polymorphism is not Associated with Long-COVID Symptomatology in Previously Hospitalized COVID-19 Survivors.
    J Infect. 2022 Dec 27:S0163-4453(22)00752-6. doi: 10.1016/j.jinf.2022.
    >> Share

  254. LI Y, Cao Y, Ding X, Yang D, et al
    Influence of the COVID-19 pandemic on Staphylococcus aureus bloodstream infection in children, Henan, China.
    J Infect. 2022 Dec 25:S0163-4453(22)00746-0. doi: 10.1016/j.jinf.2022.
    >> Share

  255. SCHILDGEN O, Lusebrink J, Schildgen V
    Recommendation for broad use of Covid-19 mRNA vaccine boosters due to waning vaccine effectiveness is taking the easy way out.
    J Infect. 2022 Dec 24:S0163-4453(22)00744-7. doi: 10.1016/j.jinf.2022.
    >> Share

  256. KRONE M, Wagenhauser I, Knies K, Hofmann D, et al
    Clinical accuracy of SARS-CoV-2 rapid antigen testing in screening children and adolescents.
    J Infect. 2022 Dec 21:S0163-4453(22)00740-X. doi: 10.1016/j.jinf.2022.
    >> Share

  257. JANKUNAS R, Sakalauskas L, Zamaryte-Sakaviciene K, Stakisaitis D, et al
    COMMENTARY ON THE IMPACT OF THE COVID-19 PASSPORTS IN LITHUANIA.
    J Infect. 2022 Dec 20:S0163-4453(22)00703-4. doi: 10.1016/j.jinf.2022.
    >> Share

  258. C O, H W, R B, E L, et al
    Following the Omicron wave, the majority of children in England have evidence of previous COVID infection.
    J Infect. 2022 Dec 18:S0163-4453(22)00701-0. doi: 10.1016/j.jinf.2022.
    >> Share

  259. LI X, Peng K, Cheng FW, Lam DC, et al
    Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).
    J Infect. 2022 Dec 17:S0163-4453(22)00706-X. doi: 10.1016/j.jinf.2022.
    >> Share

  260. ZHANG M, Gao J, Guo Q, Zhang X, et al
    Changes of respiratory syncytial virus infection in children before and after the COVID-19 pandemic in Henan, China.
    J Infect. 2022 Dec 15:S0163-4453(22)00702-2. doi: 10.1016/j.jinf.2022.
    >> Share

  261. LIANG Y, Zhang P, Du B, Zhang X, et al
    Changes of Mycoplasma pneumoniae infection in children before and after the COVID - 19 pandemic, Henan, China.
    J Infect. 2022 Dec 15:S0163-4453(22)00705-8. doi: 10.1016/j.jinf.2022.
    >> Share

  262. SUN J, Wang N, Jiang Z, Li D, et al
    Are companion animals overlooked intermediate hosts for the cross-species transmission of influenza viruses?
    J Infect. 2022 Dec 12:S0163-4453(22)00695-8. doi: 10.1016/j.jinf.2022.
    >> Share

  263. LI L, Ma J, Guo P, Gao K, et al
    Changes of coagulase-negative Staphylococci infections in children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Dec 12:S0163-4453(22)00698-3. doi: 10.1016/j.jinf.2022.
    >> Share

  264. XU J, Wang Y, Liu F, Yang H, et al
    Changes of tuberculosis infection in mainland China before and after the COVID-19 pandemic.
    J Infect. 2022 Dec 11:S0163-4453(22)00699-5. doi: 10.1016/j.jinf.2022.
    >> Share

  265. KELLENI MT
    Real-life Practice of the Egyptian Kelleni's Protocol in the Current Tripledemic: COVID-19, RSV and Influenza.
    J Infect. 2022 Dec 10:S0163-4453(22)00697-1. doi: 10.1016/j.jinf.2022.
    >> Share

  266. CHENG P, Li L, Sun H, Zhu C, et al
    Changes of pathogen distribution in children with bacterial meningitis before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Dec 10:S0163-4453(22)00696-X. doi: 10.1016/j.jinf.2022.
    >> Share

  267. HANNAWI S, Safeldin L, Abuquta A, Alamadi A, et al
    Safety and Immunogenicity of a Bivalent SARS-CoV-2 Protein Booster Vaccine, SCTV01C in Adults Previously Vaccinated with Inactivated Vaccine: A Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Trial.
    J Infect. 2022 Dec 9:S0163-4453(22)00693-4. doi: 10.1016/j.jinf.2022.
    >> Share

  268. POZO-BALADO MDM, Ramos A, Rodriguez VG, Martinez IO, et al
    LONGITUDINAL AGE DIFFERENCES IN HUMORAL RESPONSES TO THE BNT162b2 VACCINE IN THE ELDERLY ARE LOST AFTER THE THIRD DOSE.
    J Infect. 2022 Dec 8:S0163-4453(22)00692-2. doi: 10.1016/j.jinf.2022.
    >> Share

  269. LIANG Y, Qin X, Hou G, Zhang X, et al
    Changes of Moraxella catarrhalis infection in children before and after the COVID-19 pandemic, Zhengzhou, China.
    J Infect. 2022 Dec 6:S0163-4453(22)00691-0. doi: 10.1016/j.jinf.2022.
    >> Share

  270. LI L, Yu Z, Li M, Sun H, et al
    Changes of Acinetobacter baumannii infections in children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Dec 2:S0163-4453(22)00689-2. doi: 10.1016/j.jinf.2022.
    >> Share

  271. LI K, Wang D, Qu H, Rui J, et al
    Viral Dynamics of Omicron BA.2.76 Variant of SARS-CoV-2 in a Cohort of COVID-19 Patients.
    J Infect. 2022 Dec 2:S0163-4453(22)00688-0. doi: 10.1016/j.jinf.2022.
    >> Share

  272. KAKIMOTO M, Miyamori D, Omori K, Kobayashi T, et al
    Impact of the early phase of COVID-19 on the trends of isolated bacteria in the national database of Japan: an interrupted time-series analysis.
    J Infect. 2022 Dec 1:S0163-4453(22)00686-7. doi: 10.1016/j.jinf.2022.
    >> Share

  273. CHEEMA HA, Shafiee A, Athar MMT, Shahid A, et al
    No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.
    J Infect. 2022 Dec 1:S0163-4453(22)00683-1. doi: 10.1016/j.jinf.2022.
    >> Share

  274. JIANG L, Tang L, Zhu L, Zhu Y, et al
    Viral dynamics during SARS-CoV-2 omicron infection highlight presymptomatic and asymptomatic infectiousness.
    J Infect. 2022 Dec 1:S0163-4453(22)00687-9. doi: 10.1016/j.jinf.2022.
    >> Share

    November 2022
  275. TANG Y, Dang X, Lv M, Norris SL, et al
    Changes in the prevalence of respiratory pathogens in children due to the COVID-19 pandemic: a systematic review and meta-analysis.
    J Infect. 2022 Nov 29:S0163-4453(22)00685-5. doi: 10.1016/j.jinf.2022.
    >> Share

  276. DENG YK, Shi KT, Liu Z, Zeng M, et al
    Persistent olfactory dysfunction 2 years after onset of COVID-19.
    J Infect. 2022 Nov 29:S0163-4453(22)00684-3. doi: 10.1016/j.jinf.2022.
    >> Share

  277. LV L, Li A, Jiang L, Zhang L, et al
    Deficiency of HTR4 and ADRB1 caused by SARS-CoV-2 spike may partially explain multiple COVID-19 related syndromes including depression, cognitive impairment, loss of appetite, heart failure, and hypertension.
    J Infect. 2022 Nov 28:S0163-4453(22)00682-X. doi: 10.1016/j.jinf.2022.
    >> Share

  278. CHEN D, Pan Y, Wang Y, Chen X, et al
    Serological response to COVID-19 vaccine and its predictors in patients with solid malignancies: a systematic review and meta-analysis of 16 cohort studies.
    J Infect. 2022 Nov 26:S0163-4453(22)00673-9. doi: 10.1016/j.jinf.2022.
    >> Share

  279. ZHENG M
    China plans to strike a balance between socio-economic development and anti-COVID-19 policy: report from the 20th National Congress of China.
    J Infect. 2022 Nov 25:S0163-4453(22)00680-6. doi: 10.1016/j.jinf.2022.
    >> Share

  280. TRKULJA V
    There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: a comment on two recent meta-analyses advocating its use.
    J Infect. 2022 Nov 24:S0163-4453(22)00677-6. doi: 10.1016/j.jinf.2022.
    >> Share

  281. LI L, Song C, Li P, Li Y, et al
    Changes of Escherichia coli infection in children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Nov 24:S0163-4453(22)00678-8. doi: 10.1016/j.jinf.2022.
    >> Share

  282. ZHAO Y, Zhao Y, Zhou Y, Zhang Z, et al
    Inactivated COVID-19 vaccination and maternal renal function during early pregnancy: a retrospective cohort study of 6397 Chinese pregnant women.
    J Infect. 2022 Nov 22:S0163-4453(22)00676-4. doi: 10.1016/j.jinf.2022.
    >> Share

  283. YARCI-CARRION A, Esparcia-Pinedo L, Mateo-Jimenez G, Alfranca A, et al
    Effect of a SARS-CoV-2 booster vaccine dose on the immune response of adults with Down syndrome.
    J Infect. 2022 Nov 20:S0163-4453(22)00675-2. doi: 10.1016/j.jinf.2022.
    >> Share

  284. ZHOU J, Chen Y, Shao Z, Ding S, et al
    Continuing evolution and transmission of avian influenza A(H3N8) viruses is a potential threat to public health.
    J Infect. 2022 Nov 17:S0163-4453(22)00651-X. doi: 10.1016/j.jinf.2022.
    >> Share

  285. WANG G, Zhao K, Han J, Hu Z, et al
    Safety and Immunogenicity of a Bivalent SARS-CoV-2 Recombinant Protein Vaccine, SCTV01C in Unvaccinated Adults: A Randomized, Double-blinded, Placebo-controlled, Phase I Clinical Trial.
    J Infect. 2022 Nov 17:S0163-4453(22)00649-1. doi: 10.1016/j.jinf.2022.
    >> Share

  286. ROMBAUTS A, Infante C, de Lagos MDAM, Alba J, et al
    Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study.
    J Infect. 2022 Nov 17:S0163-4453(22)00650-8. doi: 10.1016/j.jinf.2022.
    >> Share

  287. MARCEC R, Dodig VM, Likic R
    A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference.
    J Infect. 2022 Nov 17:S0163-4453(22)00672-7. doi: 10.1016/j.jinf.2022.
    >> Share

  288. HOQUE SA, Kotaki T, Pham NTK, Onda Y, et al
    Abundance of viral gastroenteritis before and after the emergence of COVID-19: Molecular evidence on wastewater.
    J Infect. 2022 Nov 17:S0163-4453(22)00648-X. doi: 10.1016/j.jinf.2022.
    >> Share

  289. LI T, Li X, Gao K, Dong G, et al
    Changes in pathogen distribution in the blood culture of neonates before and after the COVID-19 pandemic, Henan, China.
    J Infect. 2022 Nov 10. pii: S0163-4453(22)00644.
    >> Share

  290. HU S, You Y, Zhang S, Tang J, et al
    Multidrug-resistant infection in COVID-19 patients: a meta-analysis.
    J Infect. 2022 Nov 5. pii: S0163-4453(22)00640.
    >> Share

  291. CHEN Y, Fan L, Deng W, Lin Q, et al
    Highly Pathogenic Avian Influenza outbreaks amongst bird populations in Europe - a view from China.
    J Infect. 2022 Nov 3. pii: S0163-4453(22)00638.
    >> Share

  292. MASHIMO Y, Yamazaki K, Kageyama T, Tanaka S, et al
    Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine.
    J Infect. 2022 Nov 2. pii: S0163-4453(22)00614.
    >> Share

  293. MARCEC R, Dodig VM, Likic R
    Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
    J Infect. 2022 Nov 1. pii: S0163-4453(22)00627.
    >> Share

    October 2022
  294. COSTA R, Signes-Costa J, Olea B, Tarraso J, et al
    Initial SARS-CoV-2 RNA load in nasopharyngeal specimens is not associated with severity and midterm resolution of pneumonia in COVID-19 patients.
    J Infect. 2022 Oct 28. pii: S0163-4453(22)00629.
    >> Share

  295. HE WQ, Gianacas C, Muscatello DJ, Newall AT, et al
    Effectiveness of influenza vaccination in reducing influenza-like illness and related antibiotic prescriptions in adults from a primary care-based case-control study.
    J Infect. 2022 Oct 23. pii: S0163-4453(22)00626.
    >> Share

  296. KANDEL C, Lee Y, Taylor M, Llanes A, et al
    Viral Dynamics of the SARS-CoV-2 Omicron Variant Among Household Contacts with 2 or 3 COVID-19 Vaccine Doses.
    J Infect. 2022 Oct 22. pii: S0163-4453(22)00625.
    >> Share

  297. TIAN J, Li M, Li Y, Bai X, et al
    H3N8 subtype avian influenza virus originated from wild birds exhibited dual receptor-binding profiles.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00622.
    >> Share

  298. SHINGLETON J, Williams H, Oligbu G, Powell A, et al
    The changing epidemiology of PIMS-TS across COVID-19 waves: prospective national surveillance, January 2021 to July 2022, England.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00617.
    >> Share

  299. GUO Y, Zhang Y, Hu Y
    COVID-19 subgroups may slow down biological age acceleration.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00616.
    >> Share

  300. ZHOU J, Zhao P, Nie M, Gao K, et al
    Changes of Haemophilus influenzae infection in children before and after the COVID-19 pandemic, Henan, China.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00615.
    >> Share

  301. NISHIKIMI A, Nakagawa T, Fujiwara M, Watanabe K, et al
    Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00621.
    >> Share

  302. ZHANG Y, Han S, Yao M, Guo X, et al
    Breakthrough Infection shapes humoral immunity against SARS-CoV-2 Omicron Variant.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00620.
    >> Share

  303. ZHENG Q, Wang M, Cheng Y, Liu J, et al
    Antibody response and safety of COVID-19 vaccine in peritoneal dialysis patients.
    J Infect. 2022 Oct 17. pii: S0163-4453(22)00612.
    >> Share

  304. NAZARETH J, Barr I, Sullivan SG, Goss C, et al
    Intra-season waning of immunity following the seasonal influenza vaccine in early and late vaccine recipients.
    J Infect. 2022 Oct 13. pii: S0163-4453(22)00604.
    >> Share

  305. CHEEMA HA, Jafar U, Elrashedy AA, Shahid A, et al
    Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: a systematic review and meta-analysis.
    J Infect. 2022 Oct 13. pii: S0163-4453(22)00608.
    >> Share

  306. WANG B, Yu Y, Yu Y, Wang N, et al
    Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China.
    J Infect. 2022 Oct 11. pii: S0163-4453(22)00466.
    >> Share

  307. LEE J, Park S, Kim JY, Lim SY, et al
    No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers.
    J Infect. 2022 Oct 9. pii: S0163-4453(22)00600.
    >> Share

  308. ELFIKY AA, Ibrahim IM, Ibrahim MN, Elshemey WM, et al
    Host-cell recognition of SARS-CoV-2 spike receptor binding domain from different variants.
    J Infect. 2022 Oct 8. pii: S0163-4453(22)00601.
    >> Share

  309. CAI H, Yan J, Wang J, Che X, et al
    Efficacy of Paxlovid in patients with acute kidney injury who developed COVID-19.
    J Infect. 2022 Oct 8. pii: S0163-4453(22)00562.
    >> Share

  310. RAFFERTY H, Cann A, Daunt A, Cooke GS, et al
    Changing patterns of clinical presentation of COVID-19 in hospital admissions: a single centre prospective cohort study.
    J Infect. 2022 Oct 7. pii: S0163-4453(22)00563.
    >> Share

  311. GREGERSEN I, Ueland T, Holter JC, Olsen MB, et al
    CXCL16 associates with adverse outcome and cardiac involvement in hospitalized patients with Covid-19.
    J Infect. 2022 Oct 7. pii: S0163-4453(22)00559.
    >> Share

  312. BERTRAN M, Pereira SMP, Nugawela MD, Stephenson T, et al
    The relationship between Post COVID symptoms in young people and their parents.
    J Infect. 2022 Oct 7. pii: S0163-4453(22)00560.
    >> Share

  313. MEDINA MJ, Nazareth J, Dillon HM, Wighton CJ, et al
    Respiratory virus transmission using a novel viral challenge model: An observational cohort study.
    J Infect. 2022;85:405-411.
    >> Share

    September 2022
  314. ZHENG Q, Ma P, Wang M, Chen Y, et al
    Efficacy and safety of Paxlovid for COVID-19:a meta-analysis.
    J Infect. 2022 Sep 30. pii: S0163-4453(22)00557.
    >> Share

  315. LIU P, Xu J
    Resurgence of influenza virus activity during COVID-19 pandemic in Shanghai, China.
    J Infect. 2022 Sep 29. pii: S0163-4453(22)00555.
    >> Share

  316. CHANDRA A, Hoeg TB
    Lack of correlation between school mask mandates and paediatric Covid-19 cases in a large cohort.
    J Infect. 2022 Sep 29. pii: S0163-4453(22)00550.
    >> Share

  317. LA Y, Hong JY, Lee HS, Lee EH, et al
    Increase of Multidrug-Resistant Bacteria After the COVID-19 Pandemic in South Korea: Time-series Analyses of a Long-term Multicenter Cohort.
    J Infect. 2022 Sep 29. pii: S0163-4453(22)00556.
    >> Share

  318. HUANG J, Xia L, Zhao Y, Wu X, et al
    Coronavirus disease 2019 vaccination and live birth outcome after fresh embryo transfer.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00552.
    >> Share

  319. AO G, Li A, Wang Y, Tran C, et al
    The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: a meta-analysis.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00553.
    >> Share

  320. YIN Y, Lin J, Yuan S, Tong S, et al
    A booster shot of vaccine against SARS-CoV-2 should be rigorously promoted and implemented in China.
    J Infect. 2022 Sep 25. pii: S0163-4453(22)00546.
    >> Share

  321. CHOI MJ, Choi JY, Hyun H, Nham E, et al
    Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: comparison between prior SARS-CoV-2-infected and infection-naive individuals.
    J Infect. 2022 Sep 23. pii: S0163-4453(22)00548.
    >> Share

  322. YAN F, Gao F
    RBD-ACE2 binding properties in five SARS-CoV-2 variants of concern with new perspectives in the design of pan-coronavirus peptide inhibitors.
    J Infect. 2022 Sep 14. pii: S0163-4453(22)00541.
    >> Share

  323. XU QY, Zheng XQ, Jia ZJ, Wu MJ, et al
    Developing new COVID-19 vaccine against the variants is urgently needed rather than boosters: A longitudinal cohort study.
    J Infect. 2022 Sep 12. pii: S0163-4453(22)00539.
    >> Share

  324. SUN H, Liu H, Liu Y, Pang Z, et al
    Genetic characterization of a novel quadruple reassortant influenza A (H1N2) virus from swine, China, 2021.
    J Infect. 2022 Sep 10. pii: S0163-4453(22)00538.
    >> Share

  325. MOUSSAOUI ME, Desmecht S, Tashkeev A, Lambert N, et al
    Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naive people living with HIV.
    J Infect. 2022 Sep 9. pii: S0163-4453(22)00534.
    >> Share

  326. ATTI A, Insalata F, Carr EJ, Otter AD, et al
    Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study.
    J Infect. 2022 Sep 8. pii: S0163-4453(22)00535.
    >> Share

  327. WONG LSY, Loo EXL, Huang CH, Yap GC, et al
    Early seasonal coronavirus seroconversion did not produce cross-protective SARS-CoV-2 antibodies.
    J Infect. 2022 Sep 3. pii: S0163-4453(22)00515.
    >> Share

  328. DIMEGLIO C, Tremeaux P, Herin F, Da-Silva I, et al
    Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00522.
    >> Share

  329. SHI T, Dai M, Liu F, Hu J, et al
    Dynamics of immune responses to inactivated COVID-19 vaccination over 8 months in China.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00521.
    >> Share

  330. PATAPNYAN E, Ronen O
    Parallel reduction in the prevalence of Bell's palsy, idiopathic sudden sensorineural hearing loss and viral infection diseases during the COVID-19 pandemic.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00518.
    >> Share

  331. ZOU P, Li G, Ge X, Wang J, et al
    Lymphocyte subset changes in neonates with respiratory syncytial virus pneumonia.
    J Infect. 2022;85:334-363.
    >> Share

  332. LI P, Niu M, Li Y, Xu M, et al
    Human infection with H3N8 avian influenza virus: A novel H9N2-original reassortment virus.
    J Infect. 2022 Sep 1. pii: S0163-4453(22)00519.
    >> Share

  333. COOPER DJ, Lear S, Watson L, Shaw A, et al
    A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital.
    J Infect. 2022 Sep 1. pii: S0163-4453(22)00514.
    >> Share

  334. YIN Y, Lin J, Yuan S, Tong S, et al
    The relationship between early isolation and the duration of viral shedding of mild and asymptomatic infection with SARS-CoV-2 Omicron BA.2 variant.
    J Infect. 2022 Sep 1. pii: S0163-4453(22)00520.
    >> Share

    August 2022
  335. LAI CK, Lui GC, Wei Y, Chong KC, et al
    Remdesivir reduced upper respiratory tract SARS-CoV-2 viral RNA concentration in COVID-19 patients who developed pneumonitis.
    J Infect. 2022 Aug 31. pii: S0163-4453(22)00513.
    >> Share

  336. LINA L, Zhendong G, Sevalie S, Fangfang Z, et al
    Comparison of the amount of SARS-CoV-2 exhaled by Delta and Omicron patients.
    J Infect. 2022 Aug 28. pii: S0163-4453(22)00512.
    >> Share

  337. KIM SH, Kyu Cho H, Jeon CH, Sung Ock H, et al
    Diagnostic value of serum KL-6 and IL-6 levels in critically ill patients with COVID-19-associated pneumonia.
    J Infect. 2022 Aug 27. pii: S0163-4453(22)00477.
    >> Share

  338. GIDARI A, Schiaroli E, Sabbatini S, Bastianelli S, et al
    Impact of SARS-CoV-2 Omicron Variants on Serum Neutralization in a Cohort of Healthcare Workers Vaccinated with BNT162b2.
    J Infect. 2022 Aug 25. pii: S0163-4453(22)00507.
    >> Share

  339. WANG Y, Zheng J, Zhu K, Wang B, et al
    The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis.
    J Infect. 2022 Aug 25. pii: S0163-4453(22)00506.
    >> Share

  340. BAYHAN GI, Korkmaz IO, Seyda E, Tekeli N, et al
    Are SARS-CoV-2 viral loads in children lower than in adults?
    J Infect. 2022 Aug 24. pii: S0163-4453(22)00509.
    >> Share

  341. MIZOUE T, Yamamoto S, Konishi M, Oshiro Y, et al
    Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants.
    J Infect. 2022 Aug 19. pii: S0163-4453(22)00480.
    >> Share

  342. WANG Y, Chen X, Xiao W, Zhao D, et al
    Rapid COVID-19 rebound in a severe COVID-9 patient during 20-day course of Paxlovid.
    J Infect. 2022 Aug 19. pii: S0163-4453(22)00478.
    >> Share

  343. NOLASCO S, Vitale F, Geremia A, Tramuto F, et al
    First case of monkeypox virus, SARS-CoV-2 and HIV co-infection.
    J Infect. 2022 Aug 19. pii: S0163-4453(22)00479.
    >> Share

  344. WAN EYF, Mok AHY, Yan VKC, Wang B, et al
    Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study.
    J Infect. 2022 Aug 16. pii: S0163-4453(22)00472.
    >> Share

  345. GOMEZ-CARBALLA A, Martinon-Torres F, Salas A
    Is SARS-CoV-2 an oncogenic virus?
    J Infect. 2022 Aug 9. pii: S0163-4453(22)00469.
    >> Share

  346. CHANG YC, Hsiao CT, Chen WL, Su YD, et al
    BioFire FilmArray Respiratory Panel RP2.1 for SARS-CoV-2 detection: The pitfalls.
    J Infect. 2022 Aug 8. pii: S0163-4453(22)00468.
    >> Share

  347. AIELLO TF, Puerta-Alcalde P, Chumbita M, Monzo P, et al
    Infection with the Omicron variant of SARS-CoV-2 is associated with less severe disease in hospitalized patients with COVID-19.
    J Infect. 2022 Aug 5. pii: S0163-4453(22)00461.
    >> Share

  348. BASSETTI M, Zuccaro V, Asperges E, Scudeller L, et al
    Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, nonneutropenic, adult patients: an update including COVID-19 data.
    J Infect. 2022 Aug 4. pii: S0163-4453(22)00465.
    >> Share

  349. AO Y, Li J, Wei Z, Wang Z, et al
    Clinical and virological characteristics of SARS-CoV-2 Omicron BA.2.2 variant outbreaks during April to May, 2022, Shanghai, China.
    J Infect. 2022 Aug 4. pii: S0163-4453(22)00462.
    >> Share

    July 2022
  350. NOH JY, Cheong HJ, Kim WJ, Choi JY, et al
    Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination: Running title: Optimal vaccination interval and ceiling effect.
    J Infect. 2022 Jul 31. pii: S0163-4453(22)00456.
    >> Share

  351. BOJKOVA D, Stack R, Rothenburger T, Kandler JD, et al
    Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants.
    J Infect. 2022 Jul 30. pii: S0163-4453(22)00455.
    >> Share

  352. DZINAMARIRA T, Moyo E, Moyo P, Pierre G, et al
    Childhood immunization services accessibility and utilization during the COVID-19 pandemic in Africa.
    J Infect. 2022 Jul 29. pii: S0163-4453(22)00445.
    >> Share

  353. MURPHY SL, Halvorsen B, Barratt-Due A, Am DR, et al
    Remdesivir modifies interferon response in hospitalized COVID-19 patients.
    J Infect. 2022 Jul 29. pii: S0163-4453(22)00450.
    >> Share

  354. PASCARELLA S, Ciccozzi M, Benvenuto D, Borsetti A, et al
    Peculiar Variations of the Electrostatic Potential of Spike Protein N-terminal Domain Associated with the Emergence of Successive SARS-CoV-2 Omicron Lineages.
    J Infect. 2022 Jul 28. pii: S0163-4453(22)00426.
    >> Share

  355. LINA L, Fangfang Z, Sevalie S, Dawei Z, et al
    Characteristics of SARS-CoV-2 exhaled by COVID-19 patients.
    J Infect. 2022 Jul 28. pii: S0163-4453(22)00424.
    >> Share

  356. LI M, Luo Q, Gong C, Li AH, et al
    Prospective Surveillance of Human Adenovirus in Acute Respiratory Infections Reveals Epidemiological Features and the Disappearance of Species B During the COVID-19 Pandemic in Beijing, China.
    J Infect. 2022 Jul 22. pii: S0163-4453(22)00423.
    >> Share

  357. FU J, Luo Y, Fang X, Lu J, et al
    Genetic variation of Golgi membrane protein 1 is associated with COVID-19 disease.
    J Infect. 2022 Jul 22. pii: S0163-4453(22)00420.
    >> Share

  358. VELLAS C, Kamar N, Izopet J
    Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment.
    J Infect. 2022 Jul 22. pii: S0163-4453(22)00422.
    >> Share

  359. HUANG L
    Adjusted control rate closely associated with the epidemiologic evolution of the recent COVID-19 wave in Shanghai, with 94.3% of all new cases being asymptomatic on first diagnosis.
    J Infect. 2022 Jul 14. pii: S0163-4453(22)00418.
    >> Share

  360. HAGIYA H, Hikita T, Habu T, Asada M, et al
    Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people.
    J Infect. 2022 Jul 11. pii: S0163-4453(22)00413.
    >> Share

  361. KHANNA R, Htun HL, Lianjie AL, Kyaw WM, et al
    Staff and patient surveillance in hospitals: good sentinels for the emergence of new SARS-CoV-2 variants.
    J Infect. 2022 Jul 7. pii: S0163-4453(22)00411.
    >> Share

  362. VERA-LISE I, Dominik E, Elisabeth R, Kerstin H, et al
    "Rapid reinfections with different or same Omicron SARS-CoV-2 sub-variants".
    J Infect. 2022 Jul 7. pii: S0163-4453(22)00412.
    >> Share

  363. LI M, Yu T
    Statistical concern on evaluating the consistency between gargle samples and nasopharyngeal (NP) swabs in RT-qPCR-based mass screening approach for the diagnosis of COVID-19.
    J Infect. 2022 Jul 6. pii: S0163-4453(22)00408.
    >> Share

  364. MARTIN-BLONDEL G, Marcelin AG, Soulie C, Kaisaridi S, et al
    Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2.
    J Infect. 2022 Jul 5. pii: S0163-4453(22)00406.
    >> Share

  365. YAN Y, Davgadorj C, Lyu C, Zhang S, et al
    Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: a cross-sectional study.
    J Infect. 2022 Jul 5. pii: S0163-4453(22)00407.
    >> Share

  366. GAO X, Zhang S, Gou J, Wen Y, et al
    Spike-mediated ACE2 down-regulation involved in the pathogenesis of SARS-CoV-2 infection.
    J Infect. 2022 Jul 3. pii: S0163-4453(22)00404.
    >> Share

  367. LUO Q, Li M, Li A, Gong C, et al
    Genetic diversity and epidemiological features of respiratory syncytial virus, Beijing, 2015-2019: A multicenter and all-age groups study.
    J Infect. 2022;85:75-85.
    >> Share

  368. YUAN W, Hou Y, Lin Q, Chen L, et al
    How China responds to Omicron.
    J Infect. 2022;85:90-122.
    >> Share

  369. WEN F, Zhang X, Guo J, Liang Z, et al
    Emergence of H3N8 avian influenza viruses possessing tri-basic hemagglutinin cleavage sites in China.
    J Infect. 2022 Jul 1. pii: S0163-4453(22)00383.
    >> Share

  370. YANG M, Li A, Wang Y, Tran C, et al
    Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: a meta-analysis.
    J Infect. 2022 Jul 1. pii: S0163-4453(22)00384.
    >> Share

    June 2022
  371. CARBONELL R, Urgeles S, Salgado M, Rodriguez A, et al
    NEGATIVE PREDICTIVE VALUE OF PROCALCITONIN TO RULE OUT BACTERIAL RESPIRATORY CO-INFECTION IN CRITICAL COVID-19 PATIENTS.
    J Infect. 2022 Jun 30. pii: S0163-4453(22)00380.
    >> Share

  372. SACERDOTE C, Milani L, Castiglione A, Pagano E, et al
    Risk of Intensive Care Unit admission or mortality in patients hospitalised for COVID-19 during the first two waves: an Italian cohort study.
    J Infect. 2022 Jun 30. pii: S0163-4453(22)00379.
    >> Share

  373. O'MORAIN N, Stack R, Doherty J, Tosetto M, et al
    Research Letter: Faecal calprotectin as a potential biomarker of disease severity in SARS-CoV-2 infection.
    J Infect. 2022 Jun 26. pii: S0163-4453(22)00372.
    >> Share

  374. REN Y, Liu Y, Zhang Z, Liu Y, et al
    SNX27-mediated endocytic recycling of GLUT1 is suppressed by SARS-CoV-2 spike, possibly explaining neuromuscular disorders in patients with COVID-19.
    J Infect. 2022 Jun 26. pii: S0163-4453(22)00377.
    >> Share

  375. FOURGEAUD J, Toubiana J, Chappuy H, Delacourt C, et al
    No durable impact of COVID-19 measures on the hospital burden of Respiratory Syncytial Virus (France, 2018-2022).
    J Infect. 2022 Jun 24. pii: S0163-4453(22)00375.
    >> Share

  376. RICHARDS A, Muddassir M, Sampson F, MacLachlan L, et al
    Evaluation of pre-hospital COVID-19 rapid antigen tests by paramedics and their use in a direct admission pathway: Pre-Hospital COVID-19 rapid antigen tests.
    J Infect. 2022 Jun 18. pii: S0163-4453(22)00371.
    >> Share

  377. YANG M, Li A, Jiang L, Wang Y, et al
    Regdanvimab improves disease mortality and morbidity in patients with COVID-19: a meta-analysis.
    J Infect. 2022 Jun 18. pii: S0163-4453(22)00369.
    >> Share

  378. NIYOMNAITHAM S, Toh ZQ, Licciardi PV, Wongprompitak P, et al
    Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: a randomized trial.
    J Infect. 2022 Jun 18. pii: S0163-4453(22)00370.
    >> Share

  379. PENG H, Wu X, Xiong S, Li C, et al
    Gout and susceptibility and severity of COVID-19: a bidirectional Mendelian randomization analysis.
    J Infect. 2022 Jun 17. pii: S0163-4453(22)00366.
    >> Share

  380. HATCHER J, Gil E, Storey N, Brown JR, et al
    Reactivation/relapse of SARS-CoV-2 in a child following haematopoietic stem cell transplantation, confirmed by whole genome sequencing, following apparent viral clearance.
    J Infect. 2022 Jun 17. pii: S0163-4453(22)00367.
    >> Share

  381. COCHINO AV, Farkas OM, Ioan A
    Pediatric Patients with Immune-Mediated Diseases on Immunosuppressants Have Low Risk of Severe COVID-19 and No Increase in Flare Rate after SARS CoV-2 Exposure.
    J Infect. 2022 Jun 17. pii: S0163-4453(22)00365.
    >> Share

  382. LAZARUS R, Taucher C, Brown C, Corbic I, et al
    Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
    J Infect. 2022 Jun 16. pii: S0163-4453(22)00361.
    >> Share

  383. COULSON JM, Adams A, Gray LA, Evans A, et al
    COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy.
    J Infect. 2022 Jun 16. pii: S0163-4453(22)00363.
    >> Share

  384. WORSLEY CM, van der Mescht MA, Hoffman D, Meyer PWA, et al
    Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00360.
    >> Share

  385. KANG SW, Kim JY, Park H, Lim SY, et al
    Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00355.
    >> Share

  386. GABBI C, Renieri A, Strandvik B
    Geographical distribution of cystic fibrosis carriers as population genetic determinant of COVID-19 spread and fatality in 37 countries.
    J Infect. 2022 Jun 11. pii: S0163-4453(22)00359.
    >> Share

  387. SANG L, Cheng B, Yu Y, Xi Y, et al
    The efficacy and safety of IBI314 on Delta and Omicron variant of SARS-CoV-2: first-in-human evidence.
    J Infect. 2022 Jun 9. pii: S0163-4453(22)00354.
    >> Share

  388. XU QY, Li QL, Jia ZJ, Wu MJ, et al
    Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study.
    J Infect. 2022 Jun 9. pii: S0163-4453(22)00356.
    >> Share

  389. IJAZ S, Dicks S, Jegatheesan K, Parker E, et al
    Mapping of SARS-CoV-2 IgM and IgG in gingival crevicular fluid: antibody dynamics and linkage to severity of COVID-19 in hospital inpatients.
    J Infect. 2022 Jun 3. pii: S0163-4453(22)00339.
    >> Share

  390. LV P, Hu B, Hua R, Zhang J, et al
    A novelly designed protein antagonist confers potent neutralization against SARS-COV-2 variants of concern.
    J Infect. 2022 Jun 3. pii: S0163-4453(22)00350.
    >> Share

  391. ABDI B, Ndoadoumgue AL, Djebara S, Zafilaza K, et al
    High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area: Seroprevalence of SARS-CoV-2 in HIV patients.
    J Infect. 2022 Jun 2. pii: S0163-4453(22)00346.
    >> Share

  392. MELLON G, Rouquette A, Fac C, Carton B, et al
    SARS-CoV-2 seroprevalence in the adult detainees of the Paris area in 2021: A multicenter cross-sectional study.
    J Infect. 2022 Jun 2. pii: S0163-4453(22)00345.
    >> Share

  393. ZHANG Y, Li J, Jiang L, Chen Q, et al
    Comparison of SARS-CoV-2 aerosol emission from patients with Omicron BA.1 or BA.2 subvariant infection.
    J Infect. 2022 Jun 1. pii: S0163-4453(22)00342.
    >> Share

  394. GUO Z, Zhao S, Ryu S, Mok CKP, et al
    Superspreading potential of infection seeded by the SARS-CoV-2 Omicron BA.1 variant in South Korea.
    J Infect. 2022 Jun 1. pii: S0163-4453(22)00344.
    >> Share

  395. STANKUNAS M, Dziugys A, Skarbalius G, Misiulis E, et al
    EVALUATING THE POTENTIAL IMPACT OF COVID-19 PASSPORTS IN LITHUANIA.
    J Infect. 2022 Jun 1. pii: S0163-4453(22)00340.
    >> Share

  396. LI Y, Guo Y, Duan Y
    Changes in Streptococcus pneumoniae infection in children before and after the COVID-19 pandemic in Zhengzhou, China.
    J Infect. 2022 Jun 1. pii: S0163-4453(22)00348.
    >> Share

    May 2022
  397. WANG B, Fu J, Lu A, Yang J, et al
    Suitability assessment of CD24 targeted-therapy in the cancer patients with COVID-19: Preliminary results from pan-cancer.
    J Infect. 2022 May 31. pii: S0163-4453(22)00337.
    >> Share

  398. GIANNONE D, Vecchione MB, Czernikier A, Polo ML, et al
    SARS-CoV-2 humoral and cellular immune responses in COVID-19 convalescent individuals with HIV.
    J Infect. 2022 May 27. pii: S0163-4453(22)00315.
    >> Share

  399. KAMALI Z, Vonk JM, Thio CHL, Vaez A, et al
    A Mendelian randomization cytokine screen reveals IL-13 as causal factor in risk of severe COVID-19.
    J Infect. 2022 May 23. pii: S0163-4453(22)00313.
    >> Share

  400. SA R, Isidro J, Borges V, Duarte S, et al
    Unravelling the hurdles of a large COVID-19 epidemiological investigation by viral genomics.
    J Infect. 2022 May 21. pii: S0163-4453(22)00302.
    >> Share

  401. SOVIK S, Barrat-Due A, Kasine T, Olasveengen T, et al
    Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation.
    J Infect. 2022 May 20. pii: S0163-4453(22)00305.
    >> Share

  402. NISHIKIMI A, Watanabe K, Watanabe A, Yasuoka M, et al
    Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey.
    J Infect. 2022 May 20. pii: S0163-4453(22)00307.
    >> Share

  403. CHENG D, Dong Y, Wen S, Shi C, et al
    A child with acute respiratory distress syndrome caused by avian influenza H3N8 virus.
    J Infect. 2022 May 13. pii: S0163-4453(22)00288.
    >> Share

  404. LIU L, Fan X, Guan Q, Yu C, et al
    Bioavailable testosterone level is associated with COVID-19 severity in female: A sex-stratified Mendelian randomization study.
    J Infect. 2022 May 13. pii: S0163-4453(22)00287.
    >> Share

  405. WU X, Peng H, Xiong S, Li C, et al
    Novel evidence revealed genetic association between COVID-19 infection, severity and endometrial cancer: COVID-19 infection, severity and risk of endometrial cancer.
    J Infect. 2022 May 10. pii: S0163-4453(22)00261.
    >> Share

  406. VAN GRONINGEN KM, Dao BL, Gounder P
    Declines in invasive pneumococcal disease (IPD) during the COVID-19 pandemic in Los Angeles county.
    J Infect. 2022 May 9. pii: S0163-4453(22)00259.
    >> Share

  407. ZHANG YM, Liu XZ, Lin MM, Zan JC, et al
    Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients.
    J Infect. 2022 May 9. pii: S0163-4453(22)00260.
    >> Share

  408. LUCIJANIC M, Cikara T, Bistrovic P, Papic I, et al
    Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis.
    J Infect. 2022 May 2. pii: S0163-4453(22)00251.
    >> Share

  409. FERNANDEZ-DE-LAS-PENAS C, Martin-Guerrero JD, Cancela-Cilleruelo I, Moro-Lopez-Menchero P, et al
    Exploring the recovery curves for long-term post-COVID functional limitations on daily living activities: The LONG-COVID-EXP-CM multicenter study.
    J Infect. 2022;84:722-746.
    >> Share

  410. MARIANI C, Borgonovo F, Capetti AF, Oreni L, et al
    Persistence of Long-COVID symptoms in a heterogenous prospective cohort.
    J Infect. 2022;84:722-746.
    >> Share

  411. WAN Z, Lu R, Zhao Y, Zhang C, et al
    Diagnostic strategy of SARS-CoV-2 for containment under China's zero-COVID-19 policy.
    J Infect. 2022 May 1. pii: S0163-4453(22)00250.
    >> Share

    April 2022
  412. JIMENEZ D, Martinez-Sanz J, Sainz T, Calvo C, et al
    Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00248.
    >> Share

  413. HIROTSU Y, Maejima M, Shibusawa M, Natori Y, et al
    SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: genomic surveillance in Japan from September 2021 to March 2022.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00247.
    >> Share

  414. GIANNITRAPANI L, Augello G, Mirarchi L, Amodeo S, et al
    Outcome predictors in SARS-CoV-2 disease (COVID-19): the prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00245.
    >> Share

  415. LI A, Zhang L
    Reduced incidence of acute pharyngitis and increased incidence of chornic pharyngitis under COVID-19 control strategy in Beijing.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00249.
    >> Share

  416. RANA MS, Usman MM, Ikram A, Salman M, et al
    The negative impact of the COVID-19 Pandemic on immunization and the positive impact on Polio eradication in Pakistan and Afghanistan. A dismal scenario.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00246.
    >> Share

  417. YUAN S, Jiang SC, Zhang ZW, Fu YF, et al
    Surface electrostatic shift on spike protein decreased antibody activities against SARS-CoV-2 Omicron variant.
    J Infect. 2022 Apr 23. pii: S0163-4453(22)00215.
    >> Share

  418. NGUYEN NN, Houhamdi L, Hoang VT, Stoupan D, et al
    High rate of reinfection with the SARS-CoV-2 Omicron variant.
    J Infect. 2022 Apr 23. pii: S0163-4453(22)00216.
    >> Share

  419. LI Y, Wei L, He L, Sun J, et al
    Interferon-induced transmembrane protein 3 gene polymorphisms are associated with COVID-19 susceptibility and severity: A meta-analysis.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00208.
    >> Share

  420. HE L, Zeng C, Xu W, Li Y, et al
    Dynamic changes of serum SARS-CoV-2 antibody levels in COVID-19 patients.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00214.
    >> Share

  421. AO G, Li A, Wang Y, Tran C, et al
    Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00210.
    >> Share

  422. CIUFFREDA L, Alcoba-Florez J, Lorenzo-Salazar JM, Gil-Campesino H, et al
    Association of the Delta SARS-CoV-2 variant with 28-day hospital mortality between December 2020 and September 2021.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00212.
    >> Share

  423. PANDIT P, Bhatt P, Sahay RR, Joshi Y, et al
    A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00205.
    >> Share

  424. CAI J, Hu S, Lin Q, Ren T, et al
    China's 'dynamic zero COVID-19 strategy' will face greater challenges in the future.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00209.
    >> Share

  425. DAVIES J, Gibani MM, Portone G, McGregor A, et al
    Cohorting inpatients with Omicron and Delta variants of Sars-CoV-2 does not increase rates of mixed infection.
    J Infect. 2022 Apr 12. pii: S0163-4453(22)00202.
    >> Share

  426. REN Y, Lv L, Li P, Zhang L, et al
    Inhibition of endocytic recycling of ACE2 by SARS-CoV-2 S protein partially explains multiple COVID-19 related diseases caused by ACE2 reduction.
    J Infect. 2022 Apr 11. pii: S0163-4453(22)00201.
    >> Share

  427. ZSIGMOND B, Breathnach AS, Mensah A, Ladhani SN, et al
    Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London, England".
    J Infect. 2022 Apr 10. pii: S0163-4453(22)00203.
    >> Share

  428. WHITAKER H, Tsang RS, Button E, Andrews N, et al
    Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00198.
    >> Share

  429. LIU X, Munro APS, Feng S, Janani L, et al
    Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00200.
    >> Share

  430. MARTIN-BLONDEL G, Marcelin AG, Soulie C, Kaisaridi S, et al
    Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S CoCoPrev study).
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00196.
    >> Share

  431. BADDAL B, Bostanci A
    The impact of COVID-19 on the molecular epidemiology of seasonal viral respiratory infections, Cyprus.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00192.
    >> Share

  432. CHENG CY, Hsiao SH, Fang TC, Lin YC, et al
    SARS-CoV2 Antibody Response After a Third Dose of Heterologous ChAdOx1 nCoV-19 and Moderna Vaccine in Chronic Dialysis Patients.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00190.
    >> Share

  433. YADAV PD, Sahay RR, Agrawal S, Shete A, et al
    Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00193.
    >> Share

  434. LIU Y, Li P, Yang L, Li P, et al
    High vaccination coverage slows down genetic diversity of SARS-CoV-2.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00191.
    >> Share

  435. AKBAR S, Pan D, Ehdode A, Islam R, et al
    Prognostic value of maximum NEWS-2 scores in addition to ISARIC 4C scores for patients admitted to hospital with COVID-19.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00195.
    >> Share

  436. ONG JY, Wang CH, Ms YT, Chen FL, et al
    Nosocomial septicemia in COVID-19 Nosocomial K. pneumoniae, A. baumannii, and Elizabethkingia meningoseptica Septicemia in a Patient of COVID-19.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00188.
    >> Share

  437. SONG W, Yang Y, Huang Y, Chen L, et al
    Acute respiratory infections in children, before and after the COVID-19 pandemic, a sentinel study.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00183.
    >> Share

  438. GAGNAIRE J, Bonjean P, Verot E, Boulamail B, et al
    SARS-CoV-2 rapid test versus RT-qPCR on noninvasive respiratory self-samples during a city mass testing campaign.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00184.
    >> Share

  439. BAEK YJ, Lee YJ, Kim JI, Lee S, et al
    Prolonged viral shedding in severely ill patients infected with SARS-CoV-2 Delta variants: a retrospective cohort study.
    J Infect. 2022 Apr 5. pii: S0163-4453(22)00186.
    >> Share

  440. DUVERGER C, Monteil C, Souyri V, Md SF, et al
    Decrease of carbapenemase-producing Enterobacteriaceae incidence during the first year of the COVID-19 pandemic.
    J Infect. 2022 Apr 1. pii: S0163-4453(22)00179.
    >> Share

    March 2022
  441. YOON JG, Yoo JS, Lee J, Hyun HJ, et al
    Viable SARS-CoV-2 Shedding Under Remdesivir and Dexamethasone Treatment.
    J Infect. 2022 Mar 26. pii: S0163-4453(22)00177.
    >> Share

  442. MENG J, Ge Q, Li J, Lu X, et al
    Protective trend of anti-androgen therapy during the COVID-19 pandemic: a meta-analysis.
    J Infect. 2022 Mar 24. pii: S0163-4453(22)00175.
    >> Share

  443. SCHILDGEN V, Lusebrink J, Schildgen O
    Compulsary SARS-CoV-2 (booster-) vaccination in healthcare facilities can not replace personal protection measures while dealing with vulnarable individuals.
    J Infect. 2022 Mar 23. pii: S0163-4453(22)00173.
    >> Share

  444. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naive vaccinees.
    J Infect. 2022 Mar 19. pii: S0163-4453(22)00170.
    >> Share

  445. YANG G, Ren Z, Zou Y, Xu Q, et al
    Antimicrobial stewardship in non-COVID-19 patients with fever and respiratory symptoms in outpatient settings: lessons from the "dynamic zero-COVID policy" in mainland China.
    J Infect. 2022 Mar 18. pii: S0163-4453(22)00141.
    >> Share

  446. MURGIA F, Fiamma M, Serra S, Olla S, et al
    The impact of secondary infections in COVID-19 critically ill patients.
    J Infect. 2022 Mar 18. pii: S0163-4453(22)00171.
    >> Share

  447. DIMEGLIO C, Loubes JM, Migueres M, Saune K, et al
    Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants.
    J Infect. 2022 Mar 17. pii: S0163-4453(22)00140.
    >> Share

  448. RYAN P, Perez-Garcia F, Torres-Macho J, Bibiano C, et al
    Misdiagnosis rate of among negative COVID-19 patients in real-life with Panbio COVID-19 Antigen Rapid Test during 2021.
    J Infect. 2022 Mar 16. pii: S0163-4453(22)00139.
    >> Share

  449. AO G, Wang Y, Li A, Tran C, et al
    The effect of canakinumab on clinical outcomes in patients with COVID-19: a meta-analysis.
    J Infect. 2022 Mar 14. pii: S0163-4453(22)00137.
    >> Share

  450. CHEN C, Tang J, Wang C, Wen W, et al
    Meta-Analysis of Post-traumatic Stress Disorder and COVID-19 in Patients Discharged.
    J Infect. 2022 Mar 10. pii: S0163-4453(22)00134.
    >> Share

  451. XIANG B, Yang L, Ye Z, Ren T, et al
    Vaccination of Susceptible Animals Against SARS-CoV-2.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00131.
    >> Share

  452. BONNET B, Chabrolles H, Archimbaud C, Brebion A, et al
    Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00132.
    >> Share

  453. FERRE VM, Lebourgeois S, Chenane HR, Menidjel R, et al
    Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00126.
    >> Share

  454. FANTINI J, Devaux CA, Yahi N, Frutos R, et al
    The novel hamster-adapted SARS-CoV-2 Delta variant may be selectively advantaged in humans.
    J Infect. 2022 Mar 6. pii: S0163-4453(22)00129.
    >> Share

  455. SUN R, Jiang W, Liu S, Peng C, et al
    Emergence of Novel Reassortant H5N6 Influenza Viruses in Poultry and Humans in Sichuan Province, China, 2021.
    J Infect. 2022 Mar 5. pii: S0163-4453(22)00128.
    >> Share

  456. AU WY, Ye C, Briner SL, Suarez GD, et al
    Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00123.
    >> Share

  457. GIMENEZ E, Albert E, Burgos JS, Peiro S, et al
    SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00124.
    >> Share

  458. BONGIOVANNI M, Spada E, De Angelis C, Liuzzi G, et al
    SARS-CoV-2: about reinfection, vaccination and neutralizing antibodies.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00125.
    >> Share

  459. SYED MA DR, A/Qotba HA Dr, Al Nuaimi AS Dr
    Effectiveness of COVID-19 vaccines in Qatar.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00121.
    >> Share

    February 2022
  460. HAYASHI JY, Simizo A, Miyamoto JG, Costa LVS, et al
    Humoral and Cellular Responses to Vaccination with Homologous CoronaVac or ChAdOx1 and Heterologous Third Dose with BNT162b2.
    J Infect. 2022 Feb 27. pii: S0163-4453(22)00115.
    >> Share

  461. KONIG S, Hohenstein S, Leiner J, Hindricks G, et al
    National mortality data for Germany before and throughout the pandemic: there is an excess mortality exceeding COVID-19-attributed fatalities.
    J Infect. 2022 Feb 26. pii: S0163-4453(22)00113.
    >> Share

  462. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load.
    J Infect. 2022 Feb 26. pii: S0163-4453(22)00114.
    >> Share

  463. PASCARELLA S, Ciccozzi M, Bianchi M, Benvenuto D, et al
    The value of electrostatic potentials of the Spike Receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 Variants. of Concern.
    J Infect. 2022 Feb 23. pii: S0163-4453(22)00112.
    >> Share

  464. DE MICHELENA P, Torres I, Ramos-Garcia A, Gozalbes V, et al
    Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant.
    J Infect. 2022 Feb 22. pii: S0163-4453(22)00110.
    >> Share

  465. SAHAY RR, Patil DY, Sapkal GN, Deshpande GR, et al
    SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00082.
    >> Share

  466. TANG K, Wu X, Luo Y, Wei Z, et al
    Meta-analysis of Immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00081.
    >> Share

  467. LIPPI G, Nocini R, Henry BM
    Is SARS-CoV-2 Omicron (B.1.1.529) variant causing different symptoms?
    J Infect. 2022 Feb 17. pii: S0163-4453(22)00077.
    >> Share

  468. SAEED A, Ahmad B, Majaz S, Nouroz F, et al
    Targeting Omicron and other reported SARS-CoV-2 lineages by Potent inhibitors of Main Protease 3CL Mpro: Molecular Simulation Analysis.
    J Infect. 2022 Feb 17. pii: S0163-4453(22)00079.
    >> Share

  469. ZHENG J, Wang Z, Li J, Zhang Y, et al
    High amounts of SARS-CoV-2 in aerosols exhaled by patients with Omicron variant infection.
    J Infect. 2022 Feb 17. pii: S0163-4453(22)00075.
    >> Share

  470. KWOK KO, Wei WI, Ma BHM, Ip M, et al
    Antibiotic use among COVID-19 patients in Hong Kong, January 2018 to March 2021.
    J Infect. 2022 Feb 17. pii: S0163-4453(22)00078.
    >> Share

  471. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Assessment 2 months after the administration of a 3rd dose mRNA: A new variant-adapted vaccine is expected.
    J Infect. 2022 Feb 15. pii: S0163-4453(22)00073.
    >> Share

  472. BLANCO I, Violan C, Suner C, Garcia-Prieto J, et al
    Comparison between mid-nasal swabs and buccal swabs for SARS-CoV-2 detection in mild COVID-19 patients.
    J Infect. 2022 Feb 13. pii: S0163-4453(22)00072.
    >> Share

  473. YADAV PD, Sapkal GN, Sahay RR, Potdar VA, et al
    Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concerns.
    J Infect. 2022 Feb 11. pii: S0163-4453(22)00070.
    >> Share

  474. RIGHI E, Mirandola M, Mazzaferri F, Dossi G, et al
    Determinants of Persistence of Symptoms and Impact on Physical and Mental Wellbeing in Long COVID: A Prospective Cohort Study.
    J Infect. 2022 Feb 9. pii: S0163-4453(22)00065.
    >> Share

  475. MIGUERES M, Dimeglio C, Tremeaux P, Abravanel F, et al
    Influence of immune escape and nasopharyngeal virus load on the spread of SARS-CoV-2 Omicron variant.
    J Infect. 2022 Feb 7. pii: S0163-4453(22)00054.
    >> Share

  476. ZHOU W, Zhong L, Tang X, Huang T, et al
    The early warning and monitoring of COVID-19 by using Baidu Search Index in China.
    J Infect. 2022 Feb 6. pii: S0163-4453(22)00063.
    >> Share

  477. LAZOR-BLANCHET C, Zygoura P, Dafni U, Lamoth F, et al
    Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period.
    J Infect. 2022 Feb 5. pii: S0163-4453(22)00062.
    >> Share

  478. WESTROP SJ, Whitaker HJ, Powell AA, Power L, et al
    Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
    J Infect. 2022 Feb 4. pii: S0163-4453(22)00055.
    >> Share

  479. WU Z, Liu J, Zhang H, Chang YF, et al
    The emergence of the novel avian influenza virus (H10N3) in China, 2020-a cause for concern?
    J Infect. 2022 Feb 3. pii: S0163-4453(22)00061.
    >> Share

  480. CUI H, Liu J, Zhang L
    The high expression of key components of inflammasome and pyroptosis might lead to severe COVID-19 infection in cancer patients.
    J Infect. 2022 Feb 3. pii: S0163-4453(22)00057.
    >> Share

  481. DIMEGLIO C, Migueres M, Mansuy JM, Saivin S, et al
    Antibody titers and breakthrough infections with Omicron SARS-CoV-2.
    J Infect. 2022 Feb 3. pii: S0163-4453(22)00060.
    >> Share

  482. KIVIT C, Groen K, Jongbloed M, Linssen C, et al
    An off-season outbreak of human metapneumovirus infections after ending of a COVID-19 lockdown.
    J Infect. 2022 Feb 3. pii: S0163-4453(22)00058.
    >> Share

  483. ESTOFOLETE CF, Fares GF, Banho CA, Sacchetto L, et al
    Predictors of death in COVID-19 vaccine breakthrough infections in Brazil.
    J Infect. 2022 Feb 2. pii: S0163-4453(22)00059.
    >> Share

  484. HAVDAL LB, Boas H, Bekkevold T, Kran AB, et al
    The burden of respiratory syncytial virus in children under 5 years of age in Norway.
    J Infect. 2022;84:205-215.
    >> Share

  485. LI Z, Tao B, Hu Z, Yi Y, et al
    Effects of short-term ambient particulate matter exposure on the risk of severe COVID-19.
    J Infect. 2022 Feb 1. pii: S0163-4453(22)00052.
    >> Share

    January 2022
  486. LIVINGSTONE R, Lin H, Brendish NJ, Poole S, et al
    Routine molecular point-of-care testing for SARS-CoV-2 reduces hospital-acquired COVID-19.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00049.
    >> Share

  487. XU W, Tang J, Chen C, Wang C, et al
    Safety and Efficacy of the Covid-19 Vaccine in children andor adolescents: A meta-analysis.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00050.
    >> Share

  488. MATTIUZZI C, Lippi G
    COVID-19 vaccines efficacy in preventing or limiting SARS-CoV-2 infections.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00051.
    >> Share

  489. JI G, Chen C, Zhou M, Wen W, et al
    Post-COVID-19 Fatigue among COVID-19 in patients discharged from hospital: A meta-analysis.
    J Infect. 2022 Jan 28. pii: S0163-4453(22)00031.
    >> Share

  490. MENSAH AA, Lacy J, Stowe J, Seghezzo G, et al
    Evaluation of disease severity during SARS-COV-2 reinfection, January 2020 to April 2021, England: an observational study.
    J Infect. 2022 Jan 24. pii: S0163-4453(22)00010.
    >> Share

  491. SCHEPERS M, Zanger P, Jahn K, Konig J, et al
    Multi-household social gatherings contribute to the second SARS-CoV-2 wave in Rhineland-Palatinate.
    J Infect. 2022 Jan 23. pii: S0163-4453(22)00028.
    >> Share

  492. RANA MS, Usman MM, Alam MM, Ikram A, et al
    Impact of previous SARS-CoV-2 infection on the rate of mortality in dengue. A preliminary report from Pakistan.
    J Infect. 2022 Jan 23. pii: S0163-4453(22)00027.
    >> Share

  493. GAO R, Xu Y, Zhu G, Zhou S, et al
    Genetic variation associated with COVID-19 is also associated with endometrial cancer.
    J Infect. 2022 Jan 22. pii: S0163-4453(22)00026.
    >> Share

  494. DUCLOUX D, Bamoulid J, Chabannes M, Colladant M, et al
    Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients.
    J Infect. 2022 Jan 21. pii: S0163-4453(22)00020.
    >> Share

  495. MAO Q, Wang C, Zhou M, Wen W, et al
    A meta-analysis of the association between calprotectin and the severity of COVID-19.
    J Infect. 2022 Jan 21. pii: S0163-4453(22)00023.
    >> Share

  496. FAVRESSE J, Bayart JL, David C, Dogne JM, et al
    Nucleocapsid Serum Antigen Determination in SARS-CoV-2 Infected Patients Using the Single Molecule Array Technology and Prediction of Disease Severity.
    J Infect. 2022 Jan 21. pii: S0163-4453(22)00022.
    >> Share

  497. ELFIKY AA, Ibrahim IM
    Host-cell recognition through Cs-GRP78 is enhanced in the new Omicron variant of SARS-CoV-2, in silico structural point of view.
    J Infect. 2022 Jan 18. pii: S0163-4453(22)00015.
    >> Share

  498. ZHANG Y, Jiang N, Qi W, Li T, et al
    Intra-host SARS-CoV-2 Single-Nucleotide Variants Emerged During the Early Stage of COVID-19 Pandemic Forecast Population Fixing Mutations.
    J Infect. 2022 Jan 15. pii: S0163-4453(22)00017.
    >> Share

  499. PILECKY M, Harm S, Bauer C, Zottl J, et al
    Performance of lateral flow assays for SARS-CoV-2 compared to RT-qPCR.
    J Infect. 2022 Jan 14. pii: S0163-4453(22)00011.
    >> Share

  500. XU Y, Gao R, Zhu G, Zhou S, et al
    Genetic variation of allergic disease is associated with the susceptibility to COVID-19.
    J Infect. 2022 Jan 14. pii: S0163-4453(22)00016.
    >> Share

  501. THANH TT, Nhan NTT, Anh NT, Chung LT, et al
    SARS-CoV-2 RNA loads in Vietnamese children.
    J Infect. 2022 Jan 13. pii: S0163-4453(22)00012.
    >> Share

  502. LIN M, Chen H, Wang Y, Qiu S, et al
    A Model Study on Predicting New COVID-19 Cases in China Based on Social and News Media.
    J Infect. 2022 Jan 9. pii: S0163-4453(22)00009.
    >> Share

  503. CHEN JM, Chen YQ, Sun YX
    Control of COVID-19 in China likely reduced the burden of multiple other infectious diseases.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00001.
    >> Share

  504. HAN X, Xu P, Wang H, Mao J, et al
    Incident changes in the prevalence of respiratory virus among children during COVID-19 pandemic in Hangzhou, China.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00006.
    >> Share

  505. FAUSTINI S, Shields A, Banham G, Wall N, et al
    Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00002.
    >> Share

  506. DE MICHELENA P, Torres I, Albert E, Bracho A, et al
    Impact of time elapsed since full vaccination on SARS-CoV-2 RNA load in Delta-variant breakthrough COVID-19.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00007.
    >> Share

  507. BORMAN AM, Fountain H, Guy R, Casale E, et al
    Increased mortality in COVID-19 patients with fungal co- and secondary infections admitted to intensive care or high dependency units in NHS hospitals in England.
    J Infect. 2022 Jan 4. pii: S0163-4453(21)00665.
    >> Share

  508. WHITAKER HJ, Tsang RS, Byford R, Andrews NJ, et al
    Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups.
    J Infect. 2022 Jan 3. pii: S0163-4453(21)00664.
    >> Share

  509. MARRAMS ARM, Kobayashi T, Suzuki H, Alsuhaibani M, et al
    Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis.
    J Infect. 2022 Jan 1. pii: S0163-4453(21)00658.
    >> Share

    December 2021
  510. SIMIONATTO VZ, Evaristo M, Santos EV, Mello R, et al
    SARS-CoV-2 SEROLOGICAL CROSS-REACTIVITY TESTING IN BRAZILIAN BLOOD DONORS, OCTOBER-DECEMBER, 2019.
    J Infect. 2021 Dec 31. pii: S0163-4453(21)00660.
    >> Share

  511. FINCH LS, Harris A, Lester C, Veal D, et al
    Implementation study of SARS-CoV-2 antigen lateral flow tests in men's professional (Premiership) rugby union sports squads in England during the COVID-19 pandemic.
    J Infect. 2021 Dec 30. pii: S0163-4453(21)00657.
    >> Share

  512. KAWAHARA T, Ueki Y, Nawa N, Miyamae S, et al
    Who is a super-spreader? Determinants of people with higher PCR copy number of SARS-CoV-2 during Mar 2020 to June 2021 in Japan.
    J Infect. 2021 Dec 30. pii: S0163-4453(21)00656.
    >> Share

  513. ARORA U, Priyadarshi M, Katiyar V, Soneja M, et al
    Novel risk factors for Coronavirus disease-associated mucormycosis(CAM): a case-control study during the outbreak in India.
    J Infect. 2021 Dec 30. pii: S0163-4453(21)00654.
    >> Share

  514. ZENG C, Ye Z, Fu L, Ye Y, et al
    Prediction analysis of porcine AXL protein as a potential receptor for SARS-CoV-2.
    J Infect. 2021 Dec 30. pii: S0163-4453(21)00655.
    >> Share

  515. XU B, Ma FQ, He C, Wu ZQ, et al
    Incidence and affecting factors of pulmonary diffusing capacity impairment with COVID-19 survivors 18 months after discharge in Wuhan, China.
    J Infect. 2021 Dec 25. pii: S0163-4453(21)00642.
    >> Share

  516. VENTERO MP, Moreno-Perez O, Molina-Pardines C, Paytuvi-Gallart A, et al
    Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients: a retrospective cohort study in a Mediterranean area.
    J Infect. 2021 Dec 25. pii: S0163-4453(21)00647.
    >> Share

  517. LAI X, Wang J, Duan J, Gong Y, et al
    Apoptosis inhibitor of macrophage differentiates bacteria from influenza or COVID-19 in hospitalized adults with community-acquired pneumonia.
    J Infect. 2021 Dec 23. pii: S0163-4453(21)00640.
    >> Share

  518. LI Y, Li P, Xi J, Yang J, et al
    Wild bird-origin H3N8 avian influenza virus exhibit well adaptation in mammalian host.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00637.
    >> Share

  519. DAVIS W, Duque J, Huang QS, Olson N, et al
    Sensitivity and specificity of surveillance case definitions in detection of influenza and respiratory syncytial virus among hospitalized patients, New Zealand, 2012-2016.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00635.
    >> Share

  520. GENG Y, Zhang L
    The impact of non-pharmaceutical interventions during COVID-19 pandemic on three children infectious diseases in China.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00645.
    >> Share

  521. MAANI AA, Wahaibi AA, Nazer W, Al-Zadjali N, et al
    The utilization of HCWs surveillance as an early warning of COVID-19 epidemic activity in the community.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00629.
    >> Share

  522. QIN G, Yang J, Zhao C, Ren J, et al
    The COVID-19 susceptibility of cancer patients might due to the high expression of SARS-CoV-2 required host factors.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00634.
    >> Share

  523. VINER R, Waddington C, Mytton O, Booy R, et al
    Transmission of SARS-CoV-2 by children and young people in households and schools: a meta-analysis of population-based and contact-tracing studies.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00633.
    >> Share

  524. SYED-ABDUL S, Babu AS, Bellamkonda RS, Itumalla R, et al
    Using Artificial Intelligence-based models to predict the risk of Mucormycosis among COVID-19 Survivors: An Experience from a public hospital in India.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00639.
    >> Share

  525. COLTELLA L, Ranno S, Piccioni L, Linardos G, et al
    Quantitative SARS-CoV-2 antigen test as a tool able to predict the stage of the infection.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00636.
    >> Share

  526. ORENES-PINERO E, Navas-Carrillo D, Moreno-Docon A, Ortega-Garcia JA, et al
    Confirmation of SARS-CoV-2 airborne dissemination indoors using "COVID-19 traps".
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00630.
    >> Share

  527. KHURRAM M, Ali G, Awan UA, Afzal MS, et al
    COVID-19 and alarming dengue co-epidemics in the dilapidated healthcare system in Pakistan: Where to focus!
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00638.
    >> Share

  528. GAO P, Zhang X, Zhang S, Yu Y, et al
    COVID-19 persists: Current risk of a recurrence of the epidemic in China.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00643.
    >> Share

  529. COSTA R, Olea B, Bracho MA, Albert E, et al
    RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00641.
    >> Share

  530. YAN F, Gao F
    Mutant EK1 with Q1004E/N1006I: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00644.
    >> Share

  531. RUBESHKUMAR P, John A, Narnaware M, M J, et al
    Persistent Post COVID-19 Symptoms and Functional Status after 12-14 weeks of recovery, Tamil Nadu, India, 2021.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00632.
    >> Share

  532. WANG R
    Genetic variation of interleukin-1 receptor type 1 is associated with severity of COVID-19 disease.
    J Infect. 2021 Dec 21. pii: S0163-4453(21)00631.
    >> Share

  533. MANOLACHE NG, Ursachi V, Scohy A, Desmet C, et al
    Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases.
    J Infect. 2021 Dec 14. pii: S0163-4453(21)00597.
    >> Share

  534. OWEN SI, Williams CT, Garrod G, Fraser AJ, et al
    Twelve lateral flow immunoassays (LFAs) to detect SARS-CoV-2 antibodies.
    J Infect. 2021 Dec 11. pii: S0163-4453(21)00598.
    >> Share

  535. FANG X, Ming C, Cen Y, Lin H, et al
    Post-sequelae one year after hospital discharge among older COVID-19 patients: a multi-center prospective cohort study.
    J Infect. 2021 Dec 10. pii: S0163-4453(21)00596.
    >> Share

  536. MAK WA, Koeleman JGM, van der Vliet M, Keuren F, et al
    SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.
    J Infect. 2021 Dec 9. pii: S0163-4453(21)00593.
    >> Share

  537. QUINTAO TSC, Slavov SN, de Oliveira PM, Bezerra RDS, et al
    Viral metagenomics in nasopharyngeal swabs of Brazilian patients negative for SARS-CoV-2 unveils the presence of Chikungunya virus infection.
    J Infect. 2021 Dec 5. pii: S0163-4453(21)00585.
    >> Share

  538. LUI G, Wong CK, Chan M, Chong KC, et al
    Host inflammatory response is the major marker of severe respiratory syncytial virus infection in older adults.
    J Infect. 2021;83:686-692.
    >> Share

    November 2021
  539. TANI N, Kawai N, Chong Y, Bando T, et al
    Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season.
    J Infect. 2021 Nov 30. pii: S0163-4453(21)00583.
    >> Share

  540. OESER C, Whitaker H, Linley E, Borrow R, et al
    Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.
    J Infect. 2021 Nov 30. pii: S0163-4453(21)00584.
    >> Share

  541. HAN X, Xu J, Hou H, Yang H, et al
    Significant association of pre-existing asthma with an increased risk for ICU admission among COVID-19 patients: Evidence based on a meta-analysis.
    J Infect. 2021 Nov 29. pii: S0163-4453(21)00582.
    >> Share

  542. MENTZER DAJ, James T, Yongya M, Cox S, et al
    Serum calprotectin is not an independent predictor of severe COVID-19 in ambulatory adult patients.
    J Infect. 2021 Nov 26. pii: S0163-4453(21)00580.
    >> Share

  543. ALDERSON MR, Arkwright PD, Bai X, Black S, et al
    Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review.
    J Infect. 2021 Nov 24. pii: S0163-4453(21)00578.
    >> Share

  544. BEHNOOD SA, Shafran R, Bennett SD, Zhang A, et al
    Persistent symptoms following SARS-CoV-2 infection among children and young people: a meta-analysis of controlled and uncontrolled studies.
    J Infect. 2021 Nov 20. pii: S0163-4453(21)00555.
    >> Share

  545. LEBOURGEOIS S, Menidjel R, Chenane HR, Ferre VM, et al
    Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
    J Infect. 2021 Nov 19. pii: S0163-4453(21)00556.
    >> Share

  546. LUO L, Luo T, Du M, Mei H, et al
    Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: a systematic review and meta-analysis.
    J Infect. 2021 Nov 19. pii: S0163-4453(21)00557.
    >> Share

  547. PAN D, Kim JW, Nazareth J, Assadi S, et al
    Quantification and prognostic significance of interferon-gamma secreting SARS-CoV-2 responsive T cells in hospitalised patients with acute COVID-19.
    J Infect. 2021 Nov 18. pii: S0163-4453(21)00554.
    >> Share

  548. TSAI SC, Chang WW, Lee WS
    Analysis of an outbreak of COVID-19(alpha-variant) with rapid progression to mortality in Taipei, Taiwan.
    J Infect. 2021 Nov 17. pii: S0163-4453(21)00553.
    >> Share

  549. TILLARD C, Chazard E, Faure K, Bartolo S, et al
    Burden of influenza disease in children under 2 years of age hospitalized between 2011 and 2020 in France.
    J Infect. 2021 Nov 13. pii: S0163-4453(21)00549.
    >> Share

  550. CHAPPELL H, Patel R, Driessens C, Tarr AW, et al
    Immunocompromised children and young people are at no increased risk of severe COVID-19.
    J Infect. 2021 Nov 13. pii: S0163-4453(21)00548.
    >> Share

  551. YAN X, Zhu S, Jin Z, Chen G, et al
    Persistence of anti-SARS-CoV-2 IgM in convalescent COVID-19 patients.
    J Infect. 2021 Nov 13. pii: S0163-4453(21)00550.
    >> Share

  552. BEN S, Xin J, Chen S, Jiang Y, et al
    Global internet search trends related to gastrointestinal symptoms predict regional COVID-19 outbreaks.
    J Infect. 2021 Nov 9. pii: S0163-4453(21)00546.
    >> Share

  553. MARTIN-VICENTE M, Berenguer J, Munoz-Gomez MJ, Diez C, et al
    Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19: Anti-SARS-CoV-2 S antibodies in PWH.
    J Infect. 2021 Nov 6. pii: S0163-4453(21)00545.
    >> Share

  554. BURGI JJ, Rosslein M, Hornung H, Jentsch J, et al
    Divergent humoral responses in mild to moderate SARS-CoV-2 infection over time - indication of persistence of the virus?: Indication of persistence of SARS-CoV-2?
    J Infect. 2021 Nov 5. pii: S0163-4453(21)00544.
    >> Share

  555. GIMENEZ E, Alberola J, Torres I, Albert E, et al
    Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2021 Nov 2. pii: S0163-4453(21)00542.
    >> Share

  556. HESKIN J, Pallett SJC, Mughal N, Jones R, et al
    Healthcare worker perceptions of routine asymptomatic SARS-CoV-2 screening using lateral flow assays: a qualitative analysis across two London hospitals.
    J Infect. 2021 Nov 1. pii: S0163-4453(21)00537.
    >> Share

    October 2021
  557. NISHIKIMI A, Watanabe K, Watanabe A, Yasuoka M, et al
    Prevalence of SARS-CoV-2 antibodies after one-year follow up among workers in a research institute in Japan.
    J Infect. 2021 Oct 30. pii: S0163-4453(21)00538.
    >> Share

  558. WANG J, Zou H, Corpe C
    An observed association between angiotensin-converting enzyme 2 polymorphisms and COVID-19 severity in China.
    J Infect. 2021 Oct 30. pii: S0163-4453(21)00536.
    >> Share

  559. YE Q, Liu H, Shang S
    Non-pharmaceutical interventions reduced the incidence and exacerbation of allergic diseases in children during the COVID-19 pandemic.
    J Infect. 2021 Oct 30. pii: S0163-4453(21)00541.
    >> Share

  560. LUMLEY SF, Richens N, Lees E, Cregan J, et al
    Changes in paediatric respiratory infections at a UK teaching hospital 2016-2021; impact of the SARS-CoV-2 pandemic.
    J Infect. 2021 Oct 29. pii: S0163-4453(21)00540.
    >> Share

  561. LI X, Chen H, Lu L, Chen LL, et al
    High compliance to infection control measures prevented guest-to-staff transmission in COVID-19 quarantine hotels.
    J Infect. 2021 Oct 26. pii: S0163-4453(21)00533.
    >> Share

  562. CHONG Y, Tani N, Goto T, Yonekawa A, et al
    Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents.
    J Infect. 2021 Oct 20. pii: S0163-4453(21)00508.
    >> Share

  563. EPAULARD O, Buisson M, Nemoz B, Marechal ML, et al
    Persistence at one year of neutralising antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use.
    J Infect. 2021 Oct 20. pii: S0163-4453(21)00507.
    >> Share

  564. GUPTA A, Bhoyar RC, Mirza S, Jolly B, et al
    SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker.
    J Infect. 2021 Oct 19. pii: S0163-4453(21)00506.
    >> Share

  565. GUO J, Yu H, Wang C, Yuan S, et al
    Re-emergence of Highly Pathogenic Avian Influenza A(H5N8) Virus In Domestic Goose, China.
    J Infect. 2021 Oct 17. pii: S0163-4453(21)00504.
    >> Share

  566. WANG MH, Lou J, Cao L, Zhao S, et al
    Characterization of key amino acid substitutions and dynamics of the influenza virus H3N2 hemagglutinin.
    J Infect. 2021 Oct 7. pii: S0163-4453(21)00498.
    >> Share

  567. BOSHIER FAT, Venturini C, Stirrup O, Guerra-Assuncao JA, et al
    The Alpha variant was not associated with excess nosocomial SARS-CoV-2 infection in a multi-centre UK hospital study.
    J Infect. 2021 Oct 2. pii: S0163-4453(21)00493.
    >> Share

  568. FERNANDEZ-DE-LAS-PENAS C, Gomez-Mayordomo V, de-la-Llave-Rincon AI, Palacios-Cena M, et al
    Anxiety, depression and poor sleep quality as long-term post-COVID sequelae in previously hospitalized patients: A multicenter study.
    J Infect. 2021;83:496-522.
    >> Share

  569. HUMBERT MV, Opurum PC, Brendish NJ, Poole S, et al
    A SARS-CoV-2 nucleocapsid ELISA represents a low-cost alternative to lateral flow testing for community screening in LMI countries.
    J Infect. 2021 Oct 1. pii: S0163-4453(21)00492.
    >> Share

    September 2021
  570. A A, M F, J CO, Ejm M, et al
    Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study.
    J Infect. 2021 Sep 30. pii: S0163-4453(21)00489.
    >> Share

  571. LEMENAND O, Coeffic T, Thibaut S, Colomb-Cotinat M, et al
    Decreasing proportion of extended-spectrum beta-lactamase among E. coli infections during the COVID-19 pandemic in France.
    J Infect. 2021 Sep 29. pii: S0163-4453(21)00486.
    >> Share

  572. FERRE VM, Lebourgeois S, Menidjel R, Collin G, et al
    Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
    J Infect. 2021 Sep 29. pii: S0163-4453(21)00488.
    >> Share

  573. LECOINTRE L, Venkatasamy A, Wehr M, Koch A, et al
    Multicentric evaluation of a 3D-printed simulator for COVID- 19 nasopharyngeal swab collection in testing centers.
    J Infect. 2021 Sep 24. pii: S0163-4453(21)00485.
    >> Share

  574. DIMEGLIO C, Herin F, Martin-Blondel G, Miedouge M, et al
    Antibody titers and protection against a SARS-CoV-2 infection.
    J Infect. 2021 Sep 21. pii: S0163-4453(21)00483.
    >> Share

  575. MCMILLAN T, Jones C, O'Connor CJ, Nolan D, et al
    Risk factors associated with bloodstream infections among critically ill patients with COVID-19.
    J Infect. 2021 Sep 16. pii: S0163-4453(21)00480.
    >> Share

  576. ALEMANY A, Millat-Martinez P, Ouchi D, Corbacho-Monne M, et al
    Self-collected mid-nasal swabs and saliva specimens, compared with nasopharyngeal swabs, for SARS-CoV-2 detection in mild COVID-19 patients.
    J Infect. 2021 Sep 16. pii: S0163-4453(21)00481.
    >> Share

  577. LUNA-MUSCHI A, Borges IC, de Faria E, Barboza AS, et al
    Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: a prospective cohort study of vaccinated and unvaccinated healthcare workers.
    J Infect. 2021 Sep 16. pii: S0163-4453(21)00474.
    >> Share

  578. FANG C, Zhou Z, Li J, Zhou M, et al
    Incident changes of rotavirus enteritis among children during the coronavirus disease-2019 pandemic in Hangzhou, China.
    J Infect. 2021 Sep 15. pii: S0163-4453(21)00478.
    >> Share

  579. AWAN UA, Malik MW, Khan MI, Khattak AA, et al
    Predicting COVID-19 incidence in war-torn Afghanistan: A timely response is required!
    J Infect. 2021 Sep 15. pii: S0163-4453(21)00473.
    >> Share

  580. CHEN H, Zhao X, Li L, Yan S, et al
    Mental health and physical symptoms of people quarantined during the COVID-19 outbreak.
    J Infect. 2021 Sep 15. pii: S0163-4453(21)00479.
    >> Share

  581. ZUO L, Ao G, Wang Y, Gao M, et al
    Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis.
    J Infect. 2021 Sep 14. pii: S0163-4453(21)00477.
    >> Share

  582. QIU S, Wang D, Zhang Y, Hu Y, et al
    Mendelian randomization reveals potential causal candidates for COVID-19 in 123 blood metabolites.
    J Infect. 2021 Sep 13. pii: S0163-4453(21)00471.
    >> Share

  583. OLEARO F, Norz D, Hoffman A, Grunwald M, et al
    Clinical performance and accuracy of a qPCR-based SARS-CoV-2 mass-screening workflow for healthcare-worker surveillance using pooled self-sampled gargling solutions: a cross-sectional study.
    J Infect. 2021 Sep 6. pii: S0163-4453(21)00451.
    >> Share

  584. QIU S, Zhang Y, Wang D, Hu Y, et al
    The high expression of SARS-CoV-2 cell receptors might lead to higher COVID-19 infection rates in cancer patients.
    J Infect. 2021 Sep 2. pii: S0163-4453(21)00449.
    >> Share

  585. LIANG J, Wang Z, Liu Y, Zeng L, et al
    Epidemiology and co-infection patterns in patients with respiratory tract infections in southern China between 2018 and 2020.
    J Infect. 2021;83:e6-e8.
    >> Share

  586. CHANDRA S, Rawal R
    The surge in Covid related mucormycosis.
    J Infect. 2021;83:381-412.
    >> Share

  587. ALKALAMOUNI H, Hitti E, Zaraket H
    Adopting fresh air ventilation may reduce the risk of airborne transmission of SARS-CoV-2 in COVID-19 unit.
    J Infect. 2021 Sep 1. pii: S0163-4453(21)00450.
    >> Share

    August 2021
  588. BHATTACHARYA A, Collin SM, Stimson J, Thelwall S, et al
    Healthcare-associated COVID-19 in England: a national data linkage study.
    J Infect. 2021 Aug 30. pii: S0163-4453(21)00443.
    >> Share

  589. STRALIN K, Bruce D, Wahlstrom E, Walther S, et al
    Impact of the Alpha VOC on disease severity in SARS-CoV-2-positive adults in Sweden.
    J Infect. 2021 Aug 30. pii: S0163-4453(21)00448.
    >> Share

  590. SNELL LB, Awan AR, Charalampous T, Alcolea-Medina A, et al
    SARS-CoV-2 variants with shortened incubation periods necessitate new definitions for nosocomial acquisition.
    J Infect. 2021 Aug 30. pii: S0163-4453(21)00445.
    >> Share

  591. QIU S, Hu Y, Cheng L
    A genome-wide cross-trait analysis highlights the shared genetic structure between COVID-19 and Alzheimer's disease.
    J Infect. 2021 Aug 26. pii: S0163-4453(21)00442.
    >> Share

  592. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected.
    J Infect. 2021 Aug 23. pii: S0163-4453(21)00433.
    >> Share

  593. QIU S, Hu Y
    Are COVID-19 susceptibility genes related to lung cancer?
    J Infect. 2021 Aug 23. pii: S0163-4453(21)00434.
    >> Share

  594. MORALES-ORTEGA A, Farfan-Sedano AI, Izquierdo-Martinez A, Llarena-Barroso C, et al
    Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients.
    J Infect. 2021 Aug 23. pii: S0163-4453(21)00436.
    >> Share

  595. GUIGON A, Faure E, Lemaire C, Chopin MC, et al
    Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance.
    J Infect. 2021 Aug 23. pii: S0163-4453(21)00435.
    >> Share

  596. KRAL S, Banfi C, Niedrist T, Sareban N, et al
    Long-lasting immune response to a mild course of PCR-confirmed SARS-CoV-2 infection: A cohort study.
    J Infect. 2021 Aug 22. pii: S0163-4453(21)00419.
    >> Share

  597. WEISSMAN YL, Cooper L, Sternbach N, Ashkenazi-Hoffnung L, et al
    Clinical efficacy and safety of high dose trivalent influenza vaccine in adults and immunosuppressed populations -a systematic review and meta-analysis.
    J Infect. 2021 Aug 20. pii: S0163-4453(21)00417.
    >> Share

  598. TEYSSOU E, Delagreverie H, Visseaux B, Lambert-Niclot S, et al
    The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19.
    J Infect. 2021 Aug 19. pii: S0163-4453(21)00416.
    >> Share

  599. BRAMLEY A, Crocker-Buque T, Breuer J, Mahungu TW, et al
    Evidence of the reduction of acute circulating communicable viruses during the SARS-CoV-2 pandemic in London.
    J Infect. 2021 Aug 19. pii: S0163-4453(21)00418.
    >> Share

  600. WANG C, Kang K, Lan X, Fei D, et al
    Cytokinelevels in sputum, not serum, may be more helpful 1 for indicating the damage in the lung and the prognosis of severe COVID-19 - A Case Series.
    J Infect. 2021 Aug 19. pii: S0163-4453(21)00415.
    >> Share

  601. YOU YS, Kim JS
    Influenza and Anosmia: important prediction factors for severity and death of COVID-19.
    J Infect. 2021 Aug 18. pii: S0163-4453(21)00413.
    >> Share

  602. GAO R, Zheng H, Liu K, Ji Z, et al
    Genesis, Evolution and Host Species Distribution of influenza A (H10N3) Virus in China.
    J Infect. 2021 Aug 17. pii: S0163-4453(21)00403.
    >> Share

  603. KRETSCHMER A, Kossow A, Grune B, Schildgen O, et al
    False positive rapid antigen tests for SARS-CoV-2 in the real-world and their economic burden.
    J Infect. 2021 Aug 17. pii: S0163-4453(21)00402.
    >> Share

  604. DOUXFILS J, Gillot C, Mullier F, Favresse J, et al
    Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ.
    J Infect. 2021 Aug 15. pii: S0163-4453(21)00405.
    >> Share

  605. ARANDA J, Oriol I, Martin M, Feria L, et al
    Long-term impact of COVID-19 associated acute respiratory distress syndrome.
    J Infect. 2021 Aug 13. pii: S0163-4453(21)00396.
    >> Share

  606. WEY EQ, Bristow C, Nandani A, O'Farrell B, et al
    Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19.
    J Infect. 2021 Aug 13. pii: S0163-4453(21)00400.
    >> Share

  607. LADHANI SN, Ireland G, Baawuah F, Beckmann J, et al
    Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: active prospective surveillance, December 2020 to March 2021, England.
    J Infect. 2021 Aug 13. pii: S0163-4453(21)00401.
    >> Share

  608. MOSELEY E, Williams P, Muir P, Marlow R, et al
    Influenza A/B and respiratory syncytial virus digital immunoassay evaluation in a paediatric emergency department.
    J Infect. 2021 Aug 11. pii: S0163-4453(21)00397.
    >> Share

  609. COSTA R, Bueno F, Gimenez E, Bracho A, et al
    Initial viral load and decay kinetics of SARS-CoV-2 lineage B.1.1.7 in the upper respiratory tract of adults and children.
    J Infect. 2021 Aug 11. pii: S0163-4453(21)00398.
    >> Share

  610. DONG M, Luo M, Li A, Xie H, et al
    Changes in the pathogenic spectrum of acute respiratory tract infections during the COVID-19 epidemic in Beijing, China: A large-scale active surveillance study.
    J Infect. 2021 Aug 11. pii: S0163-4453(21)00395.
    >> Share

  611. FURUSE Y, Tsnchiya N, Miyahara R, Yasuda D, et al
    COVID-19 case-clusters and transmission chains in the communities in Japan.
    J Infect. 2021 Aug 11. pii: S0163-4453(21)00399.
    >> Share

  612. ALLEN N, Brady M, Martin AIC, Domegan L, et al
    Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals.
    J Infect. 2021 Aug 9. pii: S0163-4453(21)00394.
    >> Share

  613. YAHI N, Chahinian H, Fantini J
    Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination ?
    J Infect. 2021 Aug 9. pii: S0163-4453(21)00392.
    >> Share

  614. KHAN MI, Qureshi H, Khattak AA, Awan UA, et al
    Predicting COVID-19 incidence in Pakistan: It's time to act now!
    J Infect. 2021 Aug 9. pii: S0163-4453(21)00393.
    >> Share

  615. FERNANDEZ-DE-LAS-PENAS C
    Post-COVID Functional Limitations on Daily Living Activities are Associated with Symptoms Experienced at the Acute Phase of SARS-CoV-2 Infection and Internal Care Unit Admission: A Multicenter Study.
    J Infect. 2021 Aug 7. pii: S0163-4453(21)00391.
    >> Share

  616. ZHANG J, Huang L, Chen Y, Wang X, et al
    Avian influenza H10 subtype viruses continuously pose threat to public health in China.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00386.
    >> Share


  617. Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00388.
    >> Share

  618. GOBBI F, Buonfrate D, Silva R, Martini D, et al
    Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine: SARS-CoV-2 infection early after the first vaccine dose.
    J Infect. 2021 Aug 6. pii: S0163-4453(21)00390.
    >> Share

  619. LAMB G, Heskin J, Randell P, Mughal N, et al
    Real-world evaluation of COVID-19 lateral flow device (LFD) mass-testing in healthcare workers at a London hospital; a prospective cohort analysis.
    J Infect. 2021 Aug 5. pii: S0163-4453(21)00383.
    >> Share


  620. Predominance of Delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021.
    J Infect. 2021 Aug 5. pii: S0163-4453(21)00387.
    >> Share

  621. TANNER AR, Phan H, Brendish NJ, Borca F, et al
    SARS-CoV-2 Viral load at presentation to hospital is independently associated with the risk of death.
    J Infect. 2021 Aug 4. pii: S0163-4453(21)00384.
    >> Share

  622. CHEN J, Li X, Xu L, Xie S, et al
    Health threats from increased antigenicity changes in H5N6-dominant subtypes, 2020 China.
    J Infect. 2021;83:e9-e11.
    >> Share

  623. FERNANDEZ-DE-LAS-PENAS C, Palacios-Cena D, Gomez-Mayordomo V, Rodriuez-Jimenez J, et al
    Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study.
    J Infect. 2021;83:237-279.
    >> Share

  624. FERNANDEZ-DE-LAS-PENAS C, Torres-Macho J, Velasco-Arribas M, Arias-Navalon JA, et al
    Similar prevalence of long-term post-COVID symptoms in patients with asthma: A case-control study.
    J Infect. 2021;83:237-279.
    >> Share

  625. MILLER E, Waight PA, Andrews NJ, McOwat K, et al
    Transmission of SARS-CoV-2 in the household setting: a prospective cohort study in children and adults in England.
    J Infect. 2021 Aug 1. pii: S0163-4453(21)00380.
    >> Share

    July 2021
  626. LUMLEY SF, Constantinides B, Sanderson N, Rodger G, et al
    Epidemiological data and genome sequencing reveals that nosocomial transmission of SARS-CoV-2 is underestimated and mostly mediated by a small number of highly infectious individuals.
    J Infect. 2021 Jul 28. pii: S0163-4453(21)00377.
    >> Share

  627. BENE MC, Bittencourt MC, Chevallier P
    Post-SARS-CoV-2 vaccination specific antibody decrease : let's get the half-full glass perspective.
    J Infect. 2021 Jul 28. pii: S0163-4453(21)00370.
    >> Share

  628. LIM SY, Kim JY, Lee JA, Kwon JS, et al
    Immune responses and reactogenicity after ChAdOx1 in individuals with past SARS-CoV-2 infection and those without.
    J Infect. 2021 Jul 28. pii: S0163-4453(21)00375.
    >> Share

  629. RAJAMANICKAM A, Kumar NP, Padmapriyadarsini C, Nancy A, et al
    Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection.
    J Infect. 2021 Jul 27. pii: S0163-4453(21)00372.
    >> Share

  630. RANA MS, Usman M, Salman M, Alam MM, et al
    Potential impact of COVID-19 Pandemic on escalating antimicrobial resistance in Pakistan.
    J Infect. 2021 Jul 27. pii: S0163-4453(21)00368.
    >> Share

  631. WHITTAKER R, Kristofferson AB, Seppala E, Salamanca BV, et al
    Trajectories of hospitalisation for patients infected with SARS-CoV-2 variant B.1.1.7 in Norway, December 2020 - April 2021.
    J Infect. 2021 Jul 27. pii: S0163-4453(21)00366.
    >> Share

  632. CIUFFREDA L, Salazar JML, Alcoba-Florez J, Rodriguez-Perez H, et al
    Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia.
    J Infect. 2021 Jul 27. pii: S0163-4453(21)00373.
    >> Share

  633. COSENTINO G, Bernard M, Ambroise J, Giannoli JM, et al
    SARS-CoV-2 viral dynamics in infections with Alpha and Beta variants of concern in the French community.
    J Infect. 2021 Jul 27. pii: S0163-4453(21)00374.
    >> Share

  634. EBANKS D, Faustini S, Shields A, Parry H, et al
    Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays.
    J Infect. 2021 Jul 26. pii: S0163-4453(21)00363.
    >> Share

  635. ROBERT TANNER A
    Increase in circulation of non-SARS-CoV-2 respiratory viruses following easing of social distancing is associated with increasing hospital attendance.
    J Infect. 2021 Jul 25. pii: S0163-4453(21)00365.
    >> Share

  636. GIDARI A, Sabbatini S, Bastianelli S, Pierucci S, et al
    Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
    J Infect. 2021 Jul 25. pii: S0163-4453(21)00362.
    >> Share

  637. LAI CK, Lui GC, Chen Z, Cheung YY, et al
    Comparison of Self-collected Mouth Gargle with Deep-throat Saliva Samples for the diagnosis of COVID-19: Mouth gargle for diagnosis of COVID-19.
    J Infect. 2021 Jul 25. pii: S0163-4453(21)00354.
    >> Share

  638. BOU-KARROUM L, Khabsa J, Jabbour M, Hilal N, et al
    Public Health Effects of Travel-Related Policies on the COVID-19 Pandemic: A Mixed-Methods Systematic Review.
    J Infect. 2021 Jul 24. pii: S0163-4453(21)00360.
    >> Share

  639. LADHANI SN
    Crossing the Rubicon: a Fine Line between Waiting and Vaccinating Adolescents against COVID-19.
    J Infect. 2021 Jul 21. pii: S0163-4453(21)00357.
    >> Share

  640. GUDIOL C, Dura-Miralles X, Aguilar-Company J, Hernandez-Jimenez P, et al
    Co-infections and superinfections complicating COVID-19 in cancer patients: a multicenter, international study.
    J Infect. 2021 Jul 21. pii: S0163-4453(21)00356.
    >> Share

  641. MOMBELLI M, Hoschler K, Cavassini M, Pascual M, et al
    Seasonal Trivalent Inactivated Influenza Vaccine with Topical Imiquimod in Immunocompromised Patients: a Randomized Controlled Trial.
    J Infect. 2021 Jul 20. pii: S0163-4453(21)00353.
    >> Share

  642. GAO S, Lu Y, Luan J, Zhang L, et al
    Low incidence rate of diarrhoea in COVID-19 patients is due to integrin.
    J Infect. 2021 Jul 15. pii: S0163-4453(21)00348.
    >> Share

  643. MATTIUZZI C, Henry BM, Lippi G
    Is diffusion of SARS-CoV-2 variants of concern associated with different symptoms?: Symptoms of COVID-19.
    J Infect. 2021 Jul 15. pii: S0163-4453(21)00347.
    >> Share

  644. VANCHEESWARAN R, Willcox ML, Stuart B, Knight M, et al
    Accuracy of Rapid Point-of-Care Antibody Test in patients with suspected or confirmed COVID-19.
    J Infect. 2021 Jul 14. pii: S0163-4453(21)00332.
    >> Share

  645. AVDEEV SN, Gaynitdinova VV, Merzhoeva ZM, Berikkhanov ZG, et al
    N-acetylcysteine for the treatment of COVID-19 among hospitalized patients.
    J Infect. 2021 Jul 10. pii: S0163-4453(21)00329.
    >> Share

  646. NIITSU T, Shiroyama T, Hirata H, Noda Y, et al
    Cytomegalovirus infection in critically ill patients with COVID-19.
    J Infect. 2021 Jul 9. pii: S0163-4453(21)00330.
    >> Share

  647. ANGELETTI S, Giovanetti M, Fogolari M, De Florio L, et al
    Detection of a SARS-CoV-2 P.1.1 variant lacking N501Y in a vaccinated Health Care worker in Italy.
    J Infect. 2021 Jul 5. pii: S0163-4453(21)00325.
    >> Share

  648. FAVRESSE J, Douxfils J
    Importance of Sample Dilution in the Evaluation of the Antibody Response after SARS-CoV-2 Vaccination.
    J Infect. 2021 Jul 4. pii: S0163-4453(21)00327.
    >> Share

  649. BARBOSA GR, Moreira LVL, Justo AFO, Perosa AH, et al
    Rapid spread and high impact of the variant of concern P.1 in the largest city of Brazil.
    J Infect. 2021;83:119-145.
    >> Share

  650. ROCHA AS, Meireles M, Vilaca H, Guimaraes TC, et al
    Outcomes of Covid-19 Organizing Pneumonia in Critically Ill Patients: OUTCOMES OF COVID-19 ORGANIZING PNEUMONIA.
    J Infect. 2021 Jul 1. pii: S0163-4453(21)00322.
    >> Share

    June 2021
  651. XIE D, Chu H, Yang D, Ding Q, et al
    A stark difference in the profiles of defective viral transcripts between SARS-CoV-2 and SARS-CoV.
    J Infect. 2021 Jun 30. pii: S0163-4453(21)00315.
    >> Share

  652. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00321.
    >> Share

  653. HSU L, Wisplinghoff H, Kossow A, Hurrass J, et al
    Limited protection against SARS-CoV-2 infection and virus transmission after mRNA vaccination.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00320.
    >> Share

  654. WANG Y, Niu S, Zhang B, Yang C, et al
    The whole genome analysis for the first human infection with H10N3 influenza virus in China.
    J Infect. 2021 Jun 27. pii: S0163-4453(21)00318.
    >> Share

  655. MENDEZ-BRITO A, Bcheraoui CE, Pozo-Martin F
    Systematic review of empirical studies comparing the effectiveness of non-pharmaceutical interventions against COVID-19.
    J Infect. 2021 Jun 20. pii: S0163-4453(21)00316.
    >> Share

  656. TRE-HARDY M, Cupaiolo R, Wilmet A, Beukinga I, et al
    Waning antibodies in SARS-CoV-2 naive vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.
    J Infect. 2021 Jun 20. pii: S0163-4453(21)00314.
    >> Share

  657. BUSKERMOLEN M, Te Paske K, van Beek J, Kortbeek T, et al
    Relapse in the first 8 weeks after onset of COVID-19 disease in outpatients: viral reactivation or inflammatory rebound?
    J Infect. 2021 Jun 17. pii: S0163-4453(21)00310.
    >> Share

  658. DIMEGLIO C, Herin F, Miedouge M, Da-Silva I, et al
    One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection.
    J Infect. 2021 Jun 17. pii: S0163-4453(21)00312.
    >> Share

  659. HOMMA Y, Katsuta T, Oka H, Inoue K, et al
    The incubation period of the SARS-CoV-2 B.1.1.7 variant is shorter than that of other strains.
    J Infect. 2021 Jun 16. pii: S0163-4453(21)00306.
    >> Share

  660. ANDERSEN MP, Ostergaard L, Phelps M, Butt JH, et al
    Risk of Coronavirus Disease 2019 (Covid-19) Contraction and Severe Infection in Home- or Healthcare Professionals.
    J Infect. 2021 Jun 15. pii: S0163-4453(21)00305.
    >> Share

  661. CENDEJAS-BUENO E, Romero-Gomez MP, Escosa L, Jimenez-Rodriguez S, et al
    Lower nasopharyngeal viral loads in pediatric population. The missing piece to understand SARS-CoV-2 infection in children?
    J Infect. 2021 Jun 13. pii: S0163-4453(21)00289.
    >> Share

  662. LOFFREDO L, Oliva A, Paraninfi A, Ceccarelli G, et al
    An observed association between conjunctivitis and severity of COVID-19.
    J Infect. 2021 Jun 9. pii: S0163-4453(21)00286.
    >> Share

  663. KWOK KO, McNeil EB, Tsoi MTF, Wei VWI, et al
    Will achieving herd immunity be a road to success to end the COVID-19 pandemic?
    J Infect. 2021 Jun 9. pii: S0163-4453(21)00287.
    >> Share

  664. NOH JY, Song JY, Hyun HJ, Yoon JG, et al
    Risk factors for SARS-CoV-2 transmission in non-household clusters.
    J Infect. 2021 Jun 8. pii: S0163-4453(21)00284.
    >> Share

  665. RISTIC S, Pavlic SD, Nadalin S, Cizmarevic NS, et al
    ACE I/D polymorphism and epidemiological findings for COVID-19: one year after the pandemic outbreak in Europe.
    J Infect. 2021 Jun 4. pii: S0163-4453(21)00282.
    >> Share

  666. LORENZO VB, Nascimento-Carvalho C
    Differences between children with severe acute lower respiratory infection with or without SARS-Cov-2 infection.
    J Infect. 2021 Jun 3. pii: S0163-4453(21)00280.
    >> Share

  667. FANTINI J, Yahi N, Azzaz F, Chahinian H, et al
    Structural dynamics of SARS-CoV-2 variants: a health monitoring strategy for anticipating Covid-19 outbreaks.
    J Infect. 2021 Jun 2. pii: S0163-4453(21)00281.
    >> Share

  668. STANG A, Robers J, Schonert B, Jockel KH, et al
    The performance of the SARS-CoV-2 RT-PCR test as a tool for detecting SARS-CoV-2 infection in the population.
    J Infect. 2021 Jun 1. pii: S0163-4453(21)00265.
    >> Share

  669. OLEA B, Albert E, Torres I, Gozalvo-Rovira R, et al
    Lower respiratory tract and plasma SARS-CoV-2 RNA load in critically ill adult COVID-19 patients: relationship with biomarkers of disease severity.
    J Infect. 2021 Jun 1. pii: S0163-4453(21)00279.
    >> Share

    May 2021
  670. KONTOGIANNI K, Cubas-Atienzar AI, Wooding D, Buist K, et al
    Lateral flow antigen tests can sensitively detect live cultured virus of the SARS-CoV-2 B.1.1.7 lineage.
    J Infect. 2021 May 29. pii: S0163-4453(21)00272.
    >> Share

  671. TANG JW, Bird PW, Holmes CW, Nicoara DC, et al
    The UK Leicester COVID-19 'exceedance' May-July 2020: An analysis of hospitalised cases.
    J Infect. 2021 May 29. pii: S0163-4453(21)00270.
    >> Share

  672. ZHANG N, Chen X, Jia W, Jin T, et al
    Evidence for lack of transmission by close contact and surface touch in a restaurant outbreak of COVID-19.
    J Infect. 2021 May 29. pii: S0163-4453(21)00273.
    >> Share

  673. YAN X, Huang H, Wang C, Jin Z, et al
    Follow-up study of pulmonary function among COVID-19 survivors 1 year after recovery.
    J Infect. 2021 May 29. pii: S0163-4453(21)00276.
    >> Share

  674. RAW RK, Kelly C, Rees J, Wroe C, et al
    Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination.
    J Infect. 2021 May 29. pii: S0163-4453(21)00277.
    >> Share

  675. BUTT AA, Khan T, Yan P, Shaikh OS, et al
    Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination.
    J Infect. 2021 May 28. pii: S0163-4453(21)00263.
    >> Share

  676. PALLOTTO C, Blanc P, Esperti S, Suardi LR, et al
    Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).
    J Infect. 2021 May 28. pii: S0163-4453(21)00267.
    >> Share

  677. THANGARAJ JWV, Kumar MS, Kumar CG, Kumar VS, et al
    Persistence of humoral immune response to SARS-CoV-2 up to 7 months post-infection: Cross-sectional study, South India, 2020-21.
    J Infect. 2021 May 28. pii: S0163-4453(21)00268.
    >> Share

  678. BREATHNACH AS, Duncan CJA, Bouzidi KE, Hanrath AT, et al
    Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies.
    J Infect. 2021 May 27. pii: S0163-4453(21)00266.
    >> Share

  679. CAPETTI AF, Borgonovo F, Mileto D, Gagliardi G, et al
    One-year durability of anti-spike IgG to SARS-CoV-2: preliminary data from the AntiCROWN prospective observational study One year durability of COVID-19 anti-spike IgG.
    J Infect. 2021 May 27. pii: S0163-4453(21)00264.
    >> Share

  680. VENTURAS J, Zamparini J, Shaddock E, Stacey S, et al
    Comparison of outcomes in HIV-positive and HIV-negative patients with COVID-19.
    J Infect. 2021 May 26. pii: S0163-4453(21)00262.
    >> Share

  681. J BP, Jolly B, John N, Bhoyar RC, et al
    Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India.
    J Infect. 2021 May 24. pii: S0163-4453(21)00260.
    >> Share

  682. YAMAMOTO S, Tanaka A, Oshiro Y, Ishii M, et al
    Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan.
    J Infect. 2021 May 24. pii: S0163-4453(21)00259.
    >> Share

  683. HASAN MJ, Rabbani R, Anam AM, Huq SMR, et al
    Secukinumab in severe COVID-19 pneumonia: does it have a clinical impact?: Secukinumab in severe COVID-19.
    J Infect. 2021 May 21. pii: S0163-4453(21)00253.
    >> Share

  684. SZARPAK L
    Mucormycosis - a serious threat in the COVID-19 pandemic?
    J Infect. 2021 May 21. pii: S0163-4453(21)00257.
    >> Share

  685. FONSECA V, de Jesus R, Adelino T, Reis AB, et al
    Genomic evidence of SARS-CoV-2 reinfection case with the emerging B.1.2 variant in Brazil.
    J Infect. 2021 May 21. pii: S0163-4453(21)00256.
    >> Share

  686. BORDI L, Parisi G, Sberna G, Amendola A, et al
    Effective screening strategy against SARS-CoV-2 on self-collected saliva samples in primary school setting: a pilot project.
    J Infect. 2021 May 20. pii: S0163-4453(21)00254.
    >> Share

  687. CARAMELLO V, Boccuzzi A, Basile V, Ferraro A, et al
    Are antigenic tests useful for detecting SARS-CoV-2 infections in patients accessing to emergency departments? Results from a North-West Italy Hospital.
    J Infect. 2021 May 20. pii: S0163-4453(21)00255.
    >> Share

  688. ZARIF A, Joy M, Sherlock J, Sheppard JP, et al
    The impact of primary care supported shielding on the risk of mortality in people vulnerable to COVID-19: English sentinel network matched cohort study.
    J Infect. 2021 May 15. pii: S0163-4453(21)00220.
    >> Share

  689. CHIRICO F, Nucera G, Szarpak L
    COVID-19 mortality in Italy: The first wave was more severe and deadly, but only in Lombardy region.
    J Infect. 2021 May 13. pii: S0163-4453(21)00248.
    >> Share

  690. KOROMPOKI E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, et al
    Epidemiology and organ specific sequelae of post-acute COVID19: A Narrative Review.
    J Infect. 2021 May 13. pii: S0163-4453(21)00247.
    >> Share

  691. KOW CS, Merchant HA, Hasan SS
    Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK.
    J Infect. 2021 May 13. pii: S0163-4453(21)00250.
    >> Share

  692. HOTHAM M
    Potential future implications of the COVID-19 pandemic on Norovirus infections in England.
    J Infect. 2021 May 13. pii: S0163-4453(21)00241.
    >> Share

  693. MANN JA, Bird PW, Bandi S, Tang JW, et al
    Asymptomatic SARS-CoV-2-infected children attending hospital with non-COVID-19 diagnoses, March 2020-February 2021.
    J Infect. 2021 May 13. pii: S0163-4453(21)00240.
    >> Share

  694. WINCHESTER S, John S, Jabbar K, John I, et al
    Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection.
    J Infect. 2021 May 13. pii: S0163-4453(21)00251.
    >> Share

  695. WHITAKER HJ, Elgohari S, Rowe C, Otter AD, et al
    Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021.
    J Infect. 2021 May 11. pii: S0163-4453(21)00224.
    >> Share

  696. FERNANDEZ-VILLA T, Vazquez-Casares A, Rivero-Rodriguez A, Carvajal-Urena A, et al
    Rapid antigen test for SARS-CoV-2 and primary health care.
    J Infect. 2021 May 7. pii: S0163-4453(21)00226.
    >> Share

  697. SANSONE E, Tiraboschi M, Sala E, Albini E, et al
    Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.
    J Infect. 2021 May 6. pii: S0163-4453(21)00225.
    >> Share

  698. MACLOT F, Bontems S, Meex C, Artesi M, et al
    Development of a multiplex RT-qPCR using the drop out strategy to screen the SARS-CoV-2 South African 501Y.V2 variant.
    J Infect. 2021 May 3. pii: S0163-4453(21)00221.
    >> Share

  699. MATAKI N, Ohmura H, Kodama T, Nakamura S, et al
    Myxovirus resistance protein A in peripheral blood predicts supplemental oxygen need in COVID-19.
    J Infect. 2021;82:186-230.
    >> Share

  700. RICCO M, Ranzieri S, Marchesi F
    Rapid antigen tests for large-scale diagnostic campaigns: A case study from North-Eastern Italy.
    J Infect. 2021;82:e39-e40.
    >> Share

    April 2021
  701. DE PAULA CSY, Palandri GG, Fonseca TS, Vendramini TCA, et al
    Gastrointestinal manifestations are associated with severe pediatric COVID-19: a study in tertiary hospital.
    J Infect. 2021 Apr 30. pii: S0163-4453(21)00217.
    >> Share

  702. GARVEY MI, Wilkinson MAC, Holden E, Shields A, et al
    Early observations on the impact of a healthcare worker COVID-19 vaccination programme at a major UK tertiary centre.
    J Infect. 2021 Apr 29. pii: S0163-4453(21)00214.
    >> Share

  703. CHUDASAMA DY, Flannagan J, Collin SM, Charlett A, et al
    Household clustering of SARS-CoV-2 variant of concern B.1.1.7 (VOC-202012-01) in England.
    J Infect. 2021 Apr 29. pii: S0163-4453(21)00216.
    >> Share

  704. VUSIRIKALA A, Whitaker H, Jones S, Tessier E, et al
    Seroprevalence of SARS-CoV-2 Antibodies in University Students: cross-sectional study, December 2020, England.
    J Infect. 2021 Apr 29. pii: S0163-4453(21)00215.
    >> Share

  705. TEYSSOU E, Soulie C, Visseaux B, Lambert-Niclot S, et al
    The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.
    J Infect. 2021 Apr 28. pii: S0163-4453(21)00211.
    >> Share

  706. BAEK YJ, Lee YJ, Yoon JS, Sohn Y, et al
    Duration of culturable SARS-CoV-2 within different specimens among mild and severe COVID-19 patients: a longitudinal study.
    J Infect. 2021 Apr 28. pii: S0163-4453(21)00212.
    >> Share

  707. BONGIOVANNI M, Arienti R, Bini F, Bodini BD, et al
    Differences between the waves in Northern Italy: how the characteristics and the outcome of COVID-19 infected patients admitted to the emergency room have changed.
    J Infect. 2021 Apr 28. pii: S0163-4453(21)00210.
    >> Share

  708. GARVEY MI, McMurray C, Casey AL, Ratcliffe L, et al
    Observations of SARS-CoV-2 variant of concern B.1.1.7 at the UK's largest hospital Trust.
    J Infect. 2021 Apr 28. pii: S0163-4453(21)00213.
    >> Share

  709. GALOW L, Haag L, Kahre E, Blankenburg J, et al
    Lower household transmission rates of SARS-CoV-2 from children compared to adults.
    J Infect. 2021 Apr 27. pii: S0163-4453(21)00209.
    >> Share

  710. MARTIN-SANCHEZ M, Lim WW, Yeung A, Adam DC, et al
    COVID-19 transmission in Hong Kong despite universal masking.
    J Infect. 2021 Apr 22. pii: S0163-4453(21)00205.
    >> Share

  711. LI KK, Woo YM, Stirrup O, Hughes J, et al
    Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - a high risk community-hospital interface.
    J Infect. 2021 Apr 22. pii: S0163-4453(21)00206.
    >> Share

  712. CHEN S, Zhang X, Zhou Y, Yang K, et al
    COVID-19 protective measures prevent the spread of respiratory and intestinal infectious diseases but not sexually transmitted and bloodborne diseases.
    J Infect. 2021 Apr 22. pii: S0163-4453(21)00204.
    >> Share

  713. STOCKDALE AJ, Fyles F, Farrell C, Lewis J, et al
    Sensitivity of SARS-CoV-2 RNA polymerase chain reaction using a clinical and radiological reference standard: Clinical sensitivity of SARS-CoV-2 PCR.
    J Infect. 2021 Apr 20. pii: S0163-4453(21)00198.
    >> Share

  714. FAROOQ HZ, Davies E, Brown B, Whitfield T, et al
    Real-world SARS CoV-2 Testing in Northern England during the first wave of the COVID-19 Pandemic.
    J Infect. 2021 Apr 20. pii: S0163-4453(21)00199.
    >> Share

  715. FU H, Zhang N, Zheng Y, Jiang N, et al
    Risk stratification of cardiac sequelae detected using cardiac magnetic resonance in late convalescence at the six-month follow-up of recovered COVID-19 patients.
    J Infect. 2021 Apr 19. pii: S0163-4453(21)00202.
    >> Share

  716. BARO B, Rodo P, Ouchi D, Bordoy AE, et al
    Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison.
    J Infect. 2021 Apr 18. pii: S0163-4453(21)00191.
    >> Share

  717. KODANA M, Kitagawa Y, Takahashi R, Matsuoka M, et al
    Concerns about the clinical usefulness of saliva specimens 1 for the diagnosis of COVID-19.
    J Infect. 2021 Apr 16. pii: S0163-4453(21)00194.
    >> Share

  718. ALCOBA-FLOREZ J, Lorenzo-Salazar JM, Gil-Campesino H, Inigo-Campos A, et al
    Monitoring the rise of the SARS-CoV-2 lineage B.1.1.7 in Tenerife (Spain) since mid-December 2020.
    J Infect. 2021 Apr 12. pii: S0163-4453(21)00168.
    >> Share

  719. DONADIO C, Rainone A, Gouronnec A, Belmin J, et al
    Asymptomatic COVID-19 cases among older patients despite BNT162b2 vaccination: a case series in a geriatric rehabilitation ward during an outbreak.
    J Infect. 2021 Apr 11. pii: S0163-4453(21)00167.
    >> Share

  720. BONGIOVANNI M, Marra AM, Bini F, Bodini BD, et al
    COVID-19 reinfection in healthcare workers: a case series.
    J Infect. 2021 Apr 8. pii: S0163-4453(21)00165.
    >> Share

  721. LIU Y, Chen H, Tan W, Kuang Y, et al
    Clinical characteristics and outcome of SARS-CoV-2 infection during pregnancy.
    J Infect. 2021 Apr 5. pii: S0163-4453(21)00163.
    >> Share

  722. TABOADA M, Gonzalez M, Alvarez A, Eiras M, et al
    First, second and third wave of COVID-19. What have we changed in the ICU management of these patients?
    J Infect. 2021 Apr 4. pii: S0163-4453(21)00160.
    >> Share

  723. NAYAGAM JS, Jeyaraj R, Mitchell T, Walder DP, et al
    Persistent cholestasis in survivors of SARS-CoV-2.
    J Infect. 2021 Apr 4. pii: S0163-4453(21)00162.
    >> Share

  724. OGURI S, Fujisawa S, Kamada K, Nakakubo S, et al
    Effect of varying storage conditions on diagnostic test outcomes of SARS-CoV-2.
    J Infect. 2021 Apr 3. pii: S0163-4453(21)00159.
    >> Share

  725. GARCIA-PACHON E, Grau-Delgado J, Soler-Sempere MJ, Zamora-Molina L, et al
    Low prevalence of post-COVID-19 syndrome in patients with asthma.
    J Infect. 2021 Apr 2. pii: S0163-4453(21)00156.
    >> Share

    March 2021
  726. MASIA M, Padilla S, Galiana A, Fernandez-Gonzalez M, et al
    Incidence of delayed asymptomatic COVID-19 recurrences in a 6-month longitudinal study.
    J Infect. 2021 Mar 29. pii: S0163-4453(21)00152.
    >> Share

  727. PILLAI A, Koduri K, Gokhale Y, Venkatesh M, et al
    Covid-19 Letter to the Editor.
    J Infect. 2021 Mar 28. pii: S0163-4453(21)00154.
    >> Share

  728. MULCHANDANI R, Taylor-Philips S, Jones HE, Ades AE, et al
    Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers.
    J Infect. 2021 Mar 25. pii: S0163-4453(21)00151.
    >> Share

  729. WILLIAMS CM, Pan D, Decker J, Wisniewska A, et al
    Exhaled SARS-CoV-2 quantified by face-mask sampling in hospitalised patients with covid-19.
    J Infect. 2021 Mar 24. pii: S0163-4453(21)00135.
    >> Share

  730. CHAU DNVV
    Rapid whole-genome sequencing to inform COVID-19 outbreak response in Vietnam.
    J Infect. 2021 Mar 24. pii: S0163-4453(21)00133.
    >> Share

  731. HARRIS RJ, Whitaker HJ, Andrews NJ, Aiano F, et al
    Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers.
    J Infect. 2021 Mar 22. pii: S0163-4453(21)00132.
    >> Share

  732. HIROTSU Y, Omata M
    Discovery of a SARS-CoV-2 variant 1 from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan.
    J Infect. 2021 Mar 22. pii: S0163-4453(21)00130.
    >> Share

  733. MURRAY MJ, McIntosh M, Atkinson C, Mahungu T, et al
    Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.
    J Infect. 2021 Mar 19. pii: S0163-4453(21)00127.
    >> Share

  734. THARMARAJAH E, Buazon A, Patel V, Hannah JR, et al
    IL-6 inhibition in the treatment of COVID-19: a meta-analysis and meta-regression.
    J Infect. 2021 Mar 18. pii: S0163-4453(21)00125.
    >> Share

  735. WILLIAMS P, McWilliams C, Soomro K, Harding I, et al
    The dynamics of procalcitonin in COVID-19 patients admitted to Intensive Care Unit - A multi-centre cohort study in the South West of England, UK.
    J Infect. 2021 Mar 18. pii: S0163-4453(21)00128.
    >> Share

  736. GARVEY MI, Casey AL, Wilkinson MAC, Ratcliffe L, et al
    Details of SARS-CoV-2 reinfections at a major UK tertiary centre.
    J Infect. 2021 Mar 17. pii: S0163-4453(21)00122.
    >> Share

  737. BIRD PW, Holmes C, Fletcher O, Badhwar V, et al
    Retrospective serosurveillance for anti-SARS-CoV-2 immunoglobulin during a time of low prevalence: A cautionary tale.
    J Infect. 2021 Mar 17. pii: S0163-4453(21)00124.
    >> Share

  738. SHAN FZ, Zhu LL, Zhang Y, Tang YH, et al
    Comparison of the role of neutrophil extracellular traps between patients admitted to the intensive care unit with influenza A and B virus infection.
    J Infect. 2021 Mar 15. pii: S0163-4453(21)00121.
    >> Share

  739. REBOIRO MLL, Fuentetaja RS, Lopez RG, Castro-Conde BA, et al
    Role of lupus anticoagulant and von Willebrand factor in chronic reactive endotheliitis in COVID-19.
    J Infect. 2021 Mar 15. pii: S0163-4453(21)00123.
    >> Share

  740. CHAUDHRY Z, Shawe-Taylor M, Rampling T, Cutfield T, et al
    Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate.
    J Infect. 2021 Mar 11. pii: S0163-4453(21)00115.
    >> Share

  741. YANG H, Hou H, Liang X, Xu J, et al
    Lack of significant association between dyslipidemia and COVID-19 mortality.
    J Infect. 2021 Mar 5. pii: S0163-4453(21)00114.
    >> Share

  742. MARTYN EM, Whitaker H, Gil E, Ighomereho P, et al
    Disproportionate impact of SARS-CoV-2 on ethnic minority and frontline healthcare workers: A cross-sectional seroprevalence survey at a North London hospital.
    J Infect. 2021 Mar 4. pii: S0163-4453(21)00098.
    >> Share

  743. YOUNG BC, Eyre DW, Jeffery K
    Use of lateral flow devices allows rapid triage of patients with SARS-CoV-2 on admission to hospital.
    J Infect. 2021 Mar 1. pii: S0163-4453(21)00096.
    >> Share

  744. BADDAL B, Bostanci A, Suer K, Sanlidag T, et al
    SARS-CoV-2 was already in circulation in Northern Cyprus in the prepandemic period.
    J Infect. 2021 Mar 1. pii: S0163-4453(21)00097.
    >> Share

    February 2021
  745. PETRONE L, Petruccioli E, Alonzi T, Vanini V, et al
    In-vitro evaluation of the immunomodulatory effects of baricitinib: implication for COVID-19 therapy.
    J Infect. 2021 Feb 24. pii: S0163-4453(21)00094.
    >> Share

  746. MENSAH AA, Sinnathamby M, Zaidi A, Coughlan L, et al
    SARS-CoV-2 infections in children following the full re-opening of schools and the impact of national lockdown: prospective, national observational cohort surveillance, July-December 2020, England.
    J Infect. 2021 Feb 24. pii: S0163-4453(21)00093.
    >> Share

  747. DENNY S, Abdolrasouli A, Elamin T, Gonzalo X, et al
    A retrospective multicenter analysis of candidaemia among COVID-19 patients during the first UK pandemic wave.
    J Infect. 2021 Feb 18. pii: S0163-4453(21)00090.
    >> Share

  748. SCIMECA M, Mauriello S, Servadei F, Caggiano B, et al
    Persistence of SARS-CoV-2 viral RNA in nasopharyngeal swabs after death.
    J Infect. 2021 Feb 17. pii: S0163-4453(21)00083.
    >> Share

  749. ANTONELLI M, Capdevila J, Chaudhari A, Granerod J, et al
    Optimal symptom combinations to aid COVID-19 case identification: analysis from a community-based, prospective, observational cohort.
    J Infect. 2021 Feb 13. pii: S0163-4453(21)00079.
    >> Share

  750. BULILETE O, Lorente P, Leiva A, Carandell E, et al
    Panbio rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care.
    J Infect. 2021 Feb 13. pii: S0163-4453(21)00080.
    >> Share

  751. TORRES I, Poujois S, Albert E, Alvarez G, et al
    Point-of-care evaluation of a rapid antigen test (CLINITEST() Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals.
    J Infect. 2021 Feb 12. pii: S0163-4453(21)00075.
    >> Share

  752. YANG H, Liang X, Hou H, Xu J, et al
    The association of dementia with COVID-19 mortality: Evidence based on adjusted effect estimates.
    J Infect. 2021 Feb 11. pii: S0163-4453(21)00078.
    >> Share

  753. LORA-TAMAYO J, Maestro G, Lalueza A, Rubio-Rivas M, et al
    Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.
    J Infect. 2021 Feb 11. pii: S0163-4453(21)00077.
    >> Share

  754. NADAL M, Lassel L, Denis M, Gibelin A, et al
    ROLE OF SUPER-SPREADER PHENOMENON IN A COVID-19 CLUSTER AMONG HEALTHCARE WORKERS IN A PRIMARY CARE HOSPITAL.
    J Infect. 2021 Feb 10. pii: S0163-4453(21)00074.
    >> Share

  755. SCUTT DG, Overall DA
    Single nucleotide polymorphisms in key aging pathways, and phenotypic markers of frailty are associated with increased odds of hospital admission with COVID-19.
    J Infect. 2021 Feb 10. pii: S0163-4453(21)00056.
    >> Share

  756. EIGNER U, Verstraeten T, Weil J
    Decrease in Norovirus infections in Germany following COVID-19 containment measures.
    J Infect. 2021 Feb 10. pii: S0163-4453(21)00076.
    >> Share

  757. ADRIELLE DOS SANTOS L, Filho PGG, Silva AMF, Santos JVG, et al
    Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers.
    J Infect. 2021 Feb 9. pii: S0163-4453(21)00043.
    >> Share

  758. KEVORKIAN JP, Lopes A, Sene D, Riveline JP, et al
    Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study.
    J Infect. 2021 Feb 9. pii: S0163-4453(21)00058.
    >> Share

  759. LI G, Niu J, Fan X, Chen T, et al
    The chilly climate may increase the chance of infecting COVID-19.
    J Infect. 2021 Feb 8. pii: S0163-4453(21)00057.
    >> Share

  760. DE MONTMOLLIN E, Faille D, Andrieu V, Ajzenberg N, et al
    Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
    J Infect. 2021 Feb 5. pii: S0163-4453(21)00054.
    >> Share

  761. BELSKY JA, Tullius BP, Lamb MG, Sayegh R, et al
    COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients.
    J Infect. 2021 Feb 4. pii: S0163-4453(21)00045.
    >> Share

  762. MORALES-ORTEGA A, Rivas-Prado L, Frutos-Perez B, Jaenes-Barrios B, et al
    Early clinical experience with imatinib in COVID-19: searching for a dual effect.
    J Infect. 2021 Feb 4. pii: S0163-4453(21)00051.
    >> Share

  763. TOOVEY OTR, Harvey KN, Bird PW, Tang JWW, et al
    Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK.
    J Infect. 2021 Feb 3. pii: S0163-4453(21)00047.
    >> Share

  764. BORGONOVO F, Passerini M, Piscaglia M, Morena V, et al
    Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study.
    J Infect. 2021 Feb 3. pii: S0163-4453(21)00048.
    >> Share

  765. WILSON-DAVIES ESW, Mahanama AIK, Samaraweera B, Ahmed N, et al
    Concerns regarding the sensitivity of the OptiGene direct SARS-CoV-2 LAMP assay and its suitability for use in at-risk groups and hospital staff.
    J Infect. 2021 Feb 2. pii: S0163-4453(21)00036.
    >> Share

  766. ALMHAWISH N, Karah N, Elferruh Y, Aksh A, et al
    Protecting healthcare workers in conflict zones during the COVID-19 pandemic: northwest Syria.
    J Infect. 2021 Feb 2. pii: S0163-4453(21)00046.
    >> Share

  767. TUBIANA S, Burdet C, Houhou N, Thy M, et al
    High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in in-hospital workers - the CoV-CONTACT cohort.
    J Infect. 2021 Feb 2. pii: S0163-4453(21)00049.
    >> Share

  768. FOWLER DV, Douglas DA, Godfrey PK, Williams PA, et al
    Critical evaluation of the methodology used by Wilson-Davies et al., (2020) entitled "Concerning the Optigene Direct LAMP assay, and it`s use in at-risk groups and hospital staff".
    J Infect. 2021;82:282-327.
    >> Share

    January 2021
  769. DIMEGLIO C, Miedouge M, Loubes JM, Mansuy JM, et al
    Side effect of a 6 p.m curfew for preventing the spread of SARS-CoV-2: a modelling study from Toulouse, France.
    J Infect. 2021 Jan 31. pii: S0163-4453(21)00044.
    >> Share

  770. TANAKA A, Yamamoto S, Miyo K, Mizoue T, et al
    Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in Tokyo, Japan.
    J Infect. 2021 Jan 29. pii: S0163-4453(21)00032.
    >> Share

  771. RANA MS, Usman M, Alam MM, Ikram A, et al
    Impact of COVID-19 preventive measures on other infectious and non-infectious respiratory diseases in Pakistan.
    J Infect. 2021 Jan 29. pii: S0163-4453(21)00041.
    >> Share

  772. T U, Am DR, Bm W, Ar H, et al
    Increased inflammatory markers reflecting fibrogenesis are independently associated with cardiac involvement in hospitalized COVID-19 patients.
    J Infect. 2021 Jan 28. pii: S0163-4453(21)00040.
    >> Share

  773. DOWNS LO, Eyre DW, O'Donnell D, Jeffery K, et al
    Home-based SARS-CoV-2 lateral flow antigen testing in hospital workers.
    J Infect. 2021 Jan 25. pii: S0163-4453(21)00033.
    >> Share

  774. ADACHI Y, Shiroyama T, Yamaguchi Y, Murakami T, et al
    Predicting recurrence of respiratory failure in critically ill patients with COVID-19: A preliminary study: Running head: Factors predicting respiratory failure in COVID-19.
    J Infect. 2021 Jan 24. pii: S0163-4453(21)00039.
    >> Share

  775. ELFIKY AA, Ibrahim IM
    Host-cell recognition through GRP78 is enhanced in the new UK variant of SARS-CoV-2, in silico.
    J Infect. 2021 Jan 22. pii: S0163-4453(21)00038.
    >> Share

  776. XU Y, Liang H, Wen H
    Frequent reassortment and potential recombination shape the genetic diversity of influenza D viruses.
    J Infect. 2021 Jan 21. pii: S0163-4453(21)00037.
    >> Share

  777. DE FRANCESCO MA, Poiesi C, Gargiulo F, Bonfanti C, et al
    Co-infection of Chlamydia pneumoniae and Mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features.
    J Infect. 2021 Jan 19. pii: S0163-4453(21)00031.
    >> Share

  778. TANG JW, Toovey OTR, Harvey KN, Hui DDS, et al
    Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK.
    J Infect. 2021 Jan 17. pii: S0163-4453(21)00030.
    >> Share

  779. MORENO-PEREZ O, Merino E, Leon-Ramirez JM, Andres M, et al
    Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study.
    J Infect. 2021 Jan 12. pii: S0163-4453(21)00009.
    >> Share

  780. BREATHNACH DAS, Riley PA, Cotter MP, Houston AC, et al
    Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months.
    J Infect. 2021 Jan 12. pii: S0163-4453(21)00010.
    >> Share

  781. GARCIA-ORTEGA A, Oscullo G, Calvillo P, Lopez-Reyes R, et al
    INCIDENCE, RISK FACTORS, AND THROMBOTIC LOAD OF PULMONARY EMBOLISM IN PATIENTS HOSPITALIZED FOR COVID-19 INFECTION.
    J Infect. 2021 Jan 10. pii: S0163-4453(21)00007.
    >> Share

  782. GARRATT AM, Ghanima W, Einvik G, Stavem K, et al
    Quality of life after COVID-19 without hospitalisation: good overall, but reduced in some dimensions.
    J Infect. 2021 Jan 9. pii: S0163-4453(21)00006.
    >> Share

  783. ALEMANY A, Baro B, Ouchi D, Rodo P, et al
    Analytical and Clinical Performance of the Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test.
    J Infect. 2021 Jan 6. pii: S0163-4453(21)00004.
    >> Share

  784. BONGIOVANNI M, Bini F, Giuliani G, Gianturco L, et al
    Insight into the reason of prolonged viral RNA shedding in patients with COVID-19 infection.
    J Infect. 2021 Jan 3. pii: S0163-4453(21)00002.
    >> Share

  785. NISHI A, Lee LF, Tsuji H, Takasaki Y, et al
    Letter to the Editor: Revisiting the County/city-level Event Risk Assessment during the COVID-19 Pandemic.
    J Infect. 2021 Jan 3. pii: S0163-4453(21)00003.
    >> Share

    December 2020
  786. LIU Y, Li M, Liu D, Luo JF, et al
    Developing a multivariable risk prediction model to predict prolonged viral clearance in patients with COVID-19.
    J Infect. 2020 Dec 30. pii: S0163-4453(20)30787.
    >> Share

  787. GUO J, Yu H, Yang J, Li Y, et al
    Weighted gene co-expression network analysis revealed host transcriptional response to H1N1 influenza A virus infection.
    J Infect. 2020 Dec 29. pii: S0163-4453(20)30779.
    >> Share

  788. TANG JW, Tambyah PA, Hui DS
    Emergence of a new SARS-CoV-2 variant in the UK.
    J Infect. 2020 Dec 28. pii: S0163-4453(20)30786.
    >> Share

  789. YANG H, Xu J, Liang X, Shi L, et al
    Autoimmune diseases are independently associated with COVID-19 severity: Evidence based on adjusted effect estimates.
    J Infect. 2020 Dec 28. pii: S0163-4453(20)30785.
    >> Share

  790. HANRATH AT, Payne BAI, Duncan CJA, van der Loeff IS, et al
    Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection.
    J Infect. 2020 Dec 26. pii: S0163-4453(20)30781.
    >> Share

  791. CHAN HT, Chao CM, Lai CC
    Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: a meta-analysis.
    J Infect. 2020 Dec 26. pii: S0163-4453(20)30783.
    >> Share

  792. TABOADA M, Carinena A, Moreno E, Rodriguez N, et al
    Post-COVID-19 functional status six-months after Hospitalization.: Functional status after COVID-19.
    J Infect. 2020 Dec 26. pii: S0163-4453(20)30784.
    >> Share

  793. KONIG S, Hohenstein S, Ueberham L, Hindricks G, et al
    Regional and temporal disparities of excess all-cause mortality for Germany in 2020: Is there more than just COVID-19?
    J Infect. 2020 Dec 23. pii: S0163-4453(20)30777.
    >> Share

  794. GANDINI O, Lubrano C
    Use of rapid ferritin test to predict clinical deterioration in at home COVID-19 patients.
    J Infect. 2020 Dec 20. pii: S0163-4453(20)30775.
    >> Share

  795. TURCATO G, Zaboli A, Pfeifer N, Ciccariello L, et al
    Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: a preliminary report.
    J Infect. 2020 Dec 18. pii: S0163-4453(20)30773.
    >> Share

  796. BELLANTI F, Buglio AL, Custodero G, Barbera L, et al
    Fatal relapse of COVID-19 after recovery? A case report of an older Italian patient.
    J Infect. 2020 Dec 16. pii: S0163-4453(20)30770.
    >> Share

  797. AGULLO V, Fernandez-Gonzalez M, Ortiz de la Tabla V, Gonzalo-Jimenez N, et al
    Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study.
    J Infect. 2020 Dec 9. pii: S0163-4453(20)30768.
    >> Share

  798. ZHOU H, Li C, Hu T, Liu T, et al
    Total Infectomes of 162 SARS-CoV-2 Cases Using Meta-Transcriptomic Sequencing.
    J Infect. 2020 Dec 8. pii: S0163-4453(20)30765.
    >> Share

  799. CHEN PJ, Chao CM, Lai CC
    Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.
    J Infect. 2020 Dec 7. pii: S0163-4453(20)30766.
    >> Share

  800. SALMON D, Slama D, De Broucker T, Karmochkine M, et al
    Clinical, virological and imaging profile in patients with Persistent or Resurgent forms of COVID-19: a cross-sectional study.
    J Infect. 2020 Dec 4. pii: S0163-4453(20)30762.
    >> Share

  801. BARRASA H, Martin A, Maynar J, Rello J, et al
    High rate of infections during ICU admission of patients with severe SARS-CoV-2 pneumonia: a matter of time?
    J Infect. 2020 Dec 4. pii: S0163-4453(20)30761.
    >> Share

  802. FRICKE LM, Glockner S, Dreier M, Lange B, et al
    Impact of non-pharmaceutical interventions targeted at COVID-19 pandemic on influenza burden - a systematic review.
    J Infect. 2020 Dec 2. pii: S0163-4453(20)30756.
    >> Share

  803. PIOVANI D, Christodoulou MN, Hadjidemetriou A, Pantavou K, et al
    Effect of early application of social distancing interventions on Covid-19 mortality over the first pandemic wave: an analysis of longitudinal data from 37 countries.
    J Infect. 2020 Dec 1. pii: S0163-4453(20)30751.
    >> Share

  804. PANDEY M, Sisodia S, Bandi S, Roland D, et al
    Incidence of spread of clinically relevant SARS-CoV2 infection between children in a tertiary emergency department: An evaluation.
    J Infect. 2020;81:979-997.
    >> Share

  805. FALCINELLI E, Petito E, Becattini C, De Robertis E, et al
    Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients.
    J Infect. 2020 Dec 1. pii: S0163-4453(20)30760.
    >> Share

    November 2020
  806. FOWLER VL, Armson B, Gonzales JL, Wise EL, et al
    A highly effective reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for the rapid detection of SARS-CoV-2 infection.
    J Infect. 2020 Nov 30. pii: S0163-4453(20)30731.
    >> Share

  807. FURUSE Y
    Risk at mass-gathering events and the usefulness of complementary events during COVID-19 pandemic.
    J Infect. 2020 Nov 30. pii: S0163-4453(20)30759.
    >> Share

  808. MAANI AA, Al-Jardani A, Karrar H, Petersen E, et al
    COVID-19 in a case previously infected with MERS-CoV: no cross immunity.
    J Infect. 2020 Nov 30. pii: S0163-4453(20)30754.
    >> Share

  809. DUBOUCHER C
    SARS-CoV-2 and superimposed infection by trichomonads.
    J Infect. 2020 Nov 30. pii: S0163-4453(20)30757.
    >> Share

  810. JONES CR, Hamilton FW, Thompson A, Morris TT, et al
    SARS-CoV-2 IgG seroprevalence in healthcare workers and other staff at North Bristol NHS Trust: a sociodemographic analysis.
    J Infect. 2020 Nov 30. pii: S0163-4453(20)30755.
    >> Share

  811. MOREIRA LVL, de Souza Luna LK, Barbosa GR, Perosa AH, et al
    Test on stool samples improves the diagnosis of hospitalized patients: detection of SARS-CoV-2 genomic and subgenomic RNA.
    J Infect. 2020 Nov 30. pii: S0163-4453(20)30753.
    >> Share

  812. GURGEL RQ, de Sa LC, Souza DRV, Martins AF, et al
    SARS-CoV-2 has been circulating in northeastern Brazil since February 2019: evidence for antibody detection in asymptomatic patients.
    J Infect. 2020 Nov 30. pii: S0163-4453(20)30752.
    >> Share

  813. LIU D, Yang J, Feng B, Lu W, et al
    Mendelian randomization analysis identified genes pleiotropically associated with the risk and prognosis of COVID-19.
    J Infect. 2020 Nov 28. pii: S0163-4453(20)30726.
    >> Share

  814. LAI CC, Chen SY, Yen MY, Lee PI, et al
    The impact of COVID-19 preventative measures on airborne/droplet-transmitted infectious diseases in Taiwan.
    J Infect. 2020 Nov 26. pii: S0163-4453(20)30724.
    >> Share

  815. LEVI M, Miglietta A, Romeo G, Bartolacci S, et al
    Letter in response to article in Journal of Infection: Impact of Routine Infant BCG Vaccination on COVID-19.
    J Infect. 2020 Nov 25. pii: S0163-4453(20)30718.
    >> Share

  816. SUI Z, Zhang Y, Tu J, Xie J, et al
    Evaluation of saliva as an alternative diagnostic specimen source for SARS-CoV-2 detection by RT-dPCR.
    J Infect. 2020 Nov 25. pii: S0163-4453(20)30716.
    >> Share

  817. BERASTEGUI-CABRERA J, Salto-Alejandre S, Valerio M, Perez-Palacios P, et al
    SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load.
    J Infect. 2020 Nov 25. pii: S0163-4453(20)30719.
    >> Share

  818. ROMERO-GOMEZ MP, Gomez-Sebastian S, Cendejas-Bueno E, Montero-Vega MD, et al
    Ct value is not enough to discriminate patients harbouring infective virus.
    J Infect. 2020 Nov 25. pii: S0163-4453(20)30720.
    >> Share

  819. MAJRA D, Benson J, Pitts J, Stebbing J, et al
    SARS-CoV-2 (COVID-19) Superspreader Events.
    J Infect. 2020 Nov 24. pii: S0163-4453(20)30717.
    >> Share

  820. KOWALL B, Nonnemacher M, Brune B, Brinkmann M, et al
    A model to identify individuals with a high probability of a SARS-CoV-2 infection.
    J Infect. 2020 Nov 24. pii: S0163-4453(20)30721.
    >> Share

  821. VOICU S, Chousterman BG, Bonnin P, Deye N, et al
    Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: Venous thrombosis prevention & COVID-19.
    J Infect. 2020 Nov 20. pii: S0163-4453(20)30714.
    >> Share

  822. CHAU NVV, Toan LM, Man DNH, Thao HP, et al
    Absence of SARS-CoV-2 antibodies in health care workers of a tertiary referral hospital for COVID-19 in southern Vietnam.
    J Infect. 2020 Nov 19. pii: S0163-4453(20)30713.
    >> Share

  823. XIONG X, Jiao X, Li H, Zeng S, et al
    Glucocorticoid benefits the ventilatory function of sever/critical COVID-19 patients.
    J Infect. 2020 Nov 18. pii: S0163-4453(20)30712.
    >> Share

  824. BAUER W, Diehl-Wiesenecker E, Ulke J, Galtung N, et al
    Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department.
    J Infect. 2020 Nov 17. pii: S0163-4453(20)30711.
    >> Share

  825. TORRES M, Collins K, Corbit M, Ramirez M, et al
    Comparison of Saliva and Nasopharyngeal Swab SARS-CoV-2 RT-qPCR Testing in a Community Setting.
    J Infect. 2020 Nov 17. pii: S0163-4453(20)30710.
    >> Share